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Development of a Dry Powder Inhaler and Nebulised Nanoparticle-Based 
Formulations of Curcuminoids for the Potential Treatment of Lung Cancer 
Yuosef AL Ayoub 
Keywords: Curcumin, Demethoxycurcumin, Bisdemethoxycurcumin, Dry 
Powder Inhaler, Air Jet Milling, Sonocrystallisation, Nebuliser, Nanoemulsion, 
Microsuspension, Particles Aerodynamic Characterisations. 
Abstract: 
Curcuminoids have strong anticancer activities but have low bioavailability. The 
highest rate of cancer deaths comes from lung tumours; therefore, inhaled 
curcuminoids could treat lung cancer locally. To date, there are no nebulised 
formulations of curcuminoids, and there are no inhalable curcuminoids particles 
without excipients using air jet mill and sonocrystallisation methods for DPI 
formulations. It is the first time; the aerodynamic parameters of curcumin, 
demethoxycurcumin and bisdemethoxycurcumin were measured individually 
using NGI. The size, shape, free surface energy, and the crystal polymorphism 
of the produced inhalable curcuminoid particles were characterised using laser 
diffraction, SEM, IGC, DSC and XRPD, respectively. Several DPI formulations 
with a variable particle size of curcuminoids were prepared in two drug-carrier 
ratios (1:9 and 1:67.5). The best performance of the DPI formulations of the 
sonocrystallised particles, which exist in crystal structure form1, were obtained 
from ethanol- heptane, as illustrated FPF 43.4%, 43.6% and 43.4% with MMAD 
of 3.6µm, 3.5µm and 3.4µm, whereas the best DPI formulation of the air jet 
milled particles was presented FPF 38.0%, 38.9%, and 39.5% with MMAD of 
3.6µm, 3.4µm and 3.2µm for curcumin, demethoxycurcumin and 
bisdemethoxycurcumin, respectively. 
Nebulised curcuminoids using nanoemulsion and microsuspension formulations 
were prepared. The physical properties, such as osmolality, pH and the 
viscosity of the aerosolised nanoemulsion and the microsuspension 
formulations were determined. The FPF% and MMAD of nebulised 
nanoemulsion ranged from 44% to 50% and from 4.5µm to 5.5µm respectively. 
In contrast, the FPF% of microsuspension ranged from 26% to 40% and the 
MMAD from 5.8µm to 7.05µm. A HPLC method was developed and validated in 
order to be used in the determination of curcuminoids from an aqueous solution.  
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1 Chapter 1:  Literature review 
1.1. General introduction 
Lung cancer is becoming the second most distributed diseases amongst other 
cancer types in worldwide. It is responsible for the highest rate of cancer deaths 
(Hitzman et al. 2006; Eramo et al. 2008; El-Gendy and Berkland 2009). 
Inappropriate treatment or insufficient drug delivery to the site of the disease 
after oral or intravenous administration is a possible cause of lung cancer 
treatment failure; it may also be the cause of the efficacy limitation of some 
chemotherapy, as well as the late detection of the disease. In addition, lung 
cancer treatment has had no significant progress in the recent years and the 
remedy rate continues to be the lowest one among all cancers or malignancies 
(Maillet et al. 2008; El-Gendy and Berkland 2009). 
Curcumin is currently the drug which has shown to have a strong effect on 
treatment of cancers in cell culture (Kunnumakkara et al. 2008; Sa and Das 
2008; Huang et al. 2013; Lee et al. 2015; Seo et al. 2016). Interestingly, 
curcumin has the ability to inhibit cell cancer throughout interactions with 
multiple molecular targets (Nagabhushan and Bhide 1992; Anand et al. 2008; 
Chen et al. 2008; Kunnumakkara et al. 2008; Kasi et al. 2016). Most of these 
molecular targets play a significant role in cancer initiation or development. 
Moreover, curcumin has proved its ability to inhibit most of the mechanism of 
cancer development (Maheshwari et al. 2006). Curcumin demonstrates that it 
can be safe even when consumed at a high dose up to 10 g/day (Sharma et al. 
2005; Goel et al. 2008). However, curcumin is poorly soluble in water, which 
limits its absorption to the body; hence reduces its pharmacological activity 
(Anand et al. 2007). These solubility problems could be solved by enhancing 




the drug formulations using different technique in drug production such as solid 
dispersion system (Paradkar et al. 2004; Anand et al. 2007; Anand et al. 2010). 
Moreover, curcumin undergoes first pass metabolism, in liver, when it is 
administrated orally. This significantly reduces the ability of the drug to reach 
the site of action, resulting in decreasing the effect of the drugs (Pond and 
Tozer 1984; Anand et al. 2007).  
In lung cancer, the chemotherapy agents are given intravenously. But this 
administration route causes a high drug concentrations in the systemic 
circulations, which leads to some side effects and low drug concentrations in 
the respiratory tract (Guilleminault et al. 2011). The drugs that treat lung 
disease, such as asthma and chronic obstructive pulmonary disease (COPD) 
are usually administrated via the airways. The advantage of this route is that 
curcumin will be directly delivered to tumour site in the bronchi, bronchioles or 
deep lungs. Theoretically, the airways drug delivery should ensure longer 
contact of intended target to higher concentration of the drugs, while reducing 
the systemic side effect. Therefore, the patients should benefit from low 
minimum drug concentrations in the systemic circulation and other body tissues. 
Hence, the airways could be an attractive route of administration for curcumin in 
lung cancer, as other routes of administrations have shown a limited success. 
Dry powder inhalers (DPIs) are considered a good drug delivery method for the 
inhalation. This is due to the improved stability of dry powders as well as the 
ease of use of the device (Bosquillon et al. 2001; Chougule et al. 2007; El-
Gendy and Berkland 2009). The dry powder inhalers have been reported to 
offer a novel formulation for localising chemotherapy in the treatment of lung 
cancer (El-Gendy and Berkland 2009). However, the DPI has some 




disadvantages such as inability to be used by children and for elderly patients; 
thus, the recommended formulation for those patients is nebulised formulations. 
Therefore, the formulation of curcumin in a nebulised form will also be 
examined in this thesis. 
In pulmonary drug delivery, particles size of the drug is a vital factor that 
determines the aerosol distribution in the lungs (Labiris and Dolovich 2003). In 
order to allow the dry powders to penetrate the respiratory system and to 
deposit in the lungs, the size of the drug particles must be in the range of 1-5μm 
in aerodynamic diameter. Aerosol particles larger than 5μm commonly stay in 
the oral cavity, where they will be swallowed and passed through the digestive 
system. However, the particles smaller than 1μm will be exhaled, this is 
because they settle down very slowly (Ahmad et al. 2009). 
Producing drug particles in inhaled range size can be a challenge for the 
formulator. The traditional method to operate the powders for inhalation is the 
milling technique. In this project, Air Jet mill has been used to obtain curcumin 
powders in the desired size. Also, a simple and rapid crystallisation method 
using ultrasound was utilised to produce inhalable curcumin particles.  
The nebulised formulations of curcumin were obtained using suspension 
formulation technique which is the most common and available method for 
water insoluble drugs. In addition, solution formulation of curcumin was 
prepared in nanoemulsion form. The advantage of later formulation is that it 
provides a soluble form of curcumin which improves its anti-inflammatory 
activity (Wang et al. 2008). 




1.2. An overview on the respiratory system  
The respiratory system is composed of upper and lower part. The upper 
respiratory system includes the nose, pharynx, larynx, and trachea. The 
function of this part is to warm and provide moisture to the air entering as well 
as to filter it. The moisture of the air is raised, in this region, from 40-60% to 
99%, as relative humidity, and is warmed from 20ºC up to 37ºC. 
The lower respiratory system includes the bronchi and the lungs. The bronchi 
rise from the trachea enters the left and the right lung. The bronchi are further 
divided into smaller branches inside the lungs to form structures known as 
bronchioles. These become narrower, shorter and more numerous as they go 
deeper in to the lung. The bronchi are lined by pseudostratified ciliated epithelial 
cells which create mucous. This part from the trachea to the terminal 
bronchioles is called the conduction zone in which the inspired air reaches to 
the gas-exchange zone of the lung. The terminal bronchioles end by respiratory 
bronchioles (connected with alveolar duct) which end with alveolar sacs. The 
respiratory zone consists of respiratory bronchioles, alveolar duct and alveolar 
sacs. The gas exchange occurs at the respiratory zone (Levitzky 2007). 





Figure 1. 1 The branching patterns of the airway from the conducting to the 
transitional and to the respiratory airway zones 
1.3. Lung cancer  
Cancer, in the most basic sense, is the abnormal, uncontrolled growth of 
previously normal cells. The alteration in the genetic information causes cells to 
stop carrying out their function properly. The transformation in the cells comes 
from modification to their DNA that accumulates over time. A primary feature of 
cancer cells is the ability of these cells to rapidly divide, which results in 
accumulation of cancer cells also known as a tumour. As the proliferation of 
these ‘abnormal’ cells occurs the tumour grows and where it does not spread to 
the surrounding tissue, is known as benign. Benign tumours are usually 
harmless. However, a benign tumour can still be harmful if the tumour 




compresses the surrounding tissue against a tough surface in the body. For 
example, a benign brain tumour can place pressure on the brain tissue forcing it 
against the skull and as a result could potentially cause paralysis, loss of 
hearing or sight and dizziness (Hansen 2008; Almeida and Barry 2010).  
A malignant tumour however, is when the tumour spreads to a far-away tissue. 
It usually grows at a fast rate and can be fatal. Metastasis is a process of 
spreading cancerous cells from their original primary tumour to another distance 
organ in where it will multiply and make secondary tumour (Hansen 2008; 
Almeida and Barry 2010). 
Lung cancer is a disease characterised by uncontrolled cell growth in the lung 
tissues. Lung cancer is also used to describe tumours which take place in the 
epithelial lining of the respiratory tract such as bronchi, bronchioles and alveoli 
(Ellison-Loschmann 2004; Harwood et al. 2005). 
Lung cancer is the most common cause of the cancer related deaths in the 
world. More than 15% of the death in the world is related to the lung cancer. In 
addition lung cancer causes more deaths than any of the other most common 
cancers combined (colon, breast and prostate) (Jemal et al. 2008). It is the 
second most frequently diagnosed cancer in both males and females after 
prostate and breast cancer. 
In the United states, according to American Cancer Society, the estimated 
deaths in 2012 due to lung cancer is higher than colon, breast, pancreases and 
prostate cancers combined (Siegel et al. 2012). According to the National 
Cancer Institute, the records of lung cancer enlarged by 28% between 1973 and 
1997 compare to an overall raise of 23.4% in all sites of cancers combined. 




The number of people who died from lung cancer has increased by 
approximately 4.3% between 1999 and 2008 (American Cancer Society 2012). 
According to a cancer research reported in 2012 in the UK, about 41,500 
people had lung cancer in 2009. Approximately 23,000 cases were diagnosed 
in males and 18,400 in females. This makes lung cancer the second common 
cancer in men after prostate cancer and the third common cancer in women 
after the breast and bowel cancer. In the 1950s, for every case of lung cancer in 
females there were six cases in the male population; however, this ratio has 
now dramatically changed, with a ratio of 3 females in every four males being 
diagnosed with lung cancer. 
1.3.1. Aetiology of lung cancer 
The major increase of lung cancer diagnosis has been a result of several 
environmental and lifestyle issues. One of the most important of these issues is 
tobacco smoke with almost 85% to 90% of lung cancer patients are smokers. 
However, lung cancer can also be diagnosed in patients who have never 
smoked; suggesting that there are other factors such as environmental tobacco 
smoke (ETS), environmental and domestic air pollution, work-related risk 
factors, asbestos exposure, and viruses which could have an effect on the 
incidence of lung cancer (Hansen 2008). 
Smoking is the most common cause of lung and other types of cancers. 
Cigarette smoke consists of a mixture of different compounds and more than 
4000 compounds have been found in the gas phase of the smoke. Reports 
have found that up to 70 of these compounds have potential to cause cancer in 
the lungs (carcinogenic). Examples of theses carcinogens are polycyclic 
hydrocarbons (PAHs), heterocyclic hydrocarbons, N –nitrosamines, aromatic 




amines, N -heterocyclic amines, aldehydes and several organic and inorganic 
compounds (Hansen 2008). Lung tumour arises from the attachment of tobacco 
carcinogens to the cell's nuclear DNA, which can result in either killing the cell 
or cause a genetic mutation. This binding with DNA is irreversible. Once the 
mutation inhibits programmed cell death, the cell can survive to become a 
cancer cell (Feng et al. 2006). Acrolein is a major cigarette-related lung cancer 
agent: Preferential binding at p53 mutational hotspots and inhibition of DNA 
repair (Feng et al. 2006).  
In addition to this, there are some metals, such as nickel, cadmium and 
chromium in the gas phase of the smoke (Cella et al. 1993; Morita et al. 2003; 
Hansen 2008). Their role in lung carcinogenesis still not fully understood. 
However, it has been reported that chromium, cadmium and nickel produce 
lung tumour in rat after inhalation (Scagliotti et al. 2002; Paccagnella et al. 
2004; Hansen 2008). Induction DNA damage in the lung cells may be the 
reason for their ability to carry out lung carcinogenesis (Hansen 2008).  
Environmental tobacco smoke, (ETS), or passive smoking, is a mixture of 
exhaled mainstream smoke and sidestream smoke diluted in air (Hansen 2008). 
There are differences in the level of particular compounds that present in 
sidestream and mainstream smoke. For instance, with a cigarette filtration, the 
level of PAHs in mainstream smoke is ten times less than those in sidestream 
smoke (Paccagnella et al. 2004; Hansen 2008). There are many studies that 
indicate a high level of risk for lung cancer incidence in those who are exposed 
to ETS and who had never smoked before. Mutations (at P53 and KRAS) have 
been found in lung cancer of ETS-exposed non-smoking patients, which are the 




same mutations, occurred in smoker patients, although with a lower frequency 
(Sculier 1995; Boussat et al. 2000; Hansen 2008) 
Air pollution is a term used to describe the quality of the air. It is a complex 
mixture of gaseous substance that causes harm to humans and other living 
organisms. Air pollutants come from various sources, in particular factories and 
heavy traffic. These involve polycyclic hydrocarbons (PAHs), petroleum 
vapours, benzene, ethylene oxide and metals. It has been reported that 
residents in urban areas with high levels of exposure to the pollutions have an 
increase in lung cancer incidence than those in rural areas by 1.5 times (Sculier 
and Markiewicz 1993; Hansen 2008). In other reports in 2011, it was found that 
the risk of lung tumour increased in people who settle in areas with high levels 
of nitrogen oxide. Also in the same study, the incidence was higher for non-
smokers than smokers (Raaschou-Nielsen et al. 2011). Work place exposure is 
reported to be a risk factor for lung cancer (Gustavsson et al. 2000). The 
international agency for research on cancer has addressed 12 workplace 
exposure factors as carcinogenic in the lungs. These factors are Aluminium 
production, arsenic, asbestos, bis-chloromethyl ether, beryllium, cadmium, 
hexavalent chromium, coke and coal gasification fumes, crystalline silica, nickel, 
radon, and soot. In addition, diesel exhaust is identified as carcinogen for the 
lungs (Tomatis et al. 1978; Steenland et al. 1996; Smoke and Smoking 2004). 
The duration and intensity of exposure to asbestos fibres could cause a lung 
tumor (Ayres et al. 2009). The European Union has banned all use of asbestos 
and extraction, manufacture and processing of asbestos products (European 
Parliament 2010) 




Oncogenic viruses are viruses that can cause a cancer. These viruses could be 
included in lung cancer aetiology (Hansen 2008). There are some studies which 
have researched papilloma viruses, however the detection frequency of the 
virus in bronchial carcinoma are significantly changeable, ranging from zero to 
100% in many reports (Booth et al. 2004; Hansen 2008). Regarding other 
oncogenic viruses such as Epstein–Barr virus, human cytomegalovirus, human 
herpes virus-8, and simian virus 40, the evidence is rare (Uchitomi et al. 2003; 
Hansen 2008). 
In conclusion, the aetiology factors on lung cancer can be divided into two 
factors; major and minor. Tobacco smoking, either active smoking or ETS, all 
have a major role in the aetiology lung cancer due to the previously addressed 
fact that tobacco has a large number of carcinogenic substances. Another 
aetiology factors such as air pollution, occupations and viruses, which although 
seem minor, can still have a significant value in lung carcinogenesis. 
1.3.2. Pathophysiology of lung cancer  
The pathophysiology of lung cancer is a complex multistep process which 
includes alterations in the intact bronchial mucosa through lesions, involving cell 
hyperplasia, metaplasia and dysplasia. 
The respiratory tract is lined by epithelial cells which undergo changes in 
structure and hence function when exposed to noxious substances in the air. 
These epithelial cells, which form a surface layer of the trachea, bronchi and 
some of the bronchioles, consist of pesudostratified columnar cells. Amongst 
these cells are specialized cells known as goblet cells which is presented in 
figure 1.2 (Almeida and Barry 2010). 





Figure 1. 2 Normal goblet cells (Almeida and Barry 2010) 
Goblet cells produce sticky and thick mucus, which traps dust and 
microorganisms and prevent them from going deeper into the lungs. The cilia, 
which are short hair-like structures present on the surface of the columnar 
epithelial cells, will trap substances that will then be swept back up to the throat. 
Exposure to chemicals or irritant and carcinogens from the tobacco over a long 
period of time will cause inflammation of the respiratory epithelium then 
paralyzes the cilia on the surface of the epithelium. This permits the mucus with 
its trapped compounds to accumulate in the respiratory tract and move further 
down to the lungs. It is found that in a tobacco smoker, the pseudstratified 
columnar epithelium is being replaced by stratified squamous epithelium which 
is showed in figure 1.3. 
 
Figure 1. 3 Stratified squamous epithelium (Almeida and Barry 2010) 
 
  




Stratified squamous cells normally exist in the inner digestive system and outer 
layer of the skin but not in respiratory system. This process of replacing a 
mature normal cell type by another mature normal cell type is called metaplasia. 
The replaced/second types of cells are normal cells but are present in the 
incorrect location and as a result will not carry out the function required. 
Nevertheless this process is reversible, when the stimulus that initiated the 
transformation is absent, healthy cells should return back to their original 
structure and function. However, permanent alterations may arise resulting from 
genetic mutations in oncogenes and tumour suppressor genes; this may 
enhance these types of cells and cause them to become cancerous.  
In addition to this, mutations in oncogenes and suppressor genes will enhance 
hyperplastic growth as a result of losing regulations at the ‘checkpoint’ of the 
cell cycle. Hyperplasia is an increase in the number of cells with normal 
organisation growth in response to a certain stimuli, which can be seen in figure 
1.4 b. Dysplasia is increasing in cell number with disorganisation growth, which 
is presented in figure 1.4 c (Almeida and Barry 2010). 
 
 





Figure 1. 4 Hyperplasia (b) and Dysplasia (c) (Almeida and Barry 2010) 
In conclusion, the pathophysiology of lung cancer development is complex and 
not fully understood. Genetic alterations and mutations carry out significant 
roles in lung carcinogenesis. Tobacco still has the most important sources of 
carcinogens which is the trigger for lung cancer. 
1.3.3. Types of lung cancer  
There are two main types of tumours in the lung, each with different treatment 
and different expected survival rate. They are non- small cell lung cancer 
(NSCLC) and small cell lung cancer (SCLS). This classification depends on the 
appearance of their cellular structure under a microscope.  
1.3.3.1.  Non-small cell lung cancer (NSCLC) 
Around 85% of lung cancers are NSCLCs, which are characterised by slow 
growth and do not spread as much as SCLCs. The expected survival rate for 
NSCLCs is five years of 60% if early diagnosed and 40% if late diagnosed. 
There are three subtypes of NSCLs and their named (subtypes) is based on the 
kind of cells in which the tumour develops and vary in their size and shape as 
presented in figure 1.5 
 





Figure 1.5 Percentage of the lung cancer types (adapted from 
mechanismsinmedicine.com) 
Squamous or epidermoid carcinoma usually arises close to the bronchus and 
grows slowly. (The main site of SCLC is in mainstream and segmental bronchi 
(Hansen 2008). Adenocarcinomas vary in size and grow near the outside 
surface of the lung. Large cell undifferentiated carcinomas might appear at any 
part of the lung and spread very quickly (Almeida and Barry 2010). (See figures 
1.6, 1.7 and 1.8) 
 
 
Figure 1. 6 Site of the squamous cell carcinoma in the central lung and the 
mucociliary epithelial cell (adopted from www.urac.org (American 



















Figure 1. 7 Site of adenocarcinoma in the lung periphery and alveolar type II 
cells (adopted from www.urac.org (American Accreditation HealthCare 
Commission) 
 
1.3.3.2. Small cell lung cancer (SCLC) 
This is also known as oat cell cancer. It is less common than NSCLC forming 
only 15% of all lung cancers, but it is more fatal. It starts in bronchi and grows at 
a significantly high rate (faster than NSCLC) and more readily able to 




Figure 1. 8 Sit of the large cell carcinoma is either in the central & peripheral 
lung area or squamous & glandular features (adopted from www.urac.org 
(American Accreditation HealthCare Commission) 





Figure 1. 9 Site of the small cell carcinoma in the central of the lung (adopted 
from www.urac.org (American Accreditation HealthCare Commission) 
 
1.3.4. Chemotherapy via inhalation for lung cancer  
Chemotherapy used in lung cancer to prolong survival time of patients. There 
are many different types of drugs for cancers with different mechanism of action 
but most of these drugs have many side effects and high level of toxicity on 
different organs of the body which affect the life style of the patients. 
1.3.4.1. Cisplatin 
Cisplatin is an alkylating drug that inhibits DNA synthesis (Ritter 2008). It is 
considered as a cornerstone from first line drugs that are used in the treatment 
lung cancer. As much as 83% response has been achieved using this drug in 
treatment of SCLC. However, most of the patients relapse (Johnson 1999b; 
Schultheis et al. 2001). 
Clinical studies have proved that adding other anticancer drug platinum 
compounds increases the therapeutic effect of these compounds and hence 
increases the life expectancy of the patients with lung cancer. The reasons for 
using the combinations may reduce the resistance of the tumour cells to the 
Cisplatin. Examples of some agents that are used in combination are Etoposid, 




Mitomycine, Gemcitabine, and Paclitaxel (Johnson 1999b; Sculier and Fry 
2004).  
Cisplatin has a high toxicity profile, causing such as nephrotoxicity and 
neurotoxicity. This toxicity prevents its use for long durations. Carboplatin is an 
analogue derivative to Cisplatin with slightly different toxicity. The toxicity has 
been reduced but it is still highly toxic to the blood (Sculier and Fry 2004). Some 
clinical studies (on NSCLC) showed no differences between these two drugs in 
the presence of Etoposide (Johnson 1999a; Schultheis et al. 2001) in terms of 
survival. However, the response to carboplatin was decreased.  Another trial 
using combination with Paclitaxel showed no difference between Cisplatin and 
Carboplatin in terms of survival and response rate (Johnson 1999a; Schultheis 
et al. 2001). 
1.3.4.2. Etoposide 
This is an alkaloid substance which acts as a cytotoxic agent by inhibiting DNA 
Topoisomerase enzyme II. This enzyme is very important in cleavage of DNA 
strands. It is a vital enzyme for both RNA transcription and DNA replication 
(Ritter 2008). 
Etoposide is the most effective medicine in the treatment of SCLC. It has been 
reported that its response rate was 86% (Johnson 1999a; Schultheis et al. 
2001). Etoposide, combined with Cisplatin was also recommended by 
Sunderom in the treatment of SCLC (Morita et al. 2003; Hansen 2008) and it 
showed that this combination was more effective than Vincristine, Epirubicin 
and Cyclophosphamide in the treatment SCLC. Furthermore, the Etoposide-
Cisplatin regimen (IV) has been compared with Topotecan-Cisplatin regimen 
(orally) in clinical studies. The results of this research showed that there was no 




difference in the survival rate between these two regimens in treatment of 
SCLC, (9.3) vs. (9.1) months (Thongprasert et al. 1999; Hansen 2008). 
However, Etoposide alone is not effective in treatment of NSCLC. Clinical 
studies have compared Etoposide-Cisplatin with other anticancer drugs such as 
Vindesine, Vinblastine, Gemcitabine and Paclitaxel. A significant reduction in 
overall response rate (ORR) was found in the regimen of Etoposide-Cisplatin 
compared with the other regimen (Sculier and Fry 2004). 
1.3.4.3. Topotecan 
This is an alkaloid compound that has anticancer properties by inhibition DNA 
Topoisomerase enzyme I. Topoisomerase Enzyme I is a vital enzyme for DNA 
unwinding in the replication process and RNA transcription. Apoptosis or 
programmed cell death is the most likely way of its cell killing (Ritter 2008). 
Topotecan is used in the treatment of SCLC and it is the only one which has 
been approved by the FDA as second line therapy for this disease. Clinical 
studies have been carried out on this drug; one of these trials presented a 22% 
of response for this drug in 30 weeks (Ardizzoni et al. 1997; Schultheis et al. 
2001). However, topotecan has many side effects as other cancer medications 
such as myelosuppression, diarrhoea and alopecia (Ritter 2008). 
1.3.4.4. Paclitaxel 
Paclitaxel is an antimicrotubule agent that is used in the treatment of different 
types of cancers including lung cancer (NSCLC). It works by inhibiting cell 
mitosis by binding to B-subunit of tubulin (Ritter 2008). Tubulin is a protein 
which plays an important role in maintaining cell structure, intracellular 




transport, formation of the mitotic spindle, as well as other cellular processes 
(Desai and Mitchison 1997). 
There are very few studies using paclitaxel in clinical trials. However, one study 
showed that when paclitaxel was used as a single agent a response of 29% in 
24 patients within a period of 3 weeks (Smit et al. 1998; Schultheis et al. 2001).  
Other studies have compared a combination of paclitaxel-cisplatin (or 
paclitaxel_carboplatin) with other anticancer drugs such as 
gemcitabine_cisplatin and docetaxel- cisplatin (Sculier and Fry 2004). The 
results have shown no improvement in survival rate or in ORR with 
paclitaxel_cisplatin. The response rate for paclitaxel_cisplatin regimen was 
21%, whereas in case of gemcitabine_cisplatin and docetaxel_platin the 
response rates were 22% and 17% respectively (Sculier and Fry 2004). 
In another trial, a comparison between carboplatin_paclitaxel with 
cisplatin_vinorelbine was carried out by Kelly (Sculier and Fry 2004). The data 
as shown in other trials showed no major difference. The response rate was 
26% with 8.6 months survival rate for the first combination and 28% and 8.1 
months for the second one.  
1.3.5. Curcumin 
Turmeric is a rhizome from the herb Curcuma longa Linn, which was used in 
Ayurveda and Chinese medicine to prevention and cure of human illnesses. 
Turmeric powder is used in cooking and it is the main ingredient of “curry spice” 
preparations. Turmeric powder is yellow pigmented and has 2% to 9% of 
curcuminoids; the word “curcuminoid” indicates a group of compounds such as 
curcumin, demethoxycurcumin and bisdemethoxycurcumin (Priyadarsini 2014). 




Out of these compounds, curcumin is about (77%), demethoxycurcumin (17%), 
and bisdemethoxycurcumin (3%) (Jadhav et al. 2007; Shanmugam et al. 2015). 
Curcumin is a polyphenol compound which entitles in Ayurvedic medicine as an 
effective medicine for various disorders such as asthma, bronchial hyperactivity, 
allergy, cough and hepatic disease (Ammon and Wahl 1991). There are many 
reports of its anti-infectious (Chan et al. 2005), anti-oxidant (Rao 1997), anti-
inflammatory (Brouet and Ohshima 1995; Dikshit et al. 1995), hepatoprotective 
(Kiso et al. 1983), cardioprotective (Venkatesan 1998), thrombosuppressive 
(Srivastava et al. 1985), anti-arthritic (Dcodhar et al. 2013), chemopreventive, 
and anti-carcinogenic (Chen et al. 2006; Divya and Pillai 2006) properties. 
Curcumin has also been shown to modulate multiple cellular molecular targets 
(Chattopadhyay et al. 2004; Shishodia et al. 2007a; Shanmugam et al. 2011). 
1.3.5.1. Pharmacological activity of curcumin on cancer  
There are many studies have shown the ability of curcumin to inhibit tumours. It 
can carry out this inhibition in cell cultures by transcription factors activation, 
tyrosine kinase enzyme inhibition (Bharat B. Aggarwal July 24, 2006). 
Genes which contribute to cell growth as well as carcinogenesis and 
angiogenesis are regulated by transcription factors such as nuclear factor-kB 
(NF-kB) and other factors. NF-KB has very important roles in cancer formation 
and also in cancer promotion. It can be activated in lung cancer through 
tobacco exposure. The activation of these factors can be inhibited strongly by 
curcumin (Shishodia et al. 2007b; Goel et al. 2008). 
Tyrosine kinase enzymes play important roles in cell cancer proliferation and in 
modulating DNA synthesis and genes transcriptions(Ritter 2008). These 
enzymes are stimulated by mutations (Goel et al. 2008). A certain number of 




these enzymes have been found in NSCLC, in particular the epidermal growth 
factor receptor (EGFR)(Hansen 2008). Studies have proven that curcumin 
totally inhibits protein kinase activity in vitro using cell line (Srivastava et al. 
1995; Nirmala and Puvanakrishnan 1996; Tikhomirov and Carpenter 2003; Goel 
et al. 2008). 
More enzymes are included in cancers, cyclooxygenase-2 has been found in 
different type tumours in human, such as breast, colon and lung cancer. A 
considerable amount of research has been focused on development of selective 
cox-2 inhibitors in the past, because it has been thought that these drugs have 
a significant impact on inhibition of carcinogensis (Grosser 2006; Goel et al. 
2008). Most studies have indicated that curcumin is able to inhibit cox-2 through 
the down regulation of the NF-kB which is vital for cox-2 activation (Goel et al. 
2008). 
Tumour suppressor gene P53 is a transcription factor. It has many functions in 
terms of cell process. These processes are genomic stability, cell cycle 
regulator, cellular response to DNA damage and apoptosis (cell programmed 
death) (Aggarwal et al. 2007). The P53 gene is able to stimulate other genes to 
induce apoptosis. It is also able to inhibit cell growth with damaged DNA 
(Furukawa et al. 2001; Aggarwal et al. 2007). Dysfunction of the P53 gene 
leads cells to produce errors and mutations as well as malignant 
transformations (Sculier and Fry 2004). In lung cancer, P53 becomes mutated 
as a result of mutations in other genes. Mutant P53 causes abnormal and 
uncontrolled cell growth and forms tumours (Aggarwal et al. 2007). It has been 
reported that P53 mutations are the most common point of mutation in lung 
cancer and its incidence around 40% (Sculier and Fry 2004). This mutation is 




present in SCLC in 90%, but only 50% and 35% in carcinoma and 
adenocarcinoma, respectively (Sculier and Fry 2004). Preclinical studies have 
found that curcumin is a potent inhibitor to mutant P53 (Natarajan and Bright 
2002; Aggarwal et al. 2007). 
Applying curcumin locally on skin showed that curcumin prevented or inhibited 
tumour formation by carcinogens. A trial on rodents involved curcumin being 
applied on the skin five minutes before cancer intonation by a carcinogen such 
as benzo[a]pyrene or DMBA.  The tumour was then improved by another 
carcinogen such as o-tetradecanoylphorbol-13-acetate. The results showed that 
curcumin was able to inhibit carcinogenesis by inhibiting inflammation.  This 
inflammation is induced by arachidonic acid, formation of hydrogen peroxidase 
and ornithine decarboxylase activity/transcription (Conney 2003; Aggarwal et al. 
2007). 
Also curcumin was topically applied on the buccal pouch of Syrian/Golden 
Hamster where oral cancer was caused by a carcinogen as DMBA (12, 7, 12-
dimethylbenz[a]antracene). The results from this experiment suggested that 
curcumin inhibits the formation of oral tumour locally. In addition to this, the 
effect of curcumin has been improved by adding or consuming green tea as a 
chemo-preventive agent (Li et al. 2002; Aggarwal et al. 2007). 
In certain clinical studies, curcumin was applied topically in oral cancer by 
Kuttan, the results of this study showed that a 10% decreasing in lesion size 
(Sharma et al. 2004; Aggarwal et al. 2007). It has been reported that some 
clinical trials were conducted for using curcumin in the treatment of patients with 
advanced colon cancer for four months (Sharma et al. 2004; Sharma et al. 
2005). It was found that five patients out of 15 had a stable disease for up to 




four months, and another patient had a significant decrease in 
carcinoembryonic antigen (colon cancer biomarker). 
It could be concluded that curcumin has potential ability in the treatment or 
inhibition of cancers through different modes of action. A possible cause for the 
importance of curcumin in the treatment of tumours may be due to the wide 
variety of mechanisms of inhibitions cells of cancer.  
1.3.5.2. Pharmacokinetics of curcumin (absorption, metabolism, and safety) 
Curcumin exerts poor oral bioavailability in both humans and rats. This may be 
attributed to low absorption of curcumin from the gut. As a result most of the 
ingested amount of curcumin is excreted in faeces unchanged. Intravenous 
injection of curcumin in rodents underwent first-pass metabolism and half of it 
was excreted in the bile within 5 hours. This may be due to the low absorption 
and rapid metabolism of curcumin (Wahlström and Blennow 1978; Goel et al. 
2008). The major metabolites (via reduction and glucuronides) of curcumin in 
the bile are tetrahydrocurcumin_glucuronides (THG) and hexahydrocurcumin 
(HHC) (Holder et al. 1978; Goel et al. 2008). Studies have indicated that the 
liver is the main site of metabolism of curcumin in both humans and rats 
(Wahlström and Blennow 1978; Garcea et al. 2004; Hoehle et al. 2006; Goel et 
al. 2008). 
Curcumin has not shown any toxicity to either humans or animals even at high 
doses (Shankar et al. 1980; Aggarwal et al. 2003; Shen and Ji 2007). It has 
been found to be very safe when used in humans, as it has been administrated 
up to 10 g/day resulting in no toxicity (Chainani-Wu 2003; Shen and Ji 2007). 
Moreover, the consumption of curcumin over a long period of time by many 
populations in some countries is an indication of its safety. 




1.3.5.3.  Physiochemical properties of curcumin  
Curcumin is considered as a polyphenol compound with chemical formula C21 
H20 O6 and molecular weight of 368.37 g/mol. The substituted phenol groups 
are attached with unsaturated carbon chain with a diketon group as it is shown 
in figure1.10. The hydroxyl group of the benzene ring, the β-diketon moiety and 
the double bond of the alkene group are responsible for the curcuminoids 
activities (Osawa and Namiki 1985; Ruby et al. 1995). 
It is a lipophilic compound which is very poorly soluble in water at acidic and 
neutral pH medium. It is sensitive to changes in the pH, as while it is stable at 
pH levels ranging from 1-7, it becomes degradable above this limit (Oetari et al. 
1996; Wang et al. 1997; Goel et al. 2008). It is also photosensitive, as changes 
in the light affect the stability of curcumin especially the solution form. 
 
 
Figure 1. 10 Chemical structures of curcuminoids 




Commercial curcumin powder presents in crystalline form. Crystal structure of 
curcumin exists in three different forms (Sanphui et al. 2011), forms 2 and 3 are 
known as orthorhombic structure whereas form 1 is monoclinic structure 
(Sanphui et al. 2011). The variation between Form 1 and Forms 2 and 3 of 
curcumin is mainly the conformation of a curcumin molecule and its interaction 
through hydrogen bonding with neighbouring curcumin molecules (Sanphui et 
al. 2011; Thorat et al. 2014). In Form 1, the curcumin molecule has a curved 
and twisted conformation as a result of hydrogen bounding between 
neighbouring curcumin molecules (Sanphui et al. 2011; Thorat et al. 2014). In 
form 2 and 3, they have a linear and planar conformation (Sanphui et al. 2011). 
The difference between forms 2 and 3 is only the keto-enol orientation of 
curcumin molecules packed in the unit cell (Sanphui et al. 2011; Thorat et al. 
2014). In form 2 the keto-enol groups in 2 molecules are cis in orientation, 
whereas in form 3 are in trans in orientation (Sanphui et al. 2011; Thorat and 
Dalvi 2015). Also the colour of the curcumin polymorph is distinguishable 
visually, as form 1 has a yellow-orange and form 2 and 3 have a red-orange 
colour (Liu et al. 2015). The onset melting point of curcumin form 1 is about 
177ºC, whereas the form 2 and 3 are 171ºC and 168ºC, respectively (Sanphui 
et al. 2011). 
 
 






Figure 1. 11 Crystal packing of curcumin polymorphs (Cambridge Structural 
Database), F1 is curcumin form1, F2 is curcumin form 2, and F3 is curcumin 
form 3 
1.4. Pulmonary drug delivery  
Drugs delivered to the lungs are generally used in the treatment of respiratory 
diseases such as bronchial asthma. Hence, they act locally. They can also be 
used systemically, as in the case of the treatment migraine with ergotamine 
(Aulton 2009). Administration of medication through the inhalation route has 
some advantages over the oral route. For example, administration through the 
inhalation route results in a more rapid onset of action with topical delivery to 
the respiratory system. This allows reducing medications dose, which could 
minimise the adverse effects of the drugs. It avoids the first pass effect in liver 




and in intestine that reduce the absorption of drugs. As well as this, the lungs 
provide a large surface area which is lipophilic in nature that helps to increase 
the absorption of poorly water soluble drugs. 
For respiratory drug delivery to take place, it is vital that the drug particles have 
very specific properties. These properties are important in allowing the drug to 
deposit in the correct location (in the bronchioles) and hence producing the 
desirable effect of the medications.  
1.5. Method of producing particles for pulmonary delivery 
The size of the particles is the most important factor that must be considered in 
production of inhaled preparation. The required particles size for inhalation is 
about 1 to 5µm. There are different methods of producing such particles, these 
methods including milling, sonocrystallisation and others. 
1.5.1. Air jet milling: 
Milling is the most common technique in particle size reduction, and it is the 
most traditionally used method in inhalable particles productions. Milling of 
powder is divided to wet-milling or dry milling. In the wet milling, a spherical 
metal beads and vehicle (such as organic solvent or water with stabiliser) are 
used to produce the desirable particles. Particle size reduction is obtained due 
to collision between the metal balls and drug powder. This process has few 
disadvantages such as contaminations of the drug; this is resulting from impact 
between the instrument walls and used metal beads. Furthermore, high energy 
(temperature) could be produced during milling process which could leads to 
amorphous formations. This technique may need another process step, such as 
spry drying or freeze drying, to obtain the final products. In the dry milling 
methods, compressed air or gas such as nitrogen, can be used to decrees the 




particles size. The mechanism of the size reduction in this technique is based 
on particle-particle and particles instrument walls impactions. Figure 1.12 shows 
a schematic diagram of air jet mill microniser, which is composed of grinding, 
injection (feed) air, material feed channels, venturi system and collection 
container. The feed material is transferred from inlet funnel into the grinding 
chamber through air vacuum which is created by venturi system from the 
injection pressure. The compressed air is forced into the grinding chamber 
through nozzles at high velocity. This high velocity of the air accelerates 
particles which leads to particles-particles collision and particles instrument wall 
impactions. Centrifugal force that developed inside the mill holds coarser 
particles in the outer area of the grinding chamber, until they are milled to finer 
particles, and allows the smaller particles to move towards the center and into 
the collection container at the bottom of the mill. The advantages of this 
technique, it is being simple, low metal contaminations, suitable for heat 
sensitive compounds, and less heat energy produced, due to absences of 
mechanical moving parts. Furthermore, it is very simple, easy to operate and 
inexpensive technique.  





Figure 1. 12 Schematic diagram of a spiral jet mill (Brodka-Pfeiffer et al. 2003) 
1.5.2. Sonocrystallisation 
Crystallisation is the formation of highly organised solid particles within a 
homogeneous phase (Deora et al. 2013). Crystals can be grown from a liquid 
phase within a solution. Any liquid solution which is saturated with a solute at a 
given temperature can be considered to be in a thermodynamic equilibrium 
(Deora et al. 2013). However, when the concentration of the solute in the 
solution exceeds its saturated (or equilibrium) concentration, crystallisation may 
occur (Deora et al. 2013). The crystallisation process is one of the most 
important techniques used in particle engineering and pharmaceutical industries 
as a method of production, purification and modification. Crystallisation is 
usually achieved throughout supersaturation, nucleation and crystal growth 
(Brito and Giulietti 2007; Bund and Pandit 2007). Supersaturation is an 
essential step in the crystallisation process and it is the driving force for 
nucleation and crystal growth (Visser 1982). A supersaturation solution can be 
defined as a solution that contains dissolved solutes other than can be found in 
saturation conditions (Mullin 2001). The supersaturation solutions are usually 




thermodynamically unstable, therefore the system will move back to the true 
saturation level, which then requires the excess of the dissolved solute to 
precipitate (Aulton 2009). The solute remains dissolved in the solution until a 
high level of supersaturation is achieved to induce a spontaneous nucleation; 
this extent of the supersaturation level is called a metastable zone width as 
shown in the solubility diagram in figure 1.13. The solubility diagram presents 
three zones which are the stable, metastable and unstable zones, in the last 
two zones (unstable and the metastable) the supersaturation solution is formed. 
In the unstable zone, nucleation spontaneously occurs, whereas in the 
metastable zone, no nucleation occurs which indicates the supersaturation itself 
is insufficient to form crystals (Shi et al. 1989; Shi et al. 2005). 
Nucleation is a small mass of the solute formation on which further crystal 
growth occurs (Aulton 2009). The nucleation is calcified as a primary and 
secondary nucleation, in the primary nucleation the nucleation occurs 
spontaneously or by adding foreign imputers or due to the wall of the container. 
In the secondary nucleation, a pre-existing solute of the same material is added 
to the solution to work as a templet (De Castro and Priego-Capote 2007). Once 
the nuclei are formed and being stable in a supersaturation system, they begin 
to grow to form crystals in a visible size (Rodríguez‐hornedo and Murphy 1999). 
A period of time elapses between the supersaturation solution achievement and 
the appearance of the crystal, this lag of time is usually called “induction time or 
period” (De Castro and Priego-Capote 2007; Patel and Murthy 2009).The 
induction time could be controlled or influenced by the supersaturation level, 
agitation, and viscosity (De Castro and Priego-Capote 2007). 




 Crystal growth is bringing more molecules of the solute to the nucleation site to 
form a defined shape and size of crystals (Aulton 2009). 
Crystallisation from solution remains the most used technique industrially. 
Typically, a supersaturation solution can be achieved by evaporation, cooling or 
by addition of another solvent, which is miscible with solution but it does not 
solubilise the solute; the second solvent is called an anti-solvent. The rate of the 
supersaturation, nucleation and crystal growth are critical in determination of the 
crystal properties such as size and shape (Deora et al. 2013). 
Sonocrystallisation is the use of ultrasound during crystallisation. Involving 
(application of) ultrasound irradiations on crystallisation has enhanced the 
crystallisation process by inducing rapid nucleation, narrowing metastable zone 
width, decreasing the induction time, producing uniform particle shape; 
inhibiting particle agglomeration and narrowing particle size distributions. 
 
 
Figure 1. 13 Solubility diagram shows metastable zone 
 




1.5.2.1. Mechanism by which ultrasound induces crystallisation 
Ultrasound produces waves that travel throughout the liquid forming a cavitation 
bubble with high energy and pressure (Richards and Loomis 1927; Suslick 
1998; Leonelli and Mason 2010; Deora et al. 2013). These waves are 
transmitted as a series of compression and rarefaction cycles affecting the 
liquid molecules (Suslick 1998; Leonelli and Mason 2010). A distance between 
the molecules is created on a rarefaction cycle which leads to forming a void; 
this is as a result of the rarefaction negative pressure that exceeds the attractive 
forces of the molecules (Hu et al. 2006; Leonelli and Mason 2010). This cavity 
contains a small amount of vapour from the surrounded solvent, so it does not 
collapse on compression but it continues to grow in successive compression 
and rarefaction cycles to form acoustic cavitation bubbles (Leonelli and Mason 
2010) as shown in figure 1.14. There are many of these bubbles, some of them 
are relatively stable (called transmission cavitation) and others keep expanding 
further to an unstable size and then collapse violently (called transient 
cavitation) (Leonelli and Mason 2010; Deora et al. 2013), producing a high local 
temperature (5000 K) and pressure of 2000 atms and heat cool rate of 1010 k/s 
(Suslick 1998; De Castro and Priego-Capote 2007). Moreover, US irradiation 
induces acoustic streaming which can be described as a steady fluid motion 
created under the influence of high amplitude acoustic waves, when they 
propagate through a dissipative fluid medium (Rayleigh 1884).  
The acoustic streaming and cavitation bubbles (microstreaming), and highly 
localized temperature and pressure within the fluid; bring considerable benefits 
to the crystallization process, such as rapid induction of primary nucleation, 
reduction of crystal size, inhibition of agglomeration, and manipulation of crystal 
size distribution (De Castro and Priego-Capote 2007). As the number of primary 




nuclei increases, the amount of solute on each primary nucleus decreases, thus 
decreasing the size of the final crystal (Louhi-Kultanen et al. 2006). 
Localised high pressure, agitation and temperature are attributed to influencing 
the nucleation during crystallisation as a result of increasing molecules which 
collide and increase the supersaturation level (Cains et al. 1998; De Castro and 
Priego-Capote 2007; Patel and Murthy 2009).  
The induction time and Metastable Zone Width has been reported to be 
influenced during ultrasound irradiation. This is by reducing the induction time 
and metastable zone width during crystallization (Thompson and Doraiswamy 
2000; Lyczko et al. 2002; Guo et al. 2005). 
 
Figure 1. 14 Formation of transient and stable cavitation bubbles by ultrasound 
(Leonelli and Mason 2010) 
 
1.5.3. Other methods 
There are few other methods can be used to produces inhalable particles. 
These techniques are the spray drying and supercritical fluids. They are usually 
costly and complicated. The spray drying consumes high energy which could 
produce amorphous products which are usually unstable. The supercritical fluid 
process a long time is required for particles productions. 




1.6. Factors affecting deposition of drug particles in the lungs 
1.6.1. Particle size 
The size of the inhaled particles is the most important factor that effects the 
deposition of these particles in the respiratory tract. Aerodynamic diameter is 
the physical diameter of a unit density sphere and is usually used to determine 
or measure the particle size of the aerosols. The size distribution is interpreted 
by geometric standard deviation (GSD). 
Particles need to be less than about 1- 5μm in aerodynamic diameter size to 
penetrate the airways (Bates et al. 1966; Telko and Hickey 2005). When the 
particles are greater than 5μm, they are more likely to settle in the upper 
respiratory tract. This includes the mouth and pharynx, so would be swallowed 
(Rees et al. 1982), whereas particles less than 0.5μm may not deposit in the 
lungs at all. It was found that particles with less than 2μm are more likely to 
deposit in the alveoli. As a result of these findings it has been recommended 
that for a potential lung deposition to take place, particles should be within the 
range of 1-5μm aerodynamic diameters (Usmani et al. 2003; Telko and Hickey 
2005). 
1.6.2. Inhalation technique 
Inhalation technique is another factor which affects the deposition of the drug 
particles in the lungs. The interaction between the inhaler-formulation and the 
patient inhalation manoeuvre (scheme) have an effect on  the volume of inhaled 
air, the flow of the inhalation, breath holding after inhalation and the lung 
volume at the beginning of the inhalation. All of these factors aid in the 
deposition of the drug particles in the patients lungs (Timsina et al. 1994; 
Yakubu 2009).  




Also in DPIs (Dry Powder inhalers), the flow and the time of the inspiration, the 
acceleration rate, the resistance to the flow of the inhaler device as well as the 
powder formulation are the most important factors that may affect the particle 
depositions (De Boer et al. 1996; Yakubu 2009).  
1.7. Method of administration of inhaled drugs 
1.7.1.  Dry powder inhalers (DPIs) 
DPIs are made of four function parts: the powder reservoir, metering system, 
the disintegration principles and a mouthpiece. There are two types of DPIs 
which are single dose inhaler and multi-dose inhalers. 
Currently there are two types of DPI formulation available on the market; 
spherical pellets and adhesive mixture. The spherical pellets formulation 
consists of agglomerated micronized particles which form a large spherical unit 
without binding agent. Lactose as a diluent may be added to the formulation 
when the dose is too low. This formulation of DPI needs to be disintegrated 
completely during the inhalation into fine particles in a respiration size to 
penetrate the respiratory system. The adhesive mixture formulation contains 
micronized drug particles and a coarse lactose carrier. The drug particles are 
attached to the surface of the carrier. This attachment of the drug-carrier must 
be released and free up the drug particles to penetrate the airways during the 
inhalation process. For the disintegration of the particles or for the drugs 
particles to be released from the surface of the carrier need a source of energy. 
This source of the energy is obtained from the patient’s inspiration flow.  





Figure 1. 15 Schematic diagram of the disintegration of spherical pellets 
through a specific disintegration mechanism, Reproduced from (Chrystyn 
2003) 
 
Table 1. 1 Advantages and disadvantages of DPI 
Advantages of DPIs Disadvantages of DPIs 
 
 Free of propellants  
 No need for patient 
co-ordination 
 Very rare for 
formulation problems 
 Good drug 
stability. 
 
 Performance based on 
the patients inspiratory flow  
 Resistance to airflow of 
the device 
 Difficulties to be 
protected from the 
environment effect 
 Difficulties to obtain 
dose uniformity and 
expensive 
 
1.7.1.1. Single dose inhaler system  
In this system, a specific amount (pre-metred dose) of the formulation of the dry 
powder is filled in a hard gelatine capsule. This capsule is loaded in inhaler 
devices such as Aerolizer. The capsules will be pierced at both ends before the 
inhalation. The disadvantage of this particular system is that some patients 




experience a difficulty of the loading procedure, especially those who are 
elderly. 
1.7.1.2. Multi-dose inhaler system 
In this system of inhalers two different types exist. These types are reservoir 
system and multi unite dose. In the former design, the formulation of the drug is 
stored in a container from which a single precise doses could be measured by a 
special dose metering unite. Accurate metering dose in this type of inhaler 
needs careful manipulation of the devices by the patients. An example for this 
system is the Easyhaler device. In the latter system, the formulation as single 
doses unit is filled in an appropriate dose compartment, such as a blister disk. 
Examples for these inhalers are Diskhaler and Accuhaler. 
1.7.2. Metered dose inhalers (MDIs)  
MDI or Pressurized Metered Dose Inhaler (pMDIs) is still the most commonly 
used inhalation formulation of medicines (Vaswani and Creticos 1998; Yakubu 
2009). MDI is composed of a canister in which the drug is dissolved or 
suspended in a liquid propellant. The predetermined dose is released on 
actuation of a metering valve which is fitted on the canister. The propellant 
produces a force to de-aggregate the particles and release them at high velocity 
which causes a high deposition in the oropharynges and also the cooling 
sensation contributes to the  oropharynges deposition (Fink 2000; Yakubu 
2009). Using MDI needs a co-ordination between the start of the inhalation and 
the actuation to produce the dose, which might be quite difficult to carry out 
correctly in children and elderly people(Crompton 1982; Yakubu 2009). 




1.7.3. Nebulisers  
Nebulisers, the oldest system for delivery of liquids to lungs, are devices that 
are able to convert a solution or suspension of medicines to aerosols mist in 
micron size which is suitable for inhalation. It is used for patients who are 
unable to use the MDI or DPI and it is more convenient for elderly patients and 
children (Fink 2000; Yakubu 2009). 
1.8. Curcumin formulations 
Development of curcumin complex formulation to avoid the low solubility of 
curcumin and poor bioavailability is an unmet challenge. Various attempts have 
been made to enhance curcumin solubility; this includes encapsulate curcumin 
in liposome (Torchilin 2005; Malam et al. 2009; Torchilin 2009), polymers as 
solid dispersion (Paradkar et al. 2004; Teixeira et al. 2016) and cyclodextrin 
(Tønnesen et al. 2002). These approaches have shown some degree of 
improvement but do not provide a practical and easy solution to the existing 
problem. Moreover, these formulations were intended for oral administrations as 
they are not suitable for inhalation. 
Inhalable curcumin particles have been recently reported in three articles as dry 
powder inhalers. These particles were prepared by supercritical fluid 
(Kurniawansyah et al. 2015), spray drying and freeze drying (Yu et al. 2016) 
and mechanical milling followed by spry drying (Hu et al. 2015). However, 
stabilisers and formulation enhancers such as polyvinylpyrrolidone 40K (1:1 w/w 
curcumin-PVP), Hydroxybutyl-β-cyclodextrin (1:4 w/w, curcumin- HB-β-CD) 
(Kurniawansyah et al. 2015), chitosan (1:1.16 curcumin-chitosan) (Yu et al. 
2016), and Tween 80 (6.25%) (Hu et al. 2015) have been used to produce 
these inhaled curcumin particles, which are not proved by FDA (Myrdal et al. 




2014; FDA 2016) and therefore, these formulations are not safe for lungs. 
Tween 80 and PVP 30K are approved by FDA at level of, 0.02% and 0.0001% 
respectively (Myrdal et al. 2014). There is no reported method for producing 
curcumin using either air jet milling or sonocrystallisation for dry powder inhaler 
formulation and with use of no excipients. There is only one study that used 
ultrasound in crystallisation of curcumin, in which curcumin polymorphs were 
investigated under using ethanol as organic solvent and water as antisolvent 
with different types of polymers (PVP, HMPC and BSA) and surfactants (tween 
80 and SDS) but the inhalation performance of the sonocrystallised curcumin 
particles was not assessed (Thorat and Dalvi 2014; Thorat and Dalvi 2016). 
Curcuminoids nanoemulsion for lung delivery has not been reported before. 
Therefore, one of the aims of this work is to prepare curcuminoids 
nanoemulsion for the potential treatment of lung cancer and other lung disease. 
Nanoemulsion formulations of curcumin have been reported to enhance the 
curcuminoids bioavailability and its activity when it has been applied locally onto 
skin or taken orally (Wang et al. 2008; Cui et al. 2009; Liu et al. 2011; Hu et al. 
2012). 
At the present, there is only a single formulation type for nebulisation of poorly 
water soluble compounds. Suspension formulations of water insoluble drugs 
(such as budesonide and beclomethasone) have been marketed and used by 
patients. In nebulised suspensions, large aerosols are required to carry the 
micron sized particles in suspension, therefore, it is likely that some aerosols 
droplets will contain no or small number of suspended drug (Knoch and Keller 
2005). Moreover, this formulation is usually associated with limited 
bioavailability, as the drug is in suspended in solid form, and low deposition 




pattern (Patravale and Kulkarni 2004). These formulations require shake before 
their use and show inconsistency when they used in different nebulisers 
(Nikander et al. 1999), therefore, an alternative formulation to nebulise water 
insoluble drug is required. 
Nanoemulsion is a preparation that provides a complete incorporation of water 
insoluble drugs in aqueous formulation, which could be nebulised. 
Nanoemulsion is a nanometre sized droplet of one liquid dispersed in another 
immiscible liquid, and it is generally optically transparent and thermodynamically 
stable(Bryant and Altria 2004). Nanoemulsion drug delivery systems have been 
used in different administration route, such as oral, parenteral and topical 
(Lawrence and Rees 2012). In addition to its small particles size (1-100nm), the 
nanoemulsion has the ability to solubilise both hydrophilic and hydrophobic 
drugs, hence increasing the bioavailability of the drug (Lawrence and Rees 
2012). There are few studies investigated nanoemulsions for respiratory drug 
delivery for water insoluble drugs such as budesonide, amphotericin B and 
ibuprofen (Amani et al. 2010; Nasr et al. 2012; Nesamony et al. 2014), but 
these formulations contain high amount of surfactant and hence this limits their 
safety on the lungs. Therefore, it has been proposed in this project to prepare a 
curcuminoid nanoemulsion using an extremely low amount of surfactant to 
avoid the formulation toxicity and to make it safer for inhalation. 
1.9. Nanoparticles genotoxicity 
There are some reports have shown that nanoparticles exert genotoxicity to 
cells by damaging their DNA (Chan 2006; Magdolenova et al. 2013). This is 
attributed to a direct interaction of the nanoparticles with genetic material, or 
indirect damage from nanoparticle-induced reactive oxygen species, or by 




releasing toxic ions (Kisin et al. 2007; Barnes et al. 2008). Nanoparticles, due to 
their unique size, have the ability to cross the cellular membrane and may reach 
the nucleus by diffusion across the nuclear membrane or by transportation 
through nuclear pore complex, and directly interact with DNA (Barillet et al. 
2010). Nanoparticles with size 8nm to 10nm enter through a nuclear pore, 
whereas larger nanoparticle size 15nm to 60nm may access to the DNA in the 
dividing cells during the mitosis when the nuclear membrane dissolves (Xing-Jie 
Liang 2008; Singh et al. 2009; Magdolenova et al. 2013). The nanoemulsion 
preparations is considered to be a nanoparticles based formulation, so their 
genotoxicity has been reported in this work. This could provide information in 
regard of the safety of the nanoemulsion preparation for further studies in 
future. 
1.10. In vitro method of assessment of drug deposition in the lung (using 
impaction method) 
In vitro lung drug deposition assessment is being used to assure the quality of 
dry powder inhaler formulation performance and to give a prediction of the 
particles deposition in the lung in vivo using parameters such as aerodynamic 
particle size distributions, fine particle dose fraction (FPD%) and total emitted 
dose. There are many different methods used in vitro to predict the particles 
deposition. However, the most common method is the inertial impaction method 
using cascade Impactors. 
The drug particles in the dry powder inhalers have an uneven shape, weight 
and surface area. This could be impossible to be described accurately by one 
variable. Therefore, particles are usually described by their aerodynamic 
diameter which is the diameter of a unit density sphere that has the same 




settling velocity in air as the particle. The aerodynamic diameter takes into 
consideration the density, shape and size of the particles (Hickey 2003; Yakubu 
2009). The mass median aerodynamic diameter (MMAD) of an aerosol is the 
diameter that separates the mass of particles equally by 50%.( i.e. 50% of the 
particles mass can be separated). According to BP and EP, the MMAD can be 
measured by plotting the cumulative particles mass versus the cut-off diameter 
on a log probability graph (Pharmacopoeia 2001). Geometric Standard 
Deviation (GSD) is used to determine the particles polydispersity (also 
described as the spread) of an aerosol. For the monodispersed inhalation 
particles, GSD is 1 and for the heterodisperse aerosol GSD is greater than 1.2. 
Fine Particle Dose represents the amount of the particles in the aerosol with an 
aerodynamic diameter less than 5µm which is able to penetrate the lungs 
(Newman et al. 1991a). As the label claims of many inhalers vary, for the simple 
comparison in terms of the performance, FPD is usually expressed as a 
percentage of the emitted dose to give the fine particle fraction (FPF%). The 
fraction dose gives an estimate of the fraction of the dose that has the ability to 
penetrate into the lungs (Fink 2000; Barry and O’Callaghan 2003). 
1.11. Principles of operation of cascade Impactor  
‘Impactor’ is a term used for the instrument where the particles can impact on a 
dry impaction plate or cup. Cascade Impactors act on the inertial impaction 
technique. The Impactor has a different number of stages and in each one there 
is a single or series of nozzles. The particles in the air stream are passed 
through these nozzles to the collection surface of the corresponding stage. 
Particles impacting on a particular stage are based on their aerodynamic 
particles size. The particles with sufficient inertia will impact at that stage, 
whereas the particles with small aerodynamic diameter and insufficient inertia 




will continue flowing in the air stream and pass onto another stage where the 
process is repeated. 
 
 
Figure 1. 16 Principle of cascade impactor operation (Reproduced 
from Copley, 2008) 
In some cases, particles might jump in response to impact when coming into 
contact with the surface of the collection plate or the stage. This might cause 
the particles to re-entrain into the air stream and to be carried into a lower 
stage. This particular issue could take place with DPI and some MDIs. This 
problem can be avoided by coating the collection plate or the stages with 
suitable surface coating (Allen 1990).  
The Impactor stages are assembled in order of decreasing particle size. The 
nozzles of the stages are getting decreased from one to another one, which 
increases the air velocity further and the finer particles are collected. The 
remaining particles are collected on a final filter. At the end of the procedure, 
the amount of particles in each stage collection plate is recovered using a 
proper solvent and then analysed using HPLC to determine the mass of the 
drug. Then, the fine particle dose, fine particle fraction and mass median 
aerodynamic diameter (MMAD) were calculated as well as the geometric 
standard deviation (GSD). 




1.11.1. Next Generation Impactor 
The Next Generation Impactor has been designed particularly for 
pharmaceutical inhaler testing. This cascade is provided with 7 stages, as 
shown in figure 1.17, and is designed to be operated at any inlet flow rate from 
30 L/min to 100 L/min for dry powder, and 15 L/min for nebulisers. The cut-off 
size at flow rate of 45 L/min and 15 L/min is presented in table 1.1. The NGI has 
several features to enhance its utility for inhaler testing: 
 Particles deposited on collection cups are held in a tray which can be 
separated from the impactor as a single unit, facilitating quick sample 
recovery.  
 The user can add up to approximately 40mL of an appropriate solvent 
directly to the cups for more efficiently.  
 The Micro-orifice Collector (MOC), in the collection cup, captures 
extremely small particles normally collected on the final filter in other 
impactors.  
 The particles captured in the MOC cup can be analysed in the same 
manner as the particles collected in the other impactor stage cups (Marple et 
al. 2003; Yakubu 2009).  





Figure 1. 17 Next Generation Impactor, (a) NGI including pre-separator and 
induction port, (b) NGI (open view) showing nozzles & collection cups, (c) NGI 
(open view) showing cup tray removed, (d) Collection cups showing typical 
deposition pattern (Reproduced from Copley, 2008) 
 
Table 1. 2 Lung cancer types and their distribution in the lungs and the 
corresponding cut off diameters (CFD) of Next Generation Impactor (NGI) at 
flow 15 and 45 L/min. 
Lung cancer types Locations 
CFD at flow 
45 L/min 
CFD at flow 
15 L/min 
1. Small cell carcinoma 
Secondary bronchus 
(Central zone) 




2. Non-small cell lung cancer 
 














2.3. Large cell carcinoma 
Secondary or tertiary 
bronchus 
S3, S4& S5 S5 & S6 
S: The stages of Next Generation cascade Impactor, CFE: Cut off diameter of NGI stages 




1.12. Hypothesis  
Lung cancer is the most common cause of cancer related death in the world. It 
is still the second most commonly diagnosed cancer in both men and women. 
Lung cancer is responsible for more than 15% of deaths worldwide. The 
incidence of lung cancer related deaths is higher than that of three other 
common cancers combined (colon, breast and prostate cancer). 
Studies have shown that curcumin is a potent anticancer and antioxidant 
compound. In addition, it is a very safe herbal drug even when consumed at 
high concentrations, as no side effects were reported when it was taken at 
quantities of up to 10g/day (Anand et al. 2007). However, the poor 
bioavailability of curcumin limits its use in clinical settings (Anand et al. 2007). 
The low bioavailability is a result of low absorption of curcumin because it is 
poorly soluble in water and also due to the first pass metabolism in the liver. 
Pulmonary delivery of curcumin as a dry powder inhaler and liquid- based 
formulation (nanoemulsion) would be beneficial, as curcumin will be directly 
delivered to the cancer cells in the bronchi, bronchioles or deep lungs. This will 
ensure longer contact of these cells to higher concentration of curcumin, while 
reducing the systemic side effect by minimizing the drug amount in the systemic 
circulations and other body tissues. The lung acts as a good medium for 
lipophilic drugs, as well as this; the first pass effect will be avoided through 
administration of drugs via inhalation. The nanoemulsion nebulised formulation 
will introduce curcumin in liquid form to the cancer cells. This may increase the 
curcumin effect at tumour site of the lungs. This is more likely to produce the 
desired effect when compared to other routes of administration. 




1.13. Aims and Objectives 
The aims of this research are: 
 To formulate and optimise a dry powder inhaler of curcumin without any 
formulation enhancers, such as polymers or surfactants, by air jet mill 
microniser and sonocrystallisation. 
 To develop and evaluate a nebulised formulation of curcumin using 
nanoemulsion (with minimum amount of surfactants) and microsuspension 
formulations.   
The objectives of this work are:  
 Development and validation HPLC method using microemulsion as 
mobile phase, and a conventional HPLC method for assay of curcuminoids. 
 Reduce the particle size of the raw materials of curcuminoids using air jet 
mill microniser into the optimum size, which is required for the DPI 
formulations. Mixing the micronized particles of curcuminoids with a carrier 
in different ratios for the best lung deposition. Determine the in vitro lung 
deposition of the micronized curcuminoids using NGI. 
 Sonocrystallisation of curcuminoids to obtain a suitable particles size for 
inhaler formulation of curcumin. Mixing the sonocrystallised curcumin with 
lactose in different ratios. In vitro assessment and evaluation of dry powder 
inhaler formulations performance using NGI.  
 Preparation of nanoemulsion of curcuminoids with a very low amount of 
surfactant for nebulisation, and in vitro aerosols characterisation of the 
nanoemulsion formulation using NGI. 




1.14. Thesis structure  
This thesis consists of eight chapters: 
 Chapter 1 involves a general introduction and back ground about lung 
cancer, curcumin and pulmonary drug delivery. 
 Chapter 2 includes the general methods and materials used in this work 
 Chapter 3 provides the development and the validation of HPLC methods 
using a conventional and nanoemulsion mobile phases for curcuminoids 
assay. 
 Chapter 4 describes the air jet milling method of raw material of 
curcuminoids, product characterisation, and the lungs deposition of DPI 
formulations, which are prepared from milled particles of curcuminoids. 
 Chapter 5 presents the sonocrystallisation procedure of curcumin, 
characterisation of the processed materials and the lung deposition 
behaviour of DPI formulations, which are prepared from sonocrystallised 
particles, using NGI. 
 Chapter 6 describes the nanoemulsion preparations, the formulation 
characterisation, and the aerosols performance of the nebulised 
formulations using NGI, as well as the genotoxicity of the nanoemulsion 
formulations.  
 Chapter 7 is the general conclusion and the future work 
 Chapter 8 is the references  





Materials and Methods 
 
 




2 Chapter 2: Materials and Methods 
2.1 Materials 
 Acetonitrile, HPLC grade, (Fisher Scientific, UK).  
 1-Butanol, HPLC grade, 99%, (Alfa Aesar, UK). 
 Ethanol, HPLC grade, 99% ,(Alfa Aesar, UK) 
 Acetone, HPLC grade, (Fisher Scientific, UK). 
 Isopropanol, HPLC grade, (Fisher Scientific, UK). 
 Heptane, HPLC grade, (Sigma-Aldrich, UK) 
 Hexane, HPLC grade, (Sigma-Aldrich, UK) 
 Octane, HPLC grade, (Sigma-Aldrich, UK) 
 Nonane, HPLC grade, (Sigma-Aldrich) 
 Chloroform, HPLC grade, (Fisher Scientific, UK). 
 Ethyl acetate HPLC grade, (Fisher Scientific, UK). 
 Isopropyl myristate, (Alfa Aesar, UKC) 
 Sodium dodecyl sulphate (SDS), (Alfa Aesar, UK ) 
 Potassium dihydrogen phosphate, (Alfa Aesar, UK) 
 Orthophosphoric acid, (Fisher Scientific ,UK) 
 Glycerol 99%, (Alfa Aesar, UK) 
 Brij® L23, (Sigma-Aldrish, UK) 
 α-Lactose monohydrate (Lactohale LH200), (DFE Pharma, Germany) 
 Pure and commercial curcuminoids, (Alfa Aesar, UK ) 
 Oleic acid oil, 99%, (Alfa Aesar, UK ) 
 Limonene oil, 97%, (Sigma-Aldrich, UK) 
 Polysorbate 80 (Tween 80), (Alfa Aesar, UK). 
 Sodium chloride, (Sigma-Aldrich, UK) 




 Low-melting point agarose, (Sigma-Aldrich, UK) 
 EDTA, (Sigma-Aldrich, UK) 
 Tris base, (Sigma-Aldrich, UK) 
 DMSO, (Sigma-Aldrich, UK) 
 Tirton X-100, (Sigma-Aldrich, UK) 
 NaOH, (Sigma-Aldrich, UK) 
 EDTA phythaemagglutinin (PHA), (Sigma-Aldrich, UK) 
 RPMI 1640 medium (with L glutamine and 25mm Hepes), (Sigma-Aldrich, 
UK) 
 Compressed air 
2.2 Instruments and Apparatus 
2.2.1 Apparatus used in high performance liquid chromatography (HPLC) 
 Pump and autosampler: Hewlett packard 1050 system with a multiple 
solvent delivery system connected to an auto sampler with a variable 
injection loop 
 Detectors: Variable wavelength UV detector HP 1050 series 
 Integrators: Prime multichannel data station (Ver 4.2.0) (HPLC 
technologies, Herts, UK) 
 HPLC columns: Phenomenex C18 magellen, 250mm X 4.6mm i.d X 5µm 
(Phenomenex, Macclesfield, Chesire, UK). Phenomenex, Gemini-NX C18, 
250mm X 4.6mm i.d X 5µm (Phenomenex; Torrance, USA). 
2.2.2 Apparatus used in particle size reduction (air jet mill) 
 Spiral air jet mill, FPS 241, (FPS, Italy). 




2.2.3 Ultrasound instrument 
 Sonics vibra-cell (VCX 500 with net power output ~ 500 W, attached to a 
sonotrode with a tip diameter of 13 mm) 
2.2.4 Apparatus used in particles characterisation and analysis   
 Laser diffraction particle size analyser, sympatec HELOS (H2419) & 
RODOS/M 
 DLS (Dynamic light scattering), Zetasizer Nano ZS (Malvern Instruments, 
Uk) 
 Differential scanning calorimeter (DSC), Serial NO 2000-0843, (TA 
Instruments, West Sussex, UK). 
 Powder x-ray diffractometer (PXRD), serial NO 202288, (Bruker, 
Kahlsruhe, Germany). 
 Scanning electron microscope (SEM), Serial No XTE 235/D 7875, (FEI, 
Cambridge, UK). 
 Carbon coater (Emitech, Kent, UK). 
 Inverse gas chromatography (IGC), surface measurement system Ltd 
(SMS), UK) 
2.2.5 Apparatus and software used to evaluate the in vitro particle 
deposition of dry powder inhalers and nanoemulsion formulations 
 Next generation cascade impactor (Copley Scientific, Nottingham, UK) 
 Critical flow controller model TPK , (Coply Scientific Ltd, Nottingham, UK). 
 Electronic flow meter model DFM, (Coply Scientific Ltd, Nottingham, UK). 
 Copley inhaler testing data analysis software (CITDAS), version 2.00, 
(Coply Scientific Ltd, Nottingham, UK). 
 Inhaler device: Easyhaler. 




 Nebuliser : sidestream jet nebuliser 
2.2.6 General laboratories apparatus  
 Ultrasonic bath (Decon Laboratories,  Hove, UK). 
 Syringe filter 0.22 micrometer pores size, (Scientific Resources Inc, NJ, 
UK) used for HPLC samples filtration.  
 Nylfao®, nylon membrane filters 0.45µm pore size (Pall Gelman) used for 
HPLC mobile phase filtration. 
 Thermo-micro balance  
 ELGA ultrapure water dispensing system, (High Wycombe, UK). 
 pH meter 
2.3 Methods 
2.3.1 Air jet milling for particle size reduction of curcuminoids 
The imcronisiation of raw material of curcumin was assessed using FPS spiral 
jet mill (FPS, Italy).  
 
Figure 2. 1 A spiral jet mill (FPS,Italy) 
 




The FPS spiral jet mill is made of a labofeeder and labomill. The labofeeder was 
connected with labomill and the then connected to power supply . All the parts 
of the spiral jet mill were held together by connection clamps. The injector, 
grinder and shaking lines of the labomill were appropriately attached too. A 
champer filter provided from the manufacturer was placed in the vibration part 
of the apparatus. The labofeeder was controlled by a switch placed on the front 
of the sprial jetmill. The sample feed rate was operated by a speed controller 
which was set at the moderate rate for each of the samples. The products were 
collected from the container after micronse 5g of the sample was produced. The 
gas which was used in this work was compressed air and adjusted up to 10 bar 
pressure. The injection pressure line was then opened to the required level and 
then the grinding pressure was opened too. The pressure of these two lines 
was controlled through an injector/grinding pressure regulator on the front of the 
sprial jetmill. The pressure reading was recorded from the injector/grinding 
pressure display. The labofeeder was then switched on and the sample started 
passing from the sample unit to to the mill chamber. The products were then 
collected from a container placed in the bottom of the mill and stored in silica 
discade to prevent moisture affecting the sample before the characterisation 
test is carried out. 
2.3.2 Sonocrystallisation of curcuminoids 
Appropriate amount of curcumin was dissolved in organic solvents (good 
solvent) by increasing the solvent temperature accordingly. Known volume of 
the antisolvent (bad solvent) was placed in a jacket vessel at adjusted 
temperature of five Celsius degrees, the ultrasound system were adjusted at the 
required sonication time and amplitude power, the ultrasound probe was 




immersed just below the bad solvent surface. The drug solvent, after it has 
been filtered, was added into the antisolvent and the ultrasound switched on at 
the simultaneously with addition of drug solvent. The ultrasound was removed 
and cleaned after completion the sonication process. The drug suspension was 
filtered using filter paper and left to dry at room temperature. The powder was 
collected and kept for characterisations.  
2.3.3 Nanoemulsion preparations for nebulisation of curcuminoids  
Nanoemulsion of curcuminoids was prepared by dissolving sufficient amount of 
the drug in a pre-measured and mixed amount of oil, surfactant and co-
surfactant. The mixture of the drug with nanoemulsion ingredients was then 
mixed well till the drug was dissolved, and then known amount of ultrapure 
water was added slowly into the previous mixture with vigorous shaking till a 
clear solution was seen. The nanoemulsion was sonicated using a sonication 
bath for about 10 mins. Suitable amount of sodium chloride was added into the 
nanoemulsion preparation for osmolality adjustment. 5ml of the nanoemulsion 
formulation was filtered into jet nebuliser chamber for aerolisation 
characterisation. 
2.3.4 Powder particles characterisation 
2.3.5 Thermal method of analysis 
 Differential scanning calorimetry (DSC):  
It is a widely used technique in thermal analysis to study and evaluate any 
phase transition and changes in polymorphic structure of a substance after 
processing or during storage. It is the measurement of the variation of the total 
energy which is required to increase the temperature of a sample and is used 




as an inert reference as a function of temperature. Both the sample of interest 
and the reference are kept up at the same temperature during the experiment. 
The temperature program in the DSC experiment is programmed in such a way 
that the temperature of sample holder increases linearly as a function of time. 
 
 
Figure 2. 2 Schematic diagram of DSC 
 
The mechanism of DSC process is as follows, when the physical state of the 
sample undergoes to transformation such as phase transition through the 
process, a heat will be needed to flow to or from the sample in order to keep the 
sample and the reference at the same temperature. The flow of the heat to or 
from the sample depends on whether the process is endothermic or exothermic. 
An example being if a sample which is in its solid state changes to a liquid state, 
which would require a higher rate of heat flow maintain a temperature close to 
that of the reference. This is a result of the heat absorbed by the sample due to 
endothermic phase transition from solid phase to a liquid phase.  Similarly, 
when the sample undergoes an exothermic transition, for example in the case 
of crystallisation, less heat is required to increase the sample temperature. This 




variation in heat flow between the sample and the reference will be measured 
by DSC and it represents the amount of absorbed and/ or released heat in the 
phase transitions. 
In this work, DSC module of the TA Instrument Q2000 Series Thermal analysis 
System   (TA Instrument, West Sussex, UK) was used in DSC analysis. 
Samples were weighed into an aluminium pan. An aluminium lid, with a central 
hole, was crimped on to the pan. The samples were then heated under nitrogen 
gas stream from 25-250ºC using heat rates of 10ºC/min. All the samples were 
analysed in duplicate. The temperature scale was calibrated using a pure 
indium standard (melting point 156.60ºC) and was confirmed using a zinc 
standard (melting point 419.5ºC). 
In this study, DSC analysis is used to see if the polymorphic structure of the 
produced curcumin remains stable after processing the raw material by Air Jet 
mill microniser and sonocrystallisation. 
2.3.6 X-ray powder diffraction (XRPD)  
XRPD is a great tool for crystalline solid evolution. By XRPD, the solid structure 
and the packing between molecules can be completely determined.  Any 
change in crystallinity state or polymorphic form can be detected by XRPD. This 
data is often very helpful when trying to understand the chemistry solid state of 
the substances of drugs. 
In this experiment XRPD analysis is used to see if the polymorphic structures of 
the processed material stay stable after reducing the raw material particle size 
by Jet mill microniser and sonocrystallisation. 




2.3.7 Particle size analysis 
Particle size was assessed for both the raw materials and the processed one 
using a Laser Diffraction Particle Size Analyser (Sympatec HELOS & RODOS 
dry dispersion unit, Sympatec Instruments, UK). Approximately 15-20mg of the 
sample was fed into the analyser by using an ASPIROS unit, under air pressure 
of 4 bars at a speed of 30 mm/sec. Trigger conditions were at five seconds at 
an optical concentration of one percent (1%). 
In laser diffraction, as the particles pass through a laser beam, light is scattered 
in response to the particles at an angle which is directly related to their sizes, 
figure 2.3. The scattering angle increases logarithmically with decrease in 
particles size. The particle distribution in laser diffraction is based on the 
comparison of the scattering pattern of the samples with a suitable optical 
model. This model considers measured particles as spherical (Aulton 2009). 
Measurement of non-spherical particles in laser diffraction may show an 
oversized and hence have exaggerated size distribution. This is due to the 
deviation from the spherical model used in the processing of data. 
 
 
Figure 2. 3 Schematic diagram of particles size analyser via laser 
diffraction 
 




2.3.8 Scanning electron microscope (SEM)  
Scanning electron microscope can give a high resolution image using electron 
beams instead of light for particle surface texture, topography, shape and size. 
SEM was performed using a Quanta 400 SEM (FEI Company, Cambridge, UK).  
Electron beams are produced from an electron gun placed at the top of the 
microscope and follow a vertical path through electromagnetic fields and lenses, 
which point the beams down to the sample, under a vacuum. When the beams 
hit the sample, electrons and x-rays are reflected from the sample. Theses 
reflections are collected by detectors and a screen similar to a television screen 
produce the sample image (Mohamed 2009). 
 
 
Figure 2.4 Schematic diagram of SEM (Adapted from 
www.purdue.edu/REM/rs/sem.htm) 
 




All samples were coated with a thin layer of gold using Sputter Coater. This is 
due to the use of conditions under a vacuum and electrons so there becomes a 
need to make the non-metal samples conductive by covering them with a thin 
layer of conductive materials. When using sputter coater an electric field and 
argon gas are used. 
2.3.9 Powder surface free energy characterisation 
The free surface energy of curcumin was characterised using inverse gas 
chromatography (IGC) by injecting a series of n-alkanes (hexane to nonane) 
and two polar probes (ethyl acetate and chloroform). In this work, surface 
energy of curcumin particles was correlated to its aerodynamic performance 
during inhalation.  
The surface free energy or surface energy (  ) is defined as the energy that 
creates a unit area of surface. The total free surface energy is composed of 
different physical forces and it is usually divided into several components 
(Grimsey et al. 2002) . Materials have non-polar (dispersive) forces, and most of 
the materials have polar forces such as hydrogen bonding or acid base forces 
(Fowkes 1964; Grimsey et al. 2002). Therefore, the surface free energy is split 
into dispersive (
d) and polar (specific 
sp ) components, thus the total free 
energy is the sum of both energies of the dispersive and the specific energy 






s          (1) 
Where, 
total
s is the total free surface energy of the solid, 
d
S  dispersive surface 
component of a solid, 
sp
s  is specific free energy of the solid. 




2.3.10 Surface energy calculation method 
To obtained dispersive and specific components of a powder using inverse gas 
chromatography, a series of homologous n-alkane (hexane to nonane) and two 
polar probes (i.e. ethyl acetated and chloroform) are injected into a packed 
column with the sample of interest and the elution time (tr) of the probes is 
recorded, the retention time measures a magnitude of interaction between the 
injected probes (non-polar and polar probes) and the stationary phase (packed 
samples). 
The methods reported by Mohammad (Mohammad 2013; Mohammad 2015) 
were used to calculate the surface energies of the processed curcumin 
samples. These methods describe the surface properties using the dispersive 
retention factor 𝐾𝐶𝐻2
𝑎  , the electron acceptor retention factor 𝐾𝑙+
𝑎 , and the 
electron donor retention factor 𝐾𝑙−
𝑎 , which are calculated using the measured 
retention times of probes: 
 The dispersive retention factor is calculated from the following eq. (2) 
ln tn= (ln KCH2
a ) n + C   (2) 
Where tn is the net retention time of the n-alkane probes, n is the carbon 
number of the homologous n-alkanes,KCH2
a  is the dispersive retention factor of 
the analysed powder and C is a constant. 
The tn is calculated from the (eq. 3) 
tn = (tr − t0)      (3) 
Where, tr and t0 (Dead time) are the retention times of the n-alkanes and a non-
adsorbing marker, respectively. 





















                 (4) 
The γs
d  of the powder is determined using eq. 5 
γs
d =




  mJ.m-2                 (5) 
The parameters of CH2 are calculated from Eq. 6  
 
(αCH2)
2 γCH2= - 1.869T + 1867.194   Å
4.mJ.m-2           (6) 
Where, T is the sample column temperature in kelvin 
 The electron acceptor and donner retention factors,Kl+
a  and  Kl−
a  , are 
calculated using eq. 7 and 8 
Kl+
a = tnl+ tnl+,ref⁄                (7) 
Kl−
a = tnl− tnl−,ref⁄                 (8) 
l Monopolar electron acceptor probe (e.g., dichloromethane or chloroform), 
l  is Monopolar electron donor probe (e.g., ethyl acetate or toluene), tnl+ and 
tnl+,ref are the retention time of  l+ and its theoretical n-alkane reference, 
respectively, tnl− and tnl−,ref are the retention time of l− and its theoretical n-
alkane reference, respectively.  
The  tnl−,ref , tnl+,ref  are calculated from eq. 9 and 10 








0.5 ) ln KCH2
a      (9) 













0.5 ) ln KCH2
a          (10) 
Where αCH2 , γCH2
, αCi , γCi
d , αl+ , γl+
d , , αl− and γl−
d  are the cross–sectional area 
and the dispersive free energy of a methylene group, an n-alkane, l+ and l−, 
respectively.  tnCi  is the retention time of the n-alkane. 
The retention factors are then used to calculate the electron donner ( 
S ) and 
acceptor ( 
S ) and component of a solid: 
γs
− =
0.477 (T ln 𝐾𝑙+
𝑎 )2 
(𝛼𝑙+)2 𝛾𝑙+
+   mJ.m
-2     (11) 
γs
+ =
0.477 (T ln 𝐾𝑙−
𝑎 )2 
(𝛼𝑙−)2 𝛾𝑙−
−   mJ.m
-2      (12) 
Where,  𝛾𝑙+
+  is the electron acceptor component of 𝑙+ ,  𝛾𝑙−
−  is the electron donor 
component of 𝑙−, and T is the sample column temperature in kelvin. The units of 
𝛼 are Å2 and of 𝛾 are mJ.m-2  in all equations. 
The parameters of polar probes are still under debate and different values were 
reported (Schultz et al. 1987; Van Oss et al. 1988; Della Volpe and Siboni 1997; 
Della Volpe et al. 2004; Das et al. 2010; Shi and Qi 2012). In this work, we 
considered the values which were recently used for ethyl acetate ( 𝛾𝑙−
− = 19.20 
mJ/m2, 𝛾𝑙−
𝑑 = 19.60 mJ/m2, 𝛼𝑙−= 48.0 Å
2) and for chloroform ( 𝛾𝑙+
+ = 3.80 mJ/m2, 
𝛾𝑙+
𝑑 = 25.90 mJ/m2, 𝛼𝑙+= 44.0 Å
2) (Das et al. 2010; Mohammad 2013). 
 The specific free energy of the solid particles is calculated as shown in 
eq.11 
 5.0).(2  ss
sp
s   




 Work of cohesion ( cW ) between curcumin particles is calculated eq.  
 total
cW 2  
 Work of adhesion ( aW ) between curcumin and lactose carrier particles is 
































2 , are dispersive and the specific energy of lactose carrier particles, 
respectively 
2.3.11 High performance liquid chromatography (HPLC)  
1.14.1.1. Preparation of conventional mobile phase  
The conventional mobile phase was prepared by mixing (55% V/V) of 
acetonitrile HPLC grade with (45% V/V) of phosphate buffer solution of 10mM in 
a volumetric flask. This solution was then filtered under vacuum using 45mm 
nylon filter and degassed by sonication under vacuum for 15 minutes. 
1.14.1.2. Preparation of microemulsion mobile phase  
A microemulsion mobile phase was prepared by weighing a phosphate buffer 
solution (% w/w), surfactant (% w/w), oil (% w/w), and co-surfactant (% w/w) in 
a volumetric flask with shaking to obtain an optically transparent solution. This 
mixture was then sonicated for 15 minutes to assure that all ingredients were 
dissolved. This microemulsion was then filtered under vacuum using a 0.45µm 




nylon filter to remove any particles that could block the HPLC system. The 
mobile phase is degassed by sonication under vacuum for 15 minutes.  
1.14.1.3. Analytical method validation 
The HPLC methods were developed and validated according to ICH and FDA 
guidelines. The validation parameters that were assessed are as follows: 
2.3.5.1.1 Linearity:  
A linearity curve is the relationship between the instrument response and known 
concentrations of the analytes.  According to ICH (1996) and FDA (2001), the 
linearity is the ability of the analytical method to give results which are directly 
proportional to the defined concentrations of the analytes. The linearity is 
usually determined by a series of five different concentrations of analytes with a 
replicate measurement.  
The regression line is represented by the following equation: y=mx + c 
Whereas C is the intercept point with y-axis, M is the slope of the regression 
line.  The correlation coefficient (R2) represents the degree of linearity of the 
relationship (the relationship between the obtained results and their 
concentrations). When the coefficient R2 produces a value of one, this suggests 
that complete linearity relationship exists. 
2.3.5.1.2 Sensitivity: 
The sensitivity is represented by the Limit of Detection (LOD) and the Limit of 
Quantification (LOQ).  Limit of Detection is the lowest concentration of the 
sample or the analytes which could be detected by the analytical method but 




not necessary to quantify it. LOD is determined by using the standard deviation 
(ICH 1996). 




Where, σ is the standard deviation of Y-intercept and S is the slope of the 
calibration curve. 
Limit of Quantification is the lowest amount of the sample which can be 
quantified by the applied assay with an acceptable level of accuracy and 
precision.  LOQ is determined by the following equation:  




Where, σ is the standard deviation of Y-intercept and S is the slope of the 
calibration curve. 
2.3.5.1.3 Precision: 
The precision is the closeness of the agreement (degree of scatter) between a 
series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions. It is determined by 
using a minimum of five determinations for each concentration. It is 
recommended to use three concentration levels in the range of expected 
concentration. Precision is divided into intra-day precision (within the days) and 
inter-day precision (between the days). The precision is expressed as the 
relative standard deviation as a percentage (RSD%) which is known as 
coefficient variation (CV). 





The accuracy of analytical methods expresses the closeness of agreement 
between the obtained values and the true values of the analytes. According to 
ICH (1996) and FDA (2000) guidelines, it is measured by a minimum of five 
determinations for each concentration.  
1.14.1.4. Preparation of phosphate buffer solution for mobile phase  
Appropriate amount of buffer salts was weighed and transferred to a volumetric 
flask. ELGA deionised water was then added and the solution was sonicated 
before being made up to the required volume. The pH of the buffer was then 
corrected by using an appropriate acidic or alkali solution before filtrations 
through a 0.45µm membrane filter. The pH meter was calibrated at pH 4.0 and 
7.0 using commercial buffer solutions. 
1.14.1.5. Stock solution preparation  
A suitable amount of curcumin powder was weighed and transferred to a 
volumetric flask. Then the mixture of acetonitrile and phosphate buffer solution 
was added and sonicated for 10 minutes to aid dissolution of curcumin. The 
solution was made up to the required volume which was then filtered through a 
syringe filter (0.33µm diameter) to remove any un-dissolved materials.  
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3 Chapter 3: Development and validation of HPLC methods for the 
determination of curcuminoids in aqueous solution 
3.1 HPLC assay for curcuminoids using conventional mobile phase 
3.1.1 Introduction  
High performance liquid Chromatography is the most widely used technique for 
qualitative and quantitative determination of drugs in separation science. 
Compounds to be separated are distributed between a stationary phase and a 
mobile phase which carries the solutes through the column. Reversed phase 
chromatography is the most popular for separation of drugs and their related 
substances. In the reversed phase chromatography, a polar mobile phase and 
non-polar stationary phase are utilised where the separation of samples is 
related to their affinity for both the stationary phase and the mobile phase. 
Several HPLC methods were reported for curcuminoids determinations and 
separations. However, most of these methods have some disadvantages, such 
as unsatisfactory separation times (Kulyal et al. 2016), poor resolution 
(Wichitnithad et al. 2009) and/or complicated solvent mixtures (Jayaprakasha et 
al. 2002) and high flow rate (Jadhav et al. 2007; Wichitnithad et al. 2009). Some 
of these methods were applied only for curcumin determination without 
considering demethoxycurcumin and bisdemethoxycurcumin (Ma et al. 2007; Li 
et al. 2009; Kim et al. 2016). 
In this work the conventional HPLC method is developed and validated to 
separate the three components of the curcuminoids, curcumin (C), 
demethoxycurcumin (DC) and bisdemethoxycurcumin (BDC), using emodin as 
an internal standard, with a good resolutions and proper separation time and 




flow rate. This method will be used for determination of curcuminoids amount in 
Next Generation Impactor stages. 
3.1.2 Method 
1.14.1.6. HPLC conditions: 
Stationary phase (column): Phenomenex C18µm  
Mobile phase: Acetonitrile and 10mM orthophosphate buffer (55%:45% v/v) 
adjusted to pH 3.0. The mobile phase was filtered through 0.45μm nylon filter 
and degassed under vacuum in ultrasonic bath for 15 mins before use. 
Internal standard: Emodin 40µg/ml 
Flow rate: 1 ml/min 
Detector: UV set at wavelength of λ= 420nm 
Integrator: Prim software (HPLC technology Ltd) 
Injection volume: 30µL 
Standard solution: 10mg of pure curcumin, demethoxycurcumin and 
bisdemethoxycurcumin powder were accurately weighed and dissolved in 
100ml flask of mobile phase solution and stored in a refrigerator. From the stock 
solution, serial dilution was made using aqueous solution of internal standard to 
prepare the standard solutions with the following concentrations 2.5, 10, 20, 40, 
60 and 80µg/ml and 40µg/ml for Emodin. The prepared samples were stored in 
light resistant volumetric flask and kept in refrigerator.  




3.1.3 Method development 
Curcumin, demethoxycurcumin and bisdemethoxycurcumin are non-polar 
compounds and very similar in their structure with a difference in the presence 
or absence of methoxy groups (O–CH3), so this means they are very similar in 
their polarity too. Optimising the mobile phase condition was very critical, mobile 
phases with varying compositions were prepared (70%:30%, 60%:40% and 
50%:50% as acetonitrile: buffer solution (v:v). the results showed that the 
amount of acetonitrile had a dramatic effect on the separations of the 
compounds. This might be attributed to the fact that acetonitrile is very selective 
for the methoxy group in each of these compounds. Poor separation and peaks 
overlapping was observed by increasing the acetonitrile above 55% (v/v). On 
the other hand, increasing in the retention time was observed in decreasing the 
acetonitrile below 55% (v/v). Furthermore the buffer concentration affected the 
separation too, peaks interfering observed by raising the buffer concentration 
above 10mM, where there was a slight increase in the retention time with 
decreasing the buffer concentration below 10mM. 
The separation of the mixture of three pure curcuminoids including the internal 
standard was achieved in 13 minutes as shown in the figure 3.1. The retention 
time for curcumin, demethoxycurcumin and bisdemethoxycurcumin was at 7.8, 
7.2 and 6.7 minutes, respectively, whereas the retention time for emodin (IS) 









Figure 3.1 Chromatograms of curcumin (C), demethoxycurcumin (DC), and 
bisdemethoxycurcumin (BDC) with emodin using conventional HPLC method 
 
3.1.4 Method validation  
The method was validated for the determination of curcuminoids in aqueous 
samples. The method validation was based on ICH guidelines (ICH 1996). 
1.14.1.7. Linearity  
To determine the linearity of the HPLC response, different concentrations of 
curcumin, demethoxycurcumin and bisdemethoxycurcumin solutions ranging 
from 2.5μg/ml to 80µg/ml were prepared. The samples including emodin 
40µg/ml as internal standard were injected twice. Blank samples were analysed 
during the experiment. The plots of the results showed a linear relationship 
between the response (peak eras) and the concentrations, Figure 3.2. The 
regression coefficient R2 for curcumin, demethoxycurcumin and 
bisdemethoxycurcumin are shown in Table 3.1. 




Table 3.1 Regression coefficient, intercept, and the slope of curcuminoids 
components using 55%:45%v/v of acetonitrile: phosphate buffer mobile phase, 
flow rate 1 ml/min, λ=420nm, injection volume: 30µl 
Drugs R² Intercept Slope 
Curcumin 0.99 0.27 0.09 
Demethoxycurcumin 0.99 0.3 0.15 
Bisdemethoxycurcumin 0.99 0.15 0.139 
 
 
Figure 3. 2 Calibration curve of curcumin (RC), demethoxycurcumin (RD) and 
bisdemethoxycurcumin (RB) using mobile phase of 55%:45%v/v (acetonitrile: 
phosphate buffer) 
 
1.14.1.8. Sensitivity  
Sensitivity is represented by the limit of detection and the limit of quantitation.  
LOD and LOQ were calculated using the following equations: 







































Where, 𝜎 is the standard deviation of Y-intercept and S is the slope of the 
calibration curve. 
The LOD and the LOQ data are illustrated in Table 3.2.  
Table 3.2 Limit of detection and limit of quantification of curcuminoid 
using the conventional method 
 
Curcumin Demethoxycurcumin Bisdemethoxycurcumin 
LOD 1.16µg/ml 1.48µg/ml 1.20µg/ml 
LOQ 3.54µg/ml 4.50µg/ml 3.64µg/ml 
 
 
1.14.1.9. Precision  
The precision is expressed as the relative standard deviation (RSD%). It was 
tested by six determinations at three levels of known concentrations, low 
(10µg/ml), medium (40µg/ml) and high (80µg/ml) levels in the range of the 
calibration curve. These experiments were repeated for five days under the 
same conditions to determine the inter-day precision. Both inter- and intra-day 
precisions were determined by calculating the relative standard deviation 
(RSD%). The lower the RSD% value the better the performance of the method. 
RSD% data for both inter-day and intra-day are shown in table (3.3). 
 
 








Curcumin Demethoxycurcumin Bisdemethoxycurcumin 
10µg/ml 0.47 0.2 0.15 
40µg/ml 0.15 0.11 0.1 
80µg/ml 0.15 0.12 0.08 
intra-day RSD % 
Sample 
concentrations 
Curcumin Demethoxycurcumin Bisdemethoxycurcumin 
10µg/ml 0.35 0.33 0.27 
40µg/ml 0.11 0.14 0.17 
80µg/ml 0.15 0.13 0.17 
 
1.14.1.10. Accuracy 
Accuracy of analytical method measures the closeness of the test results to the 
true concentration of the analytes. This test needs three different known 
concentrations (low, medium, high) within the linearity range to be analysed 
each one  six times. The accuracy was then calculated by dividing each value of 
six samples of each level by the true concentration, the accuracy results of this 
method are addressed in Table 3.4. 








Curcumin Demethoxycurcumin Bisdemethoxycurcumin 
10µg/ml 97.06 101.69 103.51 
40µg/ml 96.85 102.52 99.96 
80µg/ml 97.75 97.27 102.158 
 
3.1.5 Conclusion  
In conclusion, the conventional method for curcuminoids separation using 
acetonitrile and phosphate buffer solution (10mM) as a mobile phase(55%:45%) 
with internal standard (emodin) was linear, sensitive, precise and accurate. The 
analysis time was 13 minutes. The compounds were very sensitive to the 
concentration of acetonitrile and to the buffer solution. 
3.2 HPLC assay for curcuminoids using microemulsion mobile phase 
3.2.1 Introduction  
Microemulsion is a nanometre sized droplet of one liquid suspended or 
dispersed in another immiscible liquid. Microemulsion is usually composed of oil 
dispersed in water or water dispersed in oil. The oil and water are completely 
immiscible and this is because there is a high surface tension between them 
(Bryant and Altria 2004). Therefore adding a surfactant to reduce this surface 
tension will allow an emulsion to form. Nevertheless, for a microemulsion to be 
created the surface tension needs further reducing to zero, this can be 
approached by adding a small chain of alcohol, which is called co-surfactant, 
such as 1-butanol (Bryant and Altria 2004). 




Microemulsion is generally optically transparent and thermodynamically stable. 
The ratios of oil-water-surfactant and co-surfactant must be correct to obtain a 
stable microemulsion system; otherwise the microemulsion will not be formed or 
will decompose into two layers water and oil in short time. So the composition 
ratio of microemulsion needs to be taken into consideration.  There has been an 
increase using microemulsion in HPLC as an eluent and in separation science 
and this is due to its selectivity compared to conventional method. 
There are two types of microemulsion used as mobile phase in HPLC, oil in 
water and water in oil. The oil in water microemulsion is where the oil is 
dispersed in a continuous phase (water), and this type is used in a reversed 
phase chromatography. The other type is water in oil microemulsion, in this type 
the water is dispersed in the oil phase as droplets and it used for normal phase 
chromatography. 
The mechanism of separation in HPLC is due to the partitioning of the solutes 
between the stationary phase and the mobile phase. This theory is being 
altered in the use of microemulsion as an eluent; this is because of a surfactant 
layer is adsorbed onto the stationary phase surface. Also a second partitioning 
mechanism is created, which is where the solutes partition into the droplets 
from both the stationary and the mobile phase. In O/W microemulsion, water-
insoluble substances are involved in the oil droplets. The retention of the 
hydrophobic compounds is highly influenced by the partitioning into oil droplets 
of the microemulsion. Water-soluble substances stay in the aqueous phase and 
the retention is mostly controlled by the interaction of the solutes with the 
stationary phase. The hydrophobic droplets are also allocated to the surface of 




the stationary phase and thereby affect  solutes selectivity and the retention (El‐
Sherbiny et al. 2003; Marsh et al. 2005).  
Berthed used O/W microemulsion of heptane, 1-pentanol, SDS and aqueous 
orthophosphate buffer in separation of series of alkyl benzenes and in quick 
screen of 11 drugs used illegally in sport (Berthod et al. 1992; Marsh et al. 
2005). 
Alex March (2005) also studied the use of microemulsion of Octane, 1-n 
Butanol, SDS and aqueous orthophosphate buffer in separation of different 
compounds, such as a wide range of acidic, basic and neutral drugs and 
excipients, and the effect of each parameter on the retention (Marsh et al. 2005) 
El-Sherbiny (2005 and 2007) worked on the evaluation of the use of the 
microemulsion as an eluents in HPLC for the separation of flunarizine in the 
presences of some of its degradation components and on determination of 
loratadine and desloratadine in a pharmaceutical dosage form using octane, n-
butanol, SDS and aqueous orthophosphate buffer (El‐Sherbiny et al. 2005; El-
Sherbiny et al. 2007).  
Mohammad Althanyan (2011) used octane, 1-n-butanol, SDS and aqueous 
orthophosphate buffer , as microemulsion, in determination of some inhaled 
drugs such as formoterol and salmeterol in urine samples (Althanyan et al. 
2011). Another microemulsion was also prepared by using ethyl acetate, Brij35, 
1-butanol and aqueous orthophosphate buffer for determination of terbutaline 
sulphate in urine samples (Althanyan et al. 2016). 
AL-Jammal (2015) and Li (2016) have used a microemulsion as a mobile 
phase, which is composed of octane, 1-n-butanol, SDS and aqueous 




orthophosphate buffer, in determination of nifedipine and hydrochlorothiazide 
and losartan in pharmaceutical preparations such as tablet (AL-Jammal et al. 
2015; Li et al. 2016) 
In this work, microemulsion of isopropyl myristate, 1-n-butanol, SDS and 
aqueous orthophosphate buffer, is used to separate curcumin, 
demethoxycurcumin and bisdemethoxycurcumin to benefit from the advantage 
of using microemulsion over the conventional method.  
The microemulsion has two phases, so it has a great capacity of solubility for 
both hydrophilic and hydrophobic analytes (Marsh 2005), which can provide  
fast separations. For oil in water microemulsion, the retention time of the 
lipophilic substances can be reduced compared to conventional methods in 
which the organic solvent gradients are necessary (Marsh 2005). Also in O/W 
microemulsion, the majority composition is water which is around 90% and just 
ten percentages is organic solvent including the surfactants, whereas in the 
conventional method that was developed for the determination of curcuminoids 
contains more than 50% of organic solvent which is more expensive and 
environmentally unfriendly. 
In this part, it is proposed to study the application of microemulsion for the 
analysis of curcuminoids in aqueous solution and to examine the effects of 
experimental parameters on the separation of curcuminoids. 
3.2.2 HPLC conditions 
The experiments were carried out under the following conditions: 
Stationary phase (column):  Phenomenex C18  




Mobile phase:  0.8% isopropyl myristate (IPM), 9% 1-n-butanol, 2.7% SDS and 
88.7% (10mM) phosphate buffer solution (all w/w). 
Flow rate: 1 ml/min 
Detector:   UV set at wavelength λ=420nm 
Injection volume: 30µL 
3.2.3 Method development  
The first few experiments were carried out using the typical microemulsion 
mobile phase in which the octane was used as the oil. It was reported that this   
mobile phase separates a variety of drugs (Miola et al. 1998; Altria 1999; 
Mahuzier et al. 2001). It is usually composed of 0.8% octane (as an oil phase), 
3.3% surfactant (SDS), 6.6% co-surfactant (butan-1-ol) and 89.3% phosphate 
buffer solution 5mM (as aqueous phase). However, this mobile phase was 
unable to separate the curcuminoids components. This might be attributed to 
the low solubility of the solutes in the oil phase. The limited solubility of 
curcuminoids in the octane was very clear after dissolving a few milligrams of 
the curcuminoid samples in the oil. Hence, octane oil was replaced with 
isopropyl myristate (IPM); The IPM was able to solubilise the curcuminoids 
more than octane. IPM was also used in some drug delivery formulations of 
microemulsion of curcumin (Chen et al. 2005). The new mobile phase with 
isopropyl myristate was able to separate the solutes with acceptable retention 
time as shown in figure 3.3. 
 





Figure 3. 3 Separation of curcuminoids using microemulsion using isopropyl 
myristate as oil phase, C is curcumin, DC is demethoxycurcumin and BDC is 
bisdemethoxycurcumin. 
 
The components concentrations of the new mobile phase were optimised to 
reduce the retention time of the solutes. The optimum concentrations of the new 
mobile phase components were as follows:  
0.5% IPM, 2.7% surfactant (SDS), 9% co-surfactant (butan-1-ol) and 87.8% 
phosphate buffer solution 10mM (pH.3). The amount of individual components 
of the mobile phase was prepared as w/w. The optimised mobile phase 
significantly reduced the retention time of the solutes. Figure 3.4 shows the 
reduction in the retention time. The concentrations of these parameters have 
been studied in detail in the next section. 
 





Figure 3. 4 Chromatograms of curcuminoids using microemulsion as an eluent, 
C is curcumin, DC is demethoxycurcumin, and BDC is bisdemethoxycurcumin. 
 
3.2.4 Factors affecting the HPLC separation using microemulsion 
There are five parameters that affect the separation of curcuminoids using 
microemulsion as the mobile phase. These parameters comprise of surfactant, 
co-surfactant, oil and buffer solution and temperature. It was found that the 
concentrations of these parameters affect the retention time and the resolution 
of the compounds. 
1.14.1.11. Surfactant concentration  
The effect of different concentrations of SDS on the retention time of solutes 
was studied. It was found that as the SDS concentration is increased, the 
retention time of the curcuminoids decreases  and it was noticed that the peak 
resolutions is sensitive to the SDS. This is because of the fact that an increase 
in the surfactant concentration increases the  distribution of the solutes into the 
microemulsion, as well as increases the volume of the microemulsion in the 
mobile phase (El‐Sherbiny et al. 2003; Marsh 2005). This effect is more 
applicable for the solutes that have a greater affinity to the oil droplets; this 
means that the hydrophobic solutes will be more affected by changing the 




surfactant concentration than the hydrophilic ones (El‐Sherbiny et al. 2003; 
Marsh 2005). The analytes with no affinity to the oil droplets will not be affected 
by changing the concentration of the surfactant, and also the retention of the 
more hydrophobic compounds will be influenced to a superior degree due to 
their distribution into the droplets (El‐Sherbiny et al. 2003; Marsh 2005; McEvoy 
et al. 2006). Furthermore, it was reported that surfactants could adsorb on the 
column’s stationary phase and modify the surface of the stationary phase 
(Berthod et al. 1992). Hence, this influences the partitioning properties between 
the solutes and the stationary phase.   
The effect of SDS concentration on the separation of curcuminoids was 
assessed by preparing several mobile phases with different concentration of 
SDS ranging from 1.5% to 2.8%. It was found that the retention time of 
curcumin, demethoxycurcumin and bisdemethoxycurcumin decreased with 
increasing the SDS concentration. Increasing the concentration of SDS above 
2.8% led to an increase in the back pressure of the column which caused a halt 
in the system. Nevertheless, the microemulsion was not formed when 
decreasing the concentration of SDS below 1.5%. Figure 3.5 presents the effect 
of the SDS concentrations on the retention time of the compounds. 





Figure 3.5 The effect of SDS concentrations on the retention time of 
curcuminoids, SDS is sodium dodecyl sulphate, C is curcumin, DC is 
demethoxycurcumin, and BDC is bisdemethoxycurcumin. 
 
1.14.1.12. Co-surfactant concentration  
The use of co-surfactants such as butan-1-ol can also influence the satiability 
and the formation of the microemulsion system. Figure 3.6 illustrates the effect 
of changing the concentrations of buatn-1-ol.  It was found that raising the 
concentration of the co-surfactant from 6.6% to 11% w/w reduced the retention 
time of the curcuminoids components. However, a further increase in the 
concentrations led to a loss in the separation resolution of the solutes and an 
increase in the column pack pressure in the system. The reduction in the 
retention time of the solutes is attributed to the increase in the organic phase of 
the microemulsion system (Marsh 2005; McEvoy et al. 2006) and therefore 
enhancing the solubility of these solutes in the mobile phase by increasing the 

































Figure 3.6 The effect of butanol concentrations on the retention time of 
curcuminoids, C is curcumin, DC is demethoxycurcumin, and BDC is 
bisdemethoxycurcumin.  
1.14.1.13. Oil concentration  
The oil is dispersed as micro-droplets in a continuous water phase to form 
microemulsion with aids of surfactant/co-surfactant which are located on the 
interfaces between the oil and water (Mason et al. 2006; Althanyan 2011). The 
concentrations and the type of the oil used in the HPLC microemulsion have a 
noticeable effect on the retention time of the analytes. This effect is based on 
the nature of the analytes. The effect of oil concentration on the separation of 
curcuminoids has been examined in the range from 0.3% to 0.8% w/w. Figure 
3.7 demonstrates the effect of these concentrations on the retention time of the 
curcuminoids. The results show that increasing the concentration of the oil 
decreases the retention time of the curcumin, demethoxycurcumin and 
bisdemethoxycurcumin. This could be attributed to the increase of the solubility 
of the solutes in the mobile phase. Increasing the oil above 0.5% has a slight 
































Figure 3.7 The effect of IPM concentrations on the retention time of 
curcuminoids, IPM is isopropyl myristate oil C is curcumin, DC is 
demethoxycurcumin, and BDC is bisdemethoxycurcumin.  
 
1.14.1.14. Buffer concentration  
The effect of phosphate buffer concentrations on separation of the curcuminoids 
solutes was investigated at three levels 10, 15 and 20mM. Figure 3.8 illustrates 
the effect of changing the buffer concentrations on the retention time of the 
solutes. The retention time decreased when the concentration of the buffer 
solution of the mobile phase increased. These results are in agreement with 
those reported by Mao et al. (2001). However, the study reported by Mao et al.  
was carried out using conventional mobile phase; this shows that the retention 
time of solutes decreased with increasing buffer concentrations, whether the 
































Figure 3.8 The effect of buffer concentrations on the retention time of 
curcuminoids, C is curcumin, DC is demethoxycurcumin, and BDC is 
bisdemethoxycurcumin. 
1.14.1.15. Temperature  
The effect of the column’s temperature was investigated at three different 
temperatures ranging from 25°C to 45°C.  Figure 3.9 displays the effect of 
increasing the temperature on the separation time of curcuminoids solutes. It 
was found that increasing the temperatures decreases the retention time. 
Increasing the temperature lowers the viscosity of the microemulsion and hence 
reduces the column back pressure. This decrease in the viscosity may influence 
the distribution and the solubility of the solutes in the microemulsion system and 
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Figure 3. 9 The effect of temperature on the retention time of curcuminoids, C 
is curcumin, DC is demethoxycurcumin, and BDC is bisdemethoxycurcumin. 
 
3.2.5 Method validation  
The method was validated for the determination of curcuminoids in aqueous 
solution. The method validation was based on ICH guidelines (ICH 1996). 
1.14.1.16. Linearity  
To determine the linearity of HPLC response, different concentrations of 
curcumin, demethoxycurcumin and bisdemethoxycurcumin solutions ranging 
from 2.5µg/ml to 80µg/ml were prepared. The samples including emodin 
40µg/ml as internal standard were injected twice. Blank samples were analysed 
during the experiment. The calibration curve showed a linear relationship 
between the response (peak area) and the concentrations, Figure 3.10. 
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Table 3. 5 Linearity data of curcuminoids components using microemulsion 
mobile phase 
Samples R² Intercept slope 
Curcumin 0.99 0.33 0.09 
Demethoxycurcumin 0.99 0.44 0.15 
Bisdemethoxycurcumin 0.99 0.17 0.13 
 
 
Figure 3. 10 Calibration curves of curcuminoids using microemulsion mobile 




Sensitivity is represented by the limit of detection and the limit of quantitation.  
LOD and LOQ were calculated using the following equations: 


































Where, 𝜎 is the standard deviation of Y-intercept and S is the slope of the 
calibration curve. 
 The LOD and the LOQ data showed in Table (3.6). 
Table 3. 6 Limit of detection and Limit of quantification data of curcuminiods 
using microemulsion mobile phase 
 
Curcumin Demethoxycurcumin Bisdemethoxycurcumin 
LOD 1.20µg/ml 0.81µg/ml 0.70µg/ml 
LOQ 3.63µg/ml 2.47µg/ml 2.14µg/ml 
 
1.14.1.18. Precision  
The precision is expressed as the relative standard deviation (RSD%). It was 
tested by six determinations at three levels of known concentrations, low 
(10µg/ml), medium (40µg/ml) and high (80µg/ml) levels in the range of the 
calibration curve. These experiments were repeated for five days under the 
same conditions of the HPLC to determine the inter-day precision. Both inter- 
and intra-day precision were determined by calculating the relative standard 
deviation (RSD%). The lower RSD% value the better is the precision of the 








Table 3. 7 Inter-day and intra-day precision data of curcuminoids using the 




Curcumin Demethoxycurcumin Bisdemethoxycurcumin 
10µg/ml 0.52 0.34 0.33 
40µg/ml 0.57 0.3 0.42 




Curcumin Demethoxycurcumin Bisdemethoxycurcumin 
10µg/ml 0.25 0.72 0.76 
40µg/ml 0.58 0.57 0.5 
80µg/ml 0.42 0.37 0.36 
 
1.14.1.19. Accuracy  
Accuracy of analytical method measures the closeness of the experimental 
value to the true concentration of the analytes. The accuracy of the method was 
assessed at three different concentration levels (low, medium, and high) within 
the linearity range and each level was repeated six times. The accuracy was 
then calculated by dividing each value of six samples of each level by the true 
concentration. The accuracy results of this method are shown in Table 3.8. 
 








Curcumin Demethoxycurcumin Bisdemethoxycurcumin 
10µg/ml 96.25 101.84 97.78 
40µg/ml 98.38 96.5 99.15 
80µg/ml 100.8 99.06 99.02 
 
3.2.6 Conclusion  
The separation of curcuminoids was achieved by using two HPLC methods, 
which are the conventional and microemulsion methods. Both methods showed 
good results in terms of sensitivity, linearity, precision and accuracy. The 
microemulsion method was more sensitive for both demethoxycurcumin and 
bisdemethoxycurcumin than conventional methods. There was no difference in 
the sensitivity of both methods for curcumin. The results appear to be much 
closer to each other in both methods regarding the precision, the accuracy and 
the linearity. 
In the conventional method, the separation time for curcuminoid components 
including the internal standard was 13 minutes. On the other hand, 18 minutes 
was required to complete the separation in the microemulsion method.  In the 
conventional technique, about 50% of the mobile phase is organic solvent, 
whereas about 90% of the mobile phase in the microemulsion is aqueous 
solution, which is inexpensive and environmentally friendly.  
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4 Chapter 4: Production of inhaled curcumin particles using air jet 
milling technique 
4.1. Introduction 
Air jet milling method is the simplest milling technique used to reduce size of 
powder particles. A compressed air is used in this process to accelerate the 
particles speed and leads to particles-particles and particles instrument wall 
collisions and impactions, which in turns cause a break of the particles to a 
smaller size (Letang et al. 2002; Protonotariou et al. 2015). Also attrition occurs 
at solid surfaces of the particles as they move rapidly, in the high velocity of 
stream air, against each other, resulting in shear forces that could break the 
particles down (Loh et al. 2015). Air jet micronisation has many advantages 
over other mechanical milling methods, such as absence of product 
contamination with metal (Shariare 2011), and it is suitable for heat sensitive 
components, as less temperature is generated during the milling (Saleem and 
Smyth 2010).  
It has been reported that air jet microniser reduces the particle size of 
salbutamol sulfate (Brodka-Pfeiffer et al. 2003; Shariare et al. 2011a), and 
fenoterol hydrobromide (Brodka-Pfeiffer et al. 2005) below 5µm that allow them 
to be suitable for dry powder inhaler formulation. In DPI preparation, the API 
must be in respirable size of 1-6µm for optimal lung deposition (Pritchard 2001; 
Telko and Hickey 2005). Therefore, air jet mill has been used to investigate its 
ability to produce inhalable curcumin particles. 
In this work, inhaled curcumin particles were prepared and formulated by a 
simple method without any excipients or additives, which makes these DPI 
formulations safer and available for patients. Also in this work, the aerodynamic 




behaviour of all curcuminoids components (curcumin, demethoxycurcumin and 
bisdemethoxycurcumin) was determined.  
The processed curcumin particles have been characterised for their size, 
shapes, polymorphism alterations and the inhalation performance. The laser 
diffraction and scanning electron microscope were used to determine the size 
and shape of milled curcumin particles, respectively. The differential scanning 
calorimetry and XRPD were utilised to assess any changes in curcumin 
polymorphism after comminution. The inverse gas chromatography was used to 
examine the free surface energy of the powder before and after milling, and to 
correlate the surface energy with inhalation profile of curcumin particles. Dry 
powder inhalers (DPI) formulations were prepared by mixing the micronized 
curcumin particles with α-lactose monohydrate at two different ratios (1:9 and 
1:67.5 curcumin:lactose). Several formulations were prepared for two different 
sizes of micronized curcumin particles that have a D50 of 3.5µm and 2.5µm. DPI 
formulations were then characterised using Next Generation Impactor. The 
FPF%, MMAD and GSD were determined for each of curcuminoids components 
(curcumin, demethoxycurcumin and bisdemethoxycurcumin). 
4.2. Methods 
4.2.1. Method of milling a start material of curcumin using jet mill 
Curcuminoids’ powder was micronized by FPS spiral jet mill (FPS, Italy).The 
micronisation process was manipulated by changing grinding pressure (GP), 
injection pressure (IP) as it is shown in table 4.1. The pressure of these two 
lines was controlled through an injector/grinding pressure regulator with 
pressure display on the front of the spiral jet mill. A compressed air was used to 
create these pressures and it is adjusted up to 10 bars pressure. The injection 




pressure line was first opened to the required level and then the grinding 
pressure was opened too. The lowest and the highest pressure level of both 
injection and grinding that can be used in this machine are two and seven bar. 
During conduction the experiments, firstly, both lines of the jet mill were 
gradually increased from 2 bars to 6 bars, secondly, the injection pressure was 
kept at 7 bars and then the grinding pressure increased gradually from 2 to 4 
bars as it can be seen in experimental parameter table 4.1. In operating the jet 
mill, the injection pressure needs to be either equal to or higher than grinding 
pressure, otherwise high vacuum pressure will be generated inside the 
microniser which leads the product to disperse to the filter. In each run of the 
experiments, 5g of curcuminoids was used and then collected after one minute 
intervals from a container at the bottom of the spiral jet mill. The feed rate was 
kept constant to a medium level for all the experiments. This is because it has 
been reported that feed rate has no effect on the particles size reduction of 
powder (Brodka-Pfeiffer et al. 2003). 
  




Table 4. 1 The jet mill parameters setting, grinding pressure (GP) and Injection 
pressure. 
Experiment No GP (Bar) IP (Bar) 
1 2 2 
2 3 3 
3 4 4 
4 5 5 
5 6 6 
6 2 7 
7 3 7 
8 4 7 
 
4.2.2. Surface energy analysis 
Surface energy, of curcumin and lactose powder, was determined by an 
automated inverse gas chromatography (IGC) system (Surface Measurement 
Systems Ltd, London, UK). Powder samples were filled into a pre-silanised 
standard glass column (3mm internal diameter and 30cm long; SMS). All 
samples columns were packed by tapping for around 5 min using a jolting 
volumeter (Surface Measurement Systems Ltd, London, UK). For each 
samples, the experiment was repeated five times. Prior each first measurement 
of each sample, the system was conditioned for 2 hours, at temperature of 30ºC 
and 0% relative humidity. Non polar and polar probes were injected into the 
packed samples using helium as carrier gas (mobile phase) with a flow rate of 




10 ml/min at temperature 30ºC. Several non-polar probes were used including 
hexane, heptane, octane and nonane while the polar probes were chloroform 
and ethyl acetate (Schultz et al. 1987; Van Oss et al. 1988; Van Oss 1993). The 
net retention time of non-polar solvents were used to calculate the dispersive 
energy, whereas, net retention time of the polar probes were used to measure 
the specific surface energy of powder (Mohammad 2013).  
4.2.3. Surface energy calculation method 
See section 2.3.9.  
4.2.4. Blending of micronized curcumin with α-lactose 
The dry powder inhaler formulations of curcumin were prepared for the different 
sizes of micronized curcuminoids (D50=3.5µm and 2.5µm) by mixing the 
particles of each of the sizes with α-lactose monohydrate (Lactohale200® 50-
100μm) as a carrier. In DPI formulations, α-lactose is used as a carrier in order 
to enhance the performance and flowability of the formulation (Telko and Hickey 
2005; Kou et al. 2012). Lactose is considered to be an inert compound with 
non-toxicology profile (Pilcer et al. 2012). Lactose particles characteristics such 
as size, shape and surface morphology have an effect on the DPI performance 
(Kou et al. 2012). It has been reported by Steckel and Muller that the drugs 
concentrations to the lactose (carrier) have an effect on the fine particle fraction 
and the drug deposition in the lung (Steckel and Muller 1997; Adi et al. 2008; 
Kou et al. 2012). Therefore, two different formulations of curcuminoids-lactose 
concentrations were prepared. The ratios of these formulations were 1:9 and 
1:67.5 (curcuminoids-lactose w/w). Each of these formulae (2g) was mixed for a 
different length of time to obtain the most homogeneity sample using a tumbling 
shaker mixer. The blending times were one, five, ten and thirty minutes. The 




homogeneity (uniform) mixing was then examined by taking three samples from 
each formulation and analysed by HPLC. The percentage RSD (relative 
standard deviation, n=3) for each mixing time was calculated individually. One 
gram of powder of the most uniform formulation after blending was transferred 
into an Easyhaler device to assess the aerodynamic particles characterisation 
using Next Generation Impactor (NGI). 
4.2.5. Aerodynamic particle size characterisation 
Procedure to setup the next generation impactor (NGI):  The next generation 
impactor has been designed to have 7 stages with a Micro-orifice collector. It 
can be operated at inlet flow rate from 30 L/min to 100 L/min. It is composed of 
three parts: the bottom part which is a frame that holds the impaction cups, the 
upper part which is the seal part holding the nozzles and finally the lid that has 
the inter-stage passages as shown in figure 4.4. The collection cups were 
coated with glycerol and allowed to dry for about 10 minutes before running the 
experiment. The cups were placed in the bottom frame and the lid of the 
impactor was closed. An amount of 15ml of suitable solvent was placed into the 
central cup of the pre-separator. The use of the pre-separator is recommended 
by USP (United States Pharmacopeia Convention. 2004) for dry powder inhaler 
testing in order to entrain the active ingredient that is attached to the larger 
carrier particles (United States Pharmacopeia Convention. 2004). The induction 
port was then connected to the pre-separator which was also connected to 
impactor body. A suitable mouth piece adaptor was connected to the induction 
port to ensure there was no loss in the sample between the inhaler devices and 
the induction tube.  A vacuum pump was connected to the NGI, to obtain the 
desired flow rate throughout the flow controller. The inhalation flow rate was 
determined to be equivalent to 4kpa pressure drop across the inhaler device 




(United States Pharmacopeia Convention. 2004). This was equal to a flow rate 
of 45 L/min. A calibrated electronic flow meter was used to measure the flow 
rate each time before the inhaler devices connected to the induction port. The 
inhalation time was calculated by using the following equation (European 
Directorate for the Quality of Medicines & HealthCare. 2008): 
𝑇 =  (60 𝑠𝑒𝑐 𝑥 𝑉) / 𝑄 
T = Time duration consistent for withdrawal of 4 litres of air from the inhaler 
Q = Airflow which produces a pressure drop of 4 KPa 
V = 4 L to be drawn through the inhaler 
According to the above equation the time required for the flow rate of 45 L/min 
is 5.5 seconds. 
Dry powder inhaler formulations of curcumin were loaded into the Easyhaler, 
which was then connected to the induction port through an air tight chamber to 
ensure that it was in isolation from the atmosphere pressure as it is presented in 
figure 4.2 (Yakubu 2009). The dose was discharged from the Easyhaler into the 
NGI at flow rate of 45 L/min for 5.5 seconds. An experiment was carried out for 
each formulation three times. The deposited particles in the stages was then 
recovered by HPLC mobile phase and was analysed using HPLC. 
 









Figure 4. 2 Setting up the NGI for DPIs characterisation 
 
Calculations of FPF%, MMAD and GSD: 
The aerodynamic parameters, for each DPI formulations, have been calculated 
using Copley Inhaler testing data analysis software (CITDAS). The deposition 
profile and the aerodynamic characterisation of curcumin (C), 
demethoxycurcumin (DC) and bisdemethoxycurcumin (BDC) were determined 
for each formulation.  




These parameters were calculated as follows:  
I. Fine particle fraction (FPF):  
𝐹𝑃𝐹 =  (𝐹𝑃𝐷/𝑇𝑜𝑡𝑎𝑙 𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑑𝑜𝑠𝑒) ∗  100% 
Where fine particle dose (FPD), as specified by CITDAS, is the amount of the 
drug with aerodynamic diameter less than 5µm. The fine particle dose (FPD) is 
the amount with particles that correspond to a size less than 5μm (Telko and 
Hickey 2005).The total delivered dose is the total amount of the drug that 
deposited in throat, pre-separator and the NGI stages. 
II. The Mass median aerodynamic diameter (MMAD): 
 MMAD was calculated from the logarithm of the ECD (effective cut-off 
diameter) corresponding to 50% undersize particles (on probability scale).  
III. The Geometric standard deviation (GSD): 
GSD was calculated from the following equation:  
𝐺𝑆𝐷 =  √((𝑑84.13% / 𝑑15.87%))    
 Where d84.13%, and d15.87% are the aerodynamic particle size at 15.87% 
and at 84.13% less than the stated size, respectively for the cumulative size 
distribution.  
The mean and SD of the FPF, MMAD, and GSD were determined for each 
formulation using Microsoft excel. 
4.2.6. HPLC method 
The HPLC method for determining the amount of curcuminoids in each stage of 
NGI has been described in chapter 3. Section3.1 




4.3. Results and discussion 
4.3.1. Particle size analysis 
The mean size of the milled curcumin particles, D10, D50 and D90, are presented 
in table 4.2.  
Table 4. 2 The mean (n=3) and the standard deviation (SD) of the curcumin 
particles size before and after milling. 
Experiment No D10 (µm) +/- SD D50 (µm) +/- SD D90 (µm) +/- SD 
1 0.82 +/- 0.04 2.44 +/- 0.55 5.86 +/- 1.31 
2 0.89 +/- 0.06 2.23 +/- 0.42 5.54 +/- 1.57 
3 0.70 +/- 0.11 1.90 +/- 0.75 3.94 +/- 0.87 
4 0.79 +/- 0.01 1.85 +/- 0.02 3.96 +/- 0.12 
5 0.82 +/- 0.1 1.79 +/- 0.03 3.60 +/- 0.08 
6 0.96 +/- 0.01 3.21 +/- 0.03 7.71 +/- 0.45 
7 0.91 +/- 0.02 2.65 +/- 0.06 5.83 +/- 0.04 
8 0.84 +/- 0.04 1.88 +/- 0.13 4.75 +/- 0.81 
Start material 1.49 +/-0.48 7.85 +/- 2.77 41.3 +/- 12.54 
 
It is clear that the jet mill microniser using compressed air was able to reduce 
the particle size of curcumin (D50) down below 5µm. The size was further 
reduces by increasing the grinding and injection pressure. In the experiments (1 
to 4) in which both grinding and injection pressure raised from 2 bars to 6 bars 
gradually, the D50 of the particles was decreased simultaneously from 7.82µm 
to 1.79µm. Keeping the feed pressure (injection pressure) to the maximum (7 




bars) while raising the grinding pressure gradually, from 2 bars to 4 bars, 
showed a reduction in the curcumin particles size from 7.95µm to 1.88µm. The 
data above indicates that increasing the grinding pressure (GP) decreases the 
particle size. This may be as a result of the increasing particles and particles 
collisions and particles instrument wall impactions, which in turn leads to break 
the curcumin particles down (Brodka-Pfeiffer et al. 2003). This observation was 
in agreement with a reported study on particles size of reduction using the jet 
mill microniser (Shariare et al. 2011b; Protonotariou et al. 2015; Angelidis et al. 
2016; Kou et al. 2016). It has been observed that when grinding pressure 
increased more than 6 bars, the yield of the product was reduced. This may be 
due to the high vacuum inside the microniser that was generated by grinding 
pressure which caused the product to disperse to the filter. This work shows the 
ability of jet mill to reduce curcumin raw material with a particle size of 7.85µm 
(D50) and 41.3µm (D90) to inhalable particle size (D50 below 5µm). The 
micronized curcumin particles with size of (D50) 3.5µm and 2.5µm were chosen 
for further characterisation and for dry powder inhaler formulations.  
4.3.2. Morphology of the air jet milled curcumin particles using scanning 
electron microscope (SEM) 
The morphology (particle shape) of pulverised curcumin particles were analysed 
using SEM. Figure 4.3 shows SEM images of the unprocessed and the triturate 
curcumin particles. Raw curcumin particles exhibit irregular shapes (Figure 
4.3A). The milled curcumin (2.5µm) formed agglomerated particles as shown in 
figure 4.1 B, C and D, compared to the unprocessed curcumin. The particle 
shape of the micronized curcumin looks like partially rounded. The micronized 
particles with a size of 3.5µm (D50) shows to be less agglomerated compared to 
the particles with size of 2.5µm. this could be attributed to the difference in their 




particles size, since the smaller particles gain high energy and (including) static 
charges as they have intense energy during the milling process, therefore, 
particles aggregate to lower their total surface energy (Van Eerdenbrugh et al. 
2008; Loh et al. 2015).  
  







Figure 4. 3 SEM images of micronized curcumin particles, A is unprocessed 
curcumin particles, B, C and D milled curcumin particles with D50 of 2.5µm, E 
and F micronized curcumin particles with D50 of 3.5µm. 
 




4.3.3. Thermal analysis of milled curcumin particles (DSC) 
Different scanning calorimetry (DSC) was used to examine any changing in the 
melting point of the comminuted curcumin particle prepared as well as 
unprocessed material. The unprocessed curcumin particle has endothermic 
peak at 175ºC (Sanphui et al. 2011; Liu et al. 2015) which represents melting 
point of curcumin polymorph 1 as shown in figure 4.4A. The DSC results of 
micronized curcumin are presented in figure 4.4.  It shows that milled curcumin 
particles with the different sizes (2.5µm and 3.5µm) have the same endothermic 
peak at 176ºC, which is in agreement with endothermic peak of the 
unprocessed particles. This endothermic peak represents the melting 
temperature of curcumin polymorph 1 (Sanphui et al. 2011; Thorat and Dalvi 
2016).  
 

























DSC results of micronised curcumin particles
 
Figure 4. 4 DSC thermograms of the jet milled curcumin particles, A is 
unprocessed powder, and B and C are micronized curcumin particles with D50 
on 2.5µm and 3.5µm, respectively 
 




4.3.4. X-ray powder diffraction (XRPD)  
XRPD was used to determine any changes in curcumin crystal structure. 
Curcumin crystal structure presents in three different polymorphs, commercial 
curcumin usually exhibit form 1 which is monoclinic structure, the other two 
forms are known as orthorhombic structures (Sanphui et al. 2011). Commercial 
curcumin form 1 was reported to have characteristic peaks in 2θ region at 8.90° 
and 17.0° (Sanphui et al. 2011; Liu et al. 2015; Thorat and Dalvi 2015).  
The XRPD pattern of commercial material and the processed particles of 
curcumin alongside with curcumin polymorph 1 as a reference, which is 
obtained from Cambridge Structure Database (CSD), are illustrated in figure 
4.5. The results indicate that milled curcumin particles with different sizes have 
form1 as the unprocessed material compared with XRPD patterns reference 
form1. The obtained data from diffractometer are in agreement with DSC results 
which are both proved that no alteration on curcumin polymorphs. This finding 
shows that the energy that used in jet mill was just enough to reduce the 
particles size of curcumin powder without producing any change in curcumin 
polymorphism, whereas in mechanical milling (milling using beads) curcumin 
has converted to amorphous form (Liu et al. 2013). In mechanical milling, when 
drug particles reached a certain critical size, the extra milled energy cause 
defect and disordering in drug crystal structure (Boldyrev 2004), which leads to 
the disappearance of the ordering positions of atoms or molecules in the 
crystals, these defect could impact  the entire crystal resulting in complete 
amorphization) formed around crystalline core (Hersey and Krycer 1980; Loh et 
al. 2015). The amorphous state of a drug improved its solubility and the 
dissolution rate (Yu 2001). However, amorphous forms are usually unstable and 




usually are converted to a crystalline forms leading to alteration of the particle 
size distribution and the performance of the drug (Guinot and Leveiller 1999). 
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Figure 4. 5 Diffractograms of curcumin powder form1 (A), B is unprocessed 
curcumin; C and D are milled curcumin particles D50 of 2.5µm and 3.5µm, 
respectively. 
 
4.3.5. Surface energy analysis of curcumin powder 
The free surface energy of both raw and triturate curcumin powder were 
characterised using inverse gas chromatography (IGC). The specific, dispersive 
and total surface energy of unprocessed and processed curcumin are 
presented in figure 4.6. The work of cohesion and the work of adhesion 
between pulverised curcumin (2.5µm and 3.5µm) and α-lactose are illustrated in 
figure 4.7. The milled curcumin has shown a lower total free surface energy 
compared to the unprocessed materials. The dispersive components of 
micronized and the raw powder exhibit almost no changes as the raw curcumin 
has 38 mJ/m2 whereas the micronized curcumin has 36 mJ/m2 and 37 mJ/m2 
for particles of 3.5µm and 2.5µm (D50), respectively. Polar surface energy was 




reduced significantly after milling. A further reduction in non-dispersive energy 
was also noticed when the particles size of curcumin was further reduced. The 
analysed non-dispersive component of unprocessed curcumin was 16.0mJ/m2 
whereas the milled particles with D50 of 3.5µm and 2.5µm were 4.0mJ/m
2 and 
0.98mJ/m2, respectively. This reduction is attributed to particles agglomeration 
after comminution; also the further reduction attributed to extra particles 
agglomerations. This was confirmed by the SEM images in figure 4.3. It seems 
that the particles have agglomerated towards the polar surface sites, as it has 
more energy than non-polar sites of the particles surface which prevented the 
polar probes to interact with these sites, whereas the non-polar sites facing the 
outer surface. This finding is similar to the results reported on the surface 
energy of lactose, when the surface energy was measured after storage at 75% 
relative humidity for three months, there was increase in the polar surface 
energy and reduction in the dispersive energy. This  was due to the interaction 
of the moisture with polar sites which prevented the polar probes to access the 
polar sites of the lactose, and hiding the nearer non-polar sites, which led to the 
reduction in  the dispersive energy of lactose (Newell et al. 2001; Das et al. 
2009). 
   
  





Figure 4.6 The non-dispersive (specific energy), dispersive and total free 
surface energy of unprocessed and milled curcumin particles with particle size. 
 
 
Figure 4. 7 The work of adhesion of unprocessed and milled curcumin particles, 
and work of adhesion of processed curcumin particles (2.5µm and 3.5µm) with 
α-lactose. 
 
4.3.6. Dry powder inhaler preparations and Drug content uniformity 
DPIs of curcumin (as mentioned in section 4.2.4) were prepared by blending 
each of processed curcumin particles (D50=3.5µm and 2.5µm) with α-
monohydrate lactose as a carrier (lactohale 201) at two ratios 1:9 and 1:67.5 
curcumin:lactose (w/w). F1 and F2 are the DPIs formulations, which were 
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drug:carrier w/w, respectively.  F3 and F4 are the DPIs formulations, which 
were prepared by using processed curcumin of D50=2.5µm at ratio of 1:9 and 
1:67.5 drug: carrier w/w, respectively. 
The relative standard deviation (RSD%) for the drug content uniformity of F1 
and F2 is presented in tables 4.3 and 4.4. The optimum mixing time was found 
to be 5 mins which was then used to assess the content uniformity of 
formulations F3 and F4 as shown in table 4.5. 
Table 4.3 The mean relative standard deviation (RSD%) for the mixing content 
uniformity of micronized curcumin (D50=3.5µm) with lactose at different times 
(n=3), F1 is DPI formulation 1, which contains 1:9, curcumin: lactose w/w. 
RSD% of F1 (D50 3.5µm, ratio 1:9) 
Time 1 min 5 mins 10 mins 30 mins 
Bisdemethoxycurcumin 7.32 1.8 35.48 8.43 
Demethoxycurcumin 7.21 1.62 35.08 8.35 
Curcumin 7.22 2.2 34.55 8.78 
 
  




Table 4.4 The mean relative standard deviation (RSD%) for the mixing content 
uniformity of micronized curcumin (D50=3.5µm) with lactose at different times 
(n=3), F2 is DPI formulation 2, which contains 1:67.5, curcumin: lactose w/w. 
RSD% of F2 (D50 3.5µm, ratio 1:67.5) 
Time (min) 1 min 5 mins 10 mins 30 mins 
Bisdemethoxycurcumin 8.36 2.45 4.08 5.83 
Demethoxycurcumin 8.94 1.93 4.68 5.47 
Curcumin 8.78 2.06 4.61 5.33 
 
Table 4.5 The mean relative standard deviation (RSD%) for the mixing content 
uniformity of micronized curcumin (D50=2.5µm) with lactose at 5 mins (n=3), 
F3&F4 are DPI formulations, which contain1:9 and 1:67.5, curcumin:lactose 
w/w, respectively. 
RSD% of F3&F4 (D50 2.5µm, ratios 1:9 &1:67.5) 
 DPI formulations F3 F4 
Time (min) 5 mins 5 mins  
Bisdemethoxycurcumin 3.06 2.7 
Demethoxycurcumin 2.93 2.52 
Curcumin 3.25 2.81 
 
The results obtained from F1 have shown that the lowest value of RSD% is 
after 5 minutes of blending, whereas the highest value of RSD was after 30 
minutes, which indicates that the drug and the lactose are not well uniform and 
getting separated. The values which were obtained after 1 and 30 minutes were 




slightly close to each other; this shows the same degree of homogeneity for 
these samples. In F2, the lowest value of RSD percentage was for the sample 
blended for 5 minutes, which is closer to the results in F1.Therefore, the 
optimum mixing time was considered to be 5 minutes and this is because it has 
the lowest RSD value among the sample mixing time. 
In F3 and F4, The RSD of blending was found to be 3.25% and 2.8% for 
curcumin, respectively. It is slightly higher than RSD% which was obtained for 
F1 and F2. This may be attributed to the high energy of the agglomerated 
particles of curcumin which was obtained from the further reduction in the 
particle size of curcumin (Ward and Schultz 1995; Taylor et al. 1999). This 
energy may have an effect on the de-agglomeration of particles on the lactose 
surface in mixing as well as during the inhalation process. Therefore, increasing 
the concentration of lactose may aid the drug particles to de-agglomerate and to 
distribute among the lactose itself. 
Overall, the homogeneity profile of mixing of curcumin with α-lactose was 
slightly improved as the concentration of the curcumin related to lactose 
decreased (Ward and Schultz 1995; Taylor et al. 1999). The mixing profile 
showed that the most acceptable percentage RSD in the four DPI formulations 
was with the blending time of 5 minutes.  
4.3.7. Aerodynamic characterisation of DPI of curcumin formulations 
The aerodynamic characterisation of the DPI formulations of milled 
curcuminoids of particle size of (D50) 3.5µm (F1&F2) and 2.5µm (F3&F4) are 
presented in tables 4.6 and 4.7, respectively. The drug mass distribution of both 
DPI formulations (D50 =3.5µm and 2.5µm) for the two ratio of drug-carrier (1:9 
and 1:67.5) throughout the NGI stages is shown in figures 4.8, 4.9, 4.10 and 




4.11, respectively. F1 & F2 are the formulations contained curcumin particles 
size of D50 =3.5µm for drug:carrier ratio of 1:9 and 1:67.5, respectively. F3 &F4 
are the formulations contained curcumin particles size of D50 =2.5µm for 
curcumin:lactose ratio of 1:9 and 1:67.5, correspondingly.  
The FPFs of F1 are 30.1%, 32.63% and 30.4%, whereas FPFs of F2 are 
32.7%, 33.6% and 33.2% for bisdemethoxycurcumin, demethoxycurcumin and 
curcumin respectively. The MMAD of F1 was around 4.6µm whereas in F2 is 
about 4.0µm, it is clear that there is slight improvement in FPF and MMAD for 
F2 compared to F1. The FPF of the DPI formulations of F3&F4, for 
bisdemethoxycurcumin, bisdemethoxycurcumin and curcumin, are 36.0%, 
34.6%, 36.5%, 39.5%, 38.9% and 38.0%, respectively. The MMAD of F3 was 
ranging from 3.36µm to 3.7µm, whereas in F4 was ranging from 3.2µm to 
3.6µm. 
Table 4.6 The aerodynamic parameters of DPI formulations (of curcumin 
particles (D50=3.5µm) from easyhaler device at flow of 45 L/m for 5.5 second. 
Aerodynamic parameters of curcuminoids DPI Formulations 1&2 (D0 3.5µm) 
Drug Formulations FPF% MMAD (µm) GSD 
Bisdemethoxycurcumin 
F1(1 to 9) 30.16 4.54 1.87 
F2 (1 to 67.5) 32.78 4.21 2.69 
Demethoxycurcumin 
F1 (1 to 9) 32.63 4.66 1.77 
F 2 (1 to 67.5) 33.68 3.94 2.31 
Curcumin 
F 1(1 to 9) 30.43 4.76 1.67 
F 1(1 to 67.5) 33.28 4.18 2.13 
FPF% is fine particle fraction, MMAD is the mass median aerodynamic diameter, and GSD is the geometric standard deviation. 






Figure 4. 8 Mass distribution DPI formulation (1:9 drug:carrier ratio) of curcumin 
particles (D50=3.5µm) among NGI stages from easyhaler device at flow of 45 




Figure 4. 9 Mass distribution DPI formulation (1:67.5 drug:carrier ratio) of 
curcumin particles (D50=3.5µm) among NGI stages from easyhaler device at 
flow of 45 L/m for 5.5 second, C is curcumin, DC is demethoxycurcumin and 






















































Table 4.7 The aerodynamic parameters of DPI formulations (of curcumin 
particles (D50=2.5µm) from easyhaler device at flow of 45 L/m for 5.5 second. 
Aerodynamic parameters of curcuminoids DPI Formulations 3&4(D0 2.5µm) 
Drug Formulations FPF% MMAD (µm) GSD 
Bisdemethoxycurcumin 
F3 (1:9) 36.03 3.36 2.18 
F4 (1:67.5) 39.54 3.20 2.54 
Demethoxycurcumin 
F3 (1:9) 34.67 3.55 2.03 
F4 (1:67.5) 38.90 3.44 2.39 
Curcumin 
F3 (1:9) 36.52 3.79 2.29 
F4 (1:67.5) 38.00 3.66 2.05 




Figure 4. 10 Mass distribution DPI formulation (1:9 drug:carrier ratio) of 
curcumin particles (D50=2.5µm) among NGI stages from easyhaler device at 
flow of 45 L/m for 5.5 second, C is curcumin, DC is demethoxycurcumin and 






























Figure 4. 11 Mass distribution DPI formulation (1:67.5 drug: carrier ratio) of 
curcumin particles (D50=2.5µm) among NGI stages from easyhaler device at 
flow of 45 L/m for 5.5 second, C is curcumin, DC is demethoxycurcumin and 
BDC is bisdemethoxycurcumin. 
 
The results of both formulations, with different particle size, have shown that the 
low drug concentration (1:67.5 drug: lactose) has a slight improve in the FPF% 
and MMAD. This enhancement in the performance of the DPI preparation ,of 
the drug: lactose ratio 1:67.5, is resulted from the reduction in the formation of 
the agglomeration drug particles in the formulation as the drug has an 
opportunity to disperse more among the carrier surface (Steckel and Muller 
1997). This finding is in agreement with a reported study on the effect of the 
drug concentrations on the FPF of the DPI preparation of budesonide, which 
showed that as  drug concentration increased from 1% to 5% and 9%, the FPF 
of budesonide reduced  from 32% to 21% (Steckel and Muller 1997). Also, other 
studies, on budesonide and salmeterol xinafoate, have demonstrated the same 
findings concluded that low drug concertation produces higher FPF% (Harjunen 
et al. 2003; Adi et al. 2008). In addition, this could be explained from the IGC 





























unprocessed curcumin particles higher than work of adhesion between 
curcumin and lactose. Therefore, the effect of agglomeration between drug 
particles is more pronounced and hence it is difficult to disperse (Ganderton 
1992; Steckel and Muller 1997; Adi et al. 2008). 
The formulations with a lower particles size of 2.5µm (D50) have illustrated a 
better inhalation performance compared to curcumin particle size of 3.5µm 
(D50). The variation between two DPI formulations is attributed to the alteration 
in the particle size of the curcumin particles, also the formulations with lower 
particles size have a D90 of 5.5µm compared to 7.7µm for formulations with 
larger particle size. It is reported that  the particles above than 5µm will deposit 
on the throat (Telko and Hickey 2005), therefore the formulations with large 
particle size demonstrated lower FPF compared to those with 2.5µm particle 
size.  
It is clear from the mass distribution that the formulations with particle size of 
2.5µm has more ability to penetrate into both lung zones (central and peripheral 
zone) which is corresponding to  stages 3,4 and 5 of the NGI. Therefore, the 
formulations with curcumin particles size of 2.5µm (D50) could be more 
appropriate to target the lung cancer cells that are located in the central or 
peripheral zone. This is because these formulations showed superior 
performance with higher FPF%. Also more penetration to lung zones was 
observed with preparation with the smaller particles. 
4.4. Conclusion 
In the summary, the air jet milling is a simple and suitable method for inhalable 
curcumin particles production. In this milling technique, the grinding pressure 
was  more predominant on particles size reduction, therefore, grinding pressure 




was kept as low as possible to reduce the mechanical energy applied to the 
particles and to avoid the polymorphic transformation of the compounds. The 
thermal analysis and XRPD confirmed that the particles obtained have 
polymorph1 as in unprocessed materials. The free surface energy of 
comminuted particles was found to be lower than the unprocessed one; this is 
because of the reduction on the polar surface energy of agglomerated particles. 
The inhalation profile of the DPI formulations which contains curcumin particles 
with size of 2.5µm (F3 &F4) illustrated better performance compared to 
formulations with particles size of 3.5µm (F1&F2). The aerodynamic parameter 
values (FPF%), in F3 and F4, is similar to the published studies. The simple 
approach as well as no excipients was involved in the production of the 
curcuminoids particles was an advantage of this study compared to the 
published one. This makes this work safer and more suitable for respiratory 
system. Another advantage is that the aerodynamic parameters of curcuminoids 
components, curcumin (C), demethoxycurcumin (DC) and 
bisdemethoxycurcumin (BDC) were individually assessed.  





Sonocrystallisation of Curcuminoids for 
Inhalation Application   




5 Chapter 5: Sonocrystallisation of curcumin for inhalation application 
5.1. Introduction 
Ultrasound is a cycle of sound waves which are not detectable by human ears, 
and this is because it has a frequency greater than the upper limit of human 
hearing (Leonelli and Mason 2010). Ultrasound (with frequency 20 to 100 KHz) 
has been used to induce physical and chemical changes in materials (Richards 
and Loomis 1927; Leonelli and Mason 2010).  
The application of ultrasound energy to crystallisation is known as 
sonocrystallisation (Chen et al. 2011). The main mechanism of 
sonocrystallisation is cavitation (Suslick 1998; Bund and Pandit 2007; Leonelli 
and Mason 2010); this cavitation can be either stable or transient. The stable 
one is associated with small bubbles dissolved in a liquid, whereas the transient 
cavitation occurs when the bubble size is expanded further and collapses, and 
as a result locally produces very high pressure (100 MPa) and high temperature 
(5,000 K) with heat cool rate of 1010 K/s (Suslick 1998; McNamara et al. 1999; 
De Castro and Priego-Capote 2007; Deora et al. 2013). Therefore, during 
sonocrystallisation, nucleation is initiated at higher temperatures and at the 
lowest level of supersaturation and in shorter times, which result in more 
uniform and smaller crystals with narrower size distribution (Guo et al. 2005; Li 
et al. 2006; Chen et al. 2011). 
The particles produced by ultrasound have shown to be suitable for inhalation 
application and it has been presented to have a superior aerodynamic 
behaviour over spray dried and milled particles (Abbas et al. 2007; Dhumal et 
al. 2009). This has been attributed to the  smoothness of the sonocrystallised 
particle surface and the reduction in the cohesive and adhesive forces and also 




due to the uniform shape and the narrower particle distribution (Dhumal et al. 
2009). 
Curcumin polymorph controlled by ultrasound have been recently published 
(Thorat and Dalvi 2015; Thorat and Dalvi 2016), and it has shown the ability of 
the ultrasound in production of curcumin particles within 5µm (Thorat and Dalvi 
2014). However, this report has not studied the application of these particles for 
inhalation and has not reported any aerodynamic profile of curcumin particles 
by sonocrystallisation and also they have not examined the surface energy of 
the produced particles. 
In this chapter, ultrasound is used to obtain a suitable particle of curcumin for 
inhalation with different cohesive and adhesive energy, therefore different 
solvents and antisolvents were used (ethanol, isopropanol, acetone, water and 
heptane). The solid state of the produced particles was characterised using 
differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD). 
The micrometric properties such as particle size and shape were determined 
using laser diffraction and a scanning electron microscope, respectively. The 
cohesive, adhesive and surface energy of the processed particles were 
examined using inverse gas chromatography (IGC). The dry powder inhaler of 
curcumin was prepared by mixing the sonocrystallised particles with α-lactose 
monohydrate as a carrier; aerosol performance of the DPI was then tested 
using a next generation impactor (NGI). The aerodynamic profile (FPF,MMAD 
and GSD) of curcumin, demethoxycurcumin and bisdemethoxycurcumin has 
been reported in this work. 





5.2.1. Sonocrystallisation of curcumin 
A supersaturation solution of curcuminoids was prepared in different organic 
solvents (ethanol, isopropanol and acetone) by adding an extra amount of 
curcuminoids into the solvents, and then the solvent temperature was increased 
accordingly (in ethanol increased to 60ºC, in isopropanol increased to 70ºC and 
in acetone to 45ºC). The solvents were filtered before their use, in 
crystallisation; to remove any insoluble curcumin particles. The antisolvent 
(water 80ml) was placed in jacket vessels with a control temperature at 5ºC 
using a circulating water bath. The ultrasound probe was immersed in the 
antisolvent and the ultrasound power and timer were set before staring the 
process. Once curcumin solution (20ml) was added into the antisolvent, the 
ultrasound power was switched on. The experimental parameters (times and 
ultrasound amplitude) were shown in tables 5.1, 5.2, and 5.3. The water 
antisolvent was replaced by heptane, and the setting parameters of the 
experiment are shown in table 5.4. The precipitated curcuminoid particles were 
collected using a filter paper and left to dry at room temperature for 
characterisations. 
Table 5.1 Parametrs of sonocrystallisation of curcumionds from ethano and 
water 
Sonocrystallisation from ethanol-water 
Code Sono1 Sono2 Sono3 Sono4 Sono5 Sono6 
Time (min) 5 5 5 5 1 3 
Ultrasound 
amplitude% 
25 50 75 100 50 50 
 




Table 5.2 Parameters of sonocrystallisation of curcuminoids from isopropanol 
and water 
Sonocrystallisation from isopropanol-water 
Code Sono7 Sono8 Sono9 Sono10 Sono11 Sono12 
Time (min) 5 5 5 5 1 3 
Ultrasound 
amplitude% 
25 50 75 100 50 50 
 
Table 5.3 Parameters of sonocrystallisation of curcuminoids from acetone and 
water 
Sonocrystallisation from acetone-water 
Code Sono13 Sono14 Sono15 
Time (min) 0.5 1 3 
Ultrasound 
amplitude% 
50 50 50 
 
Table 5.4 Parameters of sonocrystallisation of curcuminoids using different 
solvent and heptane as antisolvent 
Sonocrystallisation using heptane as antisolvent 
Code Sono16 Sono17 Sono18 
Time (min) 1 1 1 
Ultrasound amplitude% 50 50 50 
Curcumin solvent  Ethanol Acetone Isopropanol 
 
 





5.3. Results and discussion 
5.3.1. Particle size analysis using laser diffraction 
The particle size, of sonocrystallised curcumin from each solvent, was 
measured using laser diffraction. The data are shown in tables 5.5, 5.6, 5.7 and 
5.8.  
 Particles precipitated from ethanol-water 
Table 5.5 shows the particle size of sonocrystallised curcumin using ethanol as 
organic solvent and water as an antisolvent. 
Table5.5 The mean size and the standard deviation (n=3) of the 
sonocrystallised curcumin particles which precipitated from ethanol and water. 
Sonocrystallisation 
from ethanol-water 
Code D10 μm +/-std D50 μm +/-std D90 μm +/-std 
Sono1 0.75 +/- 0.01 1.65 +/- 0.02 4.07 +/- 0.32 
Sono2 0.75 +/- 0.01 1.59 +/- 0.01 3.50 +/- 0.02 
Sono3 0.82 +/- 0.09 2.26 +/- 0.48 11.54 +/- 5.36 
Sono4 0.73 +/- 0.01 1.62 +/- 0.01 4.37 +/- 0.22 
Sono5 0.71 +/- 0.07 1.64 +/- 0.03 4.78 +/- 0.52 
Sono6 0.62 +/- 0.08 1.54 +/- 0.10 18.68 +/- 23.85 
 
Effect of ultrasound amplitude and ultrasound time on the particle size of 
curcuminoids has been investigated. Different amplitudes (25%, 50%, 75% and 
100%) were applied during the sonocrystallisation, the results show no 
difference between the low and high amplitude of the ultrasound on the particle 




size of curcuminoids, this could be attributed to the fact that the supersaturation 
level is  dominant over the sonication irradiation and the cavitation worked here 
as a high efficiently mixer, which increases the mass transfer and diffusion 
between the solvents and the antisolvents (Miyasaka et al. 2006), which in turn 
leads to homogenise and rapid nucleation (Guo et al. 2005; Abbas et al. 2007; 
Dhumal et al. 2009). The sonocrystallisation has been reported to be more 
effective during crystallisation at lower level of drug concentrations (Guo et al. 
2005; Miyasaka et al. 2006). 
Also, the period of sonication suggests that the particle size of curcumin at 1 
min (sono5) is similar to particle size at 5 mins (sono3), thus, sonication for 1 
min provides sufficient micro mixing during crystallisation to enhance the 
nucleation and to produce a small crystal. The particle size (D90 and D50) is 
smaller than 5µm which suggests its suitability for inhalation. However, during 
drying using filter paper, the particle forms cake, this is due to the particles 
compacting on each other through filtration and due to their size, and also may 
be due to a long period of drying as the water has low volatility compared with 
organic solvents, as the particles are kept in contact with each other in the 
presence of water–ethanol throughout drying.  
 Particles precipitated from isopropanol-water 
Table 5.6 shows the particle size of sonocrystallised curcumin using 
isopropanol as organic solvent and water as antisolvent. 
 
 




Table5. 6 The mean size and the standard deviation (n=3) of the 





Code D10 μm +/-std D50 μm +/-std D90 μm +/-std 
Sono7 0.51 +/- 0.01 1.25  +/- 0.04 4.00  +/- 0.34 
Sono8 0.57 +/- 0.04 1.50 +/- 0.23 5.38 +/- 0.14 
Sono9 0.61 +/- 0.04 1.45 +/- 0.01 3.83 +/- 0.36 
Sono10 0.64 +/- 0.00 1.44 +/- 0.01 3.38 +/- 0.07 
Sono11 0.59 +/- 0.05 1.46 +/- 0.25 4.22 +/- 0.37 
Sono12 0.68 +/- 0.02 1.83 +/- 0.14 9.72 +/- 1.06 
 
Changing the organic solvent (from ethanol to isopropanol) during 
sonocrystallisation of the curcuminoids has not shown any further reduction in 
particle size of the curcumin. 
The range of ultrasound amplitude has been examined in order to determine 
their effect on the size reduction of curcumin. The data indicates that the 
increase in the amplitude from 25% to 100% (for a period of time of 5 mins) has 
no further decrease in the particle size. Also, the effect of the sonication time 
has been tested; the results present that the sonocrystallisation of curcumin for 
1 min gives a similar particle size (D50) to those particles obtained after 5 mins. 
These findings could suggest that sonocrystallisation at low amplitude and for a 
short period of time at high supersaturation levels are able to produce a particle 
below 5µm. The production of small particles  during sonocrystallisation using a 
supersaturation solvent is attributed to the fact that the ultrasound irradiation 
produces an intensified micro mixing by cavitation bubbles,  which in turn leads 




to an enhanced  mass transfer and diffusion rate between the solvents  and the 
antisolvents , and thus enhances a high supersaturation level, which results in 
rapid nucleation (Li et al. 2006; Miyasaka et al. 2006). As the number of nuclei 
increases, the amount of the solute on each nucleus decreases; hence the 
particle size of the final crystals  is reduced (Louhi-Kultanen et al. 2006). 
It is noticeable that at a at shorter time (1 min) of sonication was enough to 
induce rapid nucleation and reduce the crystal growth of the particles and a 
complete release of the supersaturation has occurred within 1 min,  therefore 
increasing the sonication time has not shown any further change in the particle 
size. 
 Particle precipitated from acetone-water 
Table 5.7 shows the particle size of sonocrystallised curcumin using acetone as 
organic solvent and water as antisolvent. 
Table 5.7 The mean size and the standard deviation (n=3) of the 




Code D10 μm +/-std D50 μm +/-std D90 μm +/-std 
Sono13 0.82 +/- 0.06 2.30 +/- 0.28 10.05 +/- 3.92 
Sono14 0.62 +/- 0.06 1.33 +/- 0.01 3.08 +/- 0.48 
Sono15 0.47 +/- 0.07 1.24 +/- 0.05 4.33 +/- 1.09 
 
The sonication time has been reduced to start from 30 second up to 3 mins, and 
the amplitude has been set to 50%, as the results from previous data (ethanol 
and isopropanol) have illustrated that sonication for a short period of time is 
enough to produce an inhalable particle size. The data have shown an increase 




in the particle size when the sonocrystallisation was conducted for 30 seconds, 
but no alteration in particle size when it was carried out at 1 min and 3 mins. 
The higher particle size at 30 seconds illustrates that a rapid nucleation occurs 
and then is followed by crystal growth and agglomeration; this means the 
ultrasound at 30 seconds was not enough to reduce the crystal growth and to 
allow a complete liberation of the supersaturation to occur as it does at 1 min. 
Therefore, the optimum condition was considered to be 50% amplitude for 1 
min. The variation in particle size of D90 between sono12 and sono13 and 
sono14 is due to cake formation during drying by filtration. 
The particle size obtained from ethanol, isopropanol and acetone at 1 min and 3 
mins and 5 mins (in case of ethanol and isopropanol) is very similar and there is 
no big variance between them. In terms of particle size, it could be concluded 
that sonocrystallisation is independent of the organic solvent of the solute to 
obtain inhalable particles.  
Drying the processed particles using an ordinary filtration technique like filter 
paper, is a slow procedure of removing the solvent and the antisolvent from the 
product, in turn leads to cake formation of the particles. If these cakes do not 
disperse during mixing with lactose it will produce heterogeneous distribution of 
the drug in the formulation, which is not suitable for inhalation. Therefore, the 
antisolvent was replaced with another one with higher vapour pressure and less 
polar than water to prevent a long contact between the crystal particles with 
solvents and the antisolvent during filtration and the drying process of the 
product, which will reduce the possibility of having hard cake particles. 
Choosing the second antisolvent with no polarity properties (or less polar than 
water) helps to modify the surface energy of the produced particle. The water 




antisolvent was replaced by heptane and three experiments were processed at 
50% amplitude and for 1 min sonication. 
 Particles precipitated from ethanol, isopropanol, acetone and heptane 
Table 5.8 shows the particle size of sonocrystallised curcumin using ethanol, 
isopropanol and acetone as organic solvents and heptane as an antisolvent. 
Table 5. 8 The mean size and the standard deviation (n=3) of the 
sonocrystallised curcumin particles which precipitated from different solvents 
and heptane. 
Sonocrystallisation 
using heptane as 
antisolvent 
Code D10 μm +/-std D50 μm +/-std D90 μm +/-std 
Sono19 0.91 +/- 0.01 2.49 +/- 0.05 5.47 +/- 0.21 
Sono20 0.73 +/- 0.01 2.40 +/- 0.06 8.92 +/- 0.47 
Sono21 0.72 +/- 0.11 2.37 +/- 0.05 11.54 +/- 0.02 
 
Replacing water (anti-solvent) by heptane using the optimum conditions which 
were obtained previously (time 1 min and amplitude 50%). The sonication time 
is for 1 min and the amplitude is 50%, these conditions produced a suitable 
particle size for inhalation and there was no need to increase sonication time or 
power of the ultrasound. However, the particle size of curcuminoids shows 
some increase in their size when heptane was used. This is because the 
heptane is volatile during sonication and thus increases the level of the 
supersaturation and therefore the effect of nucleation by supersaturation 
becomes more prominent over that of sonication. However, the crashing out of 
the crystals at concentrations above supersaturation is controlled by both 
supersaturation nucleation and sonication driving forces (Abbas et al. 2007; 
Dhumal et al. 2009). The D50 is 2.5µm in the heptane system, whereas it was 




1.5µm in the water system. D90 is 5.4µm when ethanol-heptane (sono19) 
system was used, which is close to those particles produced by ethanol 
(sono5), isopropanol (sono11) and acetone-water (sono14) system. The D90 for 
both sono20 and sono21 was higher than sono19, and so higher than those 
produced from isopropanol-water (sono11) and acetone water (sono14) system. 
These findings indicate the ability of the ultrasound to produce a small particle 
size of curcuminoids within short period of time and even with low amplitude. 
Furthermore, the sonocrystallisation technique could be a drug solvent 
independent, as the inhalable particles of the drugs was obtained using three 
different organic solvents. 
5.3.2. Morphology of sonocrystallised curcumin particles using scanning 
electron microscope (SEM) 
The morphology (particle shape) of sonocrystallised curcumin were analysed 
using SEM. The particle shapes vary depending on the curcumin organic 
solvent during sonocrystallisation as well as the time of the sonication process.  
Figure 5.1 (from sono1 to sono4) shows the SEM images of curcumin particles 
precipitated using ethanolic curcumin solution and water antisolvent at different 
applied amplitude (25% to 100%) for 5 mins. The particles exhibit a long plate-
like shape. The edge ends of these particles look to be broken down later, 
which could be as a result of long sonication time (5 min). The SEM images of 
sono5 and sono6 particles, which are processed at less time of sonication (1 
and 3 mins); seem to have different particle morphology. In sono5, a dendritic 
morphology could be seen. Each particle is composed of a stem–like in the 
middle from which branches originate, it can be seen that a break occurs in this 
stem to give a hand shape with its branches and each branch has a needle 




structure. This structure/shape (stem–like) has been reported by Alpha without 
using ultrasound. Therefore, this break could be attributed to sonication energy. 
These particles have probably started from the middle (stem) point and are then 
stretched by a secondary nucleation to grow on each side of that stem to form 
branches (Thorat and Dalvi 2014). In sono6, a rice seed-like shape of curcumin 
particles could be seen, also this particle shape was reported and it is attributed 
to that curcumin particle that is made of several layers which are fused by time 
(Thorat and Dalvi 2014). It seems that sonocrystallisation for a long time (such 
as 5 mins) has broken down the already formed particles at early stage of 
precipitations (1 min or 3 mins). It is likely that the curcumin particles have been 
formed within 3 mins of time and any extra time of ultrasound breaks these 
particles, which gives them a different shape and plates with irregular edges too 
as is shown in sono1, 2, 3 and sosn4. This theory was reported by (Dhumal et 
al. 2009; Chen et al. 2011) that sonocrystallisation could further reduce the 
particles size (which in turn changes the particle’s shape) of formed particles. 
This hypothesis has also been examined in this work, by precipitating curcumin 
particles from ethanol-water with absence of the ultrasound, after completion of 
the precipitation, a gentle sonication (using a sonication bath) was applied into 
these particles. The SEM images are shown in figure 5.2 and named as after 
and before sono. It is clear that particle shapes have been modified from long 
rectangular plates (at zero time) to a square plate by increasing the sonication 
time to 15 mins. 
The results of SEM images of curcumin particles produced using isopropanol 
solvent are presented in figure 5.1 (sono7, 8, 9, 10, 11 and sono12). The 
morphology of the particle has shown some changes compared to the one that 
produced from ethanol solvent. The particles, at power of amplitude from 50% 




to 100% for a period of 5 mins process, look like a fusiform muscle as they are 
wider in the middle and tapered toward the end with small branches at each 
end. The particle shape of curcumin, at power 25% for 5 mins, look like spindles 
(they are wider in the middle and narrower at each end with no further 
branches). The fusiform shape was observed in curcumin particles, which are 
sonocrystallised for a different period of time too (1, 3 mins), these particles also 
have small branches on each edge of the particles. It seems these branches 
are an extension of the single groups of particles arranged (fused) on tope to 
each other (Thorat and Dalvi 2014). 
The SEM results of the curcumin particles obtained from acetone curcumin 
solution are presented in figures 5.1, sono13, 14 and sono15. The particle 
shapes with less time of sonication (i.e. 30 sec; sono13) seem to be less 
uniform in their shape, as they look like a long wide plate with a smaller break 
on too. The morphology of curcumin particles at longer time process, (time 1 
and 3 mins which represent sono14 and 15, respectively), also has a plate like 
structure, which are further broken down to a smaller one. 
Interesting changes in the curcumin morphology were observed when heptane 
was used as an antisolvent. Figures 5.1 of sono16, sono17 and sono18 are 
illustrated with curcumin particle shapes produced from ethanol, acetone and 
isopropanol, respectively. SEM images of particles obtained from ethanol and 
acetone solvents present plate morphology of curcumin particles with more 
elongation when acetone solvent is used. More interestingly, a flower shape 
was observed when isopropanol was used. It is noticed that in both solvents 
(ethanol and acetone), the crystal particle has been broken down during 
sonication, but not in the case of isopropanol, this indicates a faster crystal 
growth is obtained and the particles crashed out later, whereas in isopropanol a 




slow crystal growth was gained. This could be attributed to the higher viscosity 
of isopropanol compared to both acetone and ethanol. 
  















Figure 5.1 SEM images of sonocrystallised curcumin particles which 
precipitated from different organic solvents with water and heptane. 
 
 
Figure 5. 2 SEM images of curcumin particles which precipitated from ethanol 
and water without ultrasound. *Before-sono is the curcumin particles prepared 
without ultrasound,*After-sono is the formed particles sonicated for 15 minutes.  
 
5.3.3. Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) was used to examine any changes in 
the melting point of the curcumin particle prepared by ultrasound compared to 
unprocessed material. The unprocessed curcumin particle has an endothermic 
peak at 175ºC (Sanphui et al. 2011; Liu et al. 2015), which represents the 
melting point of curcumin polymorph 1 as is shown in chapter 4. 




DSC results of sonocrystallised curcumin particles, which were produced by 
using ethanol curcumin and water as an antisolvent (from sono1 to sono6), are 
presented in figures 5.3 & 5.4 and table 5.9. The results illustrate one 
endothermic peak of sonocrystallised curcumin particles, which represent the 
melting temperature of curcumin form 1 (Thorat and Dalvi 2015). The DSC data 
indicates no effect of different amplitude of ultrasound on the melting point of 
the formed particles, as well as the time of sonication.  
Table 5. 9 Endothermic peak temperature for precipitated curcumin particles 
from ethanol-water. 












































DSC results of sonocrustallized curcumin from Ethanol-water
 
Figure 5. 3 DSC thermograms of precipitated curcumin particles from ethanol-









Figure 5.4 DSC thermograms of precipitated curcumin particles from 
ethanol-water at different sonication time 




























DSC results of sonocrysillized curcumin from Ethanol-water




The DSC data of sonocrystallised curcumin particles, which are produced from 
isopropanol solvents and water as antisolvents (from sono7 to sono12), are 
shown in figure 5.5 and 5.6 and the average endothermic melting temperature 
(n=3) in table 5.10. DSC thermograms present two peaks; the presence of 
multiple melting peaks is usually associated with polymorphic transformation 
(Giron 2001; Maher et al. 2012; Thorat and Dalvi 2015). Therefore, the first 
endothermic peak is around 160ºC, and the second at 177ºC. The former peak 
is attributed to a polymorph transformation of curcumin particles from form 3 to 
form 1, and the second peak corresponds to the melting peak of curcumin form 
1 (Thorat and Dalvi 2015). This polymorphic transformation was observed in all 
curcumin samples at either different sonication times or variations of sonication 
amplitude (sono7 to sono12). 
 












































DSC results of sonocrystalliztion of curcumin from isopropanol-water
 
Figure 5. 5 DSC thermograms of precipitated curcumin particles from 
isopropanol-water at different ultrasound amplitude 
 
 































DSC results of sonocrystalliztion of curcumin from isopropanol-water
 
Figure 5.6 DSC thermograms of precipitated curcumin particles from 
isopropanol-water at different sonication time 
 
 
Table 5. 10 Polymorph transformation and melting temperature of precipitated 
curcumin particles from isopropanol-water 
Sample code Transition temperature ºC Endothermic peak temperature ºC 
Sono7 160 176 
Sono8 158 177 
Sono9 160 177 
Sono10 158 177 
Sono11 163 179 
Sono12 162 177 
 
The DSC thermograms of sono13 to sono15, which are prepared from acetone 
solvents and water as antisolvents, are illustrated in figure 5.7 and the 
associated melting peak temperature in table 5.11. The DSC curves exhibit one 




endothermic peak at 177ºC, which corresponds to the melting temperature of 
curcumin particles  form 1 (Liu et al. 2015). 
























DSC resutls of sonocrystallized curcumin from acetone-water (time)
 
Figure 5. 7 DSC thermograms of precipitated curcumin particles from acetone-
water at different sonication time 
 
Table 5. 11 Endothermic peak temperature of precipitated curcumin particles 
from acetone-water 





The DSC data of sono16 to sono18 are shown in figure 5.8 and their melting 
peak temperature in table5.12. The thermograms of the DSC show only one 
endothermic peak at 178ºC, this melting peak temperature corresponds to the 
melting temperature of curcumin particles form 1. 
 





























DSC results of sonocrystallized curcumin using heptane anitsolvent
 
Figure 5. 8 DSC thermograms of sonocrystallised curcumin particles from 




Table 5. 12 Endothermic peak temperature of sonocrystallised curcumin 
particles from ethanol, isopropanol and acetone as good solvents and heptane 
as an antisolvent 





To conclude, the DSC results of the sonocrystallised curcumin, which are 
prepared from acetone and ethanol solvents and water as an antisolvent, have 
shown one endothermic peak. Whereas low thermal events were seen when 
isopropanol solvents were used, in which the first endothermic peak represents 
curcumin polymorph transformation (form  3 to form 1) and the second melting 
peak corresponds to the melting temperature of form 1 (Thorat and Dalvi 2015; 
Thorat and Dalvi 2016). The DSC curves of sonocrystallised curcumin using the 




above three solvents (ethanol, isopropanol and acetone) and heptane as an 
antisolvent, exhibit only one endothermic peak which agrees with the melting 
temperature of curcumin form 1. These findings were confirmed using XRPD in 
the next section 
5.3.4. X-ray powder diffraction (XRPD)  
XRPD is used to determine any changes in curcumin crystal structure. 
Curcumin crystal structure exists in three different forms (Sanphui et al. 2011), 
forms 2 and 3 are known as orthorhombic structure (form 2 and 3, and form 1 is 
a monoclinic structure (Sanphui et al. 2011). 
The variation between form 1 and forms 2 and 3 of curcumin is mainly the 
conformation of a curcumin molecule and its interaction through hydrogen 
bonding with neighbouring curcumin molecules (Sanphui et al. 2011; Thorat et 
al. 2014). In form 1, the curcumin molecule has a curved and twisted 
conformation as a result of hydrogen bonding between neighbouring curcumin 
molecules (Sanphui et al. 2011; Thorat et al. 2014). In forms 2 and 3, they have 
a linear and planar conformation (Sanphui et al. 2011). The difference between 
forms 2 and 3 is only the keto-enol orientation of curcumin molecules packed in 
the unit cell (Sanphui et al. 2011; Thorat et al. 2014). In form 2 the keto-enol 
groups in 2 molecules are cis in orientation, whereas in form 3 they are in trans 
in orientation (Sanphui et al. 2011; Thorat and Dalvi 2015).  Also the colour of 
the curcumin polymorph is distinguishable visually, as form 1 has a yellow-
orange and forms 2 and 3 have a red-orange colour (Liu et al. 2015). The 
XRPD patterns of these polymorphs are shown in figure 5.9.  Curcumin form 1 
has characteristics peaks in 2θ region at 8.9º and 17º, form 2 has 
characteristics peaks at 13.8º and 25.9º- 27º and 27.5º and form 3 at 14.1º and 
26.7º and 27.1º (Sanphui et al. 2011; Liu et al. 2015; Thorat and Dalvi 2015). 




















Figure 5. 9 XRPD patterns of curcumin polymorphs reproduced from 
Cambridge Crystallographic Data Centre (CCDC) 
 
The XRPD patterns of sonocrystallised curcumin, which is produced using an 
ethanol solvent, (from sono1 to sono6) are illustrated in figures 5.10 and 5.11. 
The results indicate that curcumin particles formed are similar to curcumin form 
1. The different irradiation amplitude (25% to 100%) and time of sonication (1 to 
5 min) did not show any changes on curcumin polymorph, these results are in 
agreement with the DSC data, where both results suggest form 1 is produced. 
These findings are in disagreement with recent published data (Thorat and 
Dalvi 2015) which show that curcumin obtained from an ethanol solvent using 
ultrasound has form 3. This conflict in the results could be attributed to the 
different levels of supersaturation level of curcumin, as the used curcumin 
concentration was 5mg/ml, whereas in this work the solution curcumin has a 
concentration of 15mg/ml. It is clearly that solution concentration that plays a 
role in the determination of the final polymorph, since the rate of nucleation will 
be affected by the supersaturation level of the used solution (McCrone 1965; 
Bernstein et al. 1999; Thorat and Dalvi 2016).        






















Xray pattern of sonocrystallized curcumin from Ethanol-water
 
Figure 5. 10 XRPD patterns of sonocrystallised curcumin particles from 
ethanol-water at different ultrasound amplitude 
 
 













Xray pattern of sonocrystallized curcumin from Ethanol-water
 
Figure 5. 11 XRPD patterns of sonocrystallised curcumin particles from 
ethanol-water at different times of sonication 
 
The diffractograms of sonocrystallised curcumin particles, which are obtained 
from isopropanol solvent and water as an antisolvent, are displayed in figures 
5.12 and 5.13. The XRPD patterns have formed in curcumin form 3. Comparing 




these patterns with curcumin reference patterns indicates the precipitated 
curcumin particles have a polymorph 3. Form 3 of curcumin particles was 
observed among the samples that were produced at different levels of 
amplitude and sonication time. These results are agreed with DSC 
thermograms, which showed polymorph transformations. This change of 
curcumin form during ultrasound was attributed to the ability of the ultrasound 
irradiation to disturbance and the prevention of hydrogen bonding among 
curcumin molecules by cavitation (Thorat and Dalvi 2014; Thorat and Dalvi 
2015). It is also the processing conditions that could induce polymorphic 
transformation during crystallisation such as temperature, supersaturation levels 
and nucleation rate (McCrone 1965; Bernstein et al. 1999).  
 

















Xray pattern of sonocrystallized curcumin from isopropanol-water
 
Figure 5. 12 XRPD patterns of sonocrystallised curcumin particles from 
isopropanol-water at different ultrasound amplitude 


















Xray pattern of sonocrystallized curcumin from isopropanol-water
 
Figure 5.13 XRPD patterns of sonocrystallised curcumin particles from 
isopropanol-water at different times of sonication 
 
XRPD patterns of curcumin particles (sono13, 14 and 15), which are 
precipitated from acetone and water, are shown in figure 5.14. The 
diffractograms of processed particles shows the same trend of curcumin as 
form 1. These findings support the data of DSC, in which the endothermic peak 
was related to curcumin form 1. 
  














Xray pattern of sonocrystallized curcumin from Acetone
 
Figure 5. 14 XRPD patterns of sonocrystallised curcumin particles from 
acetone-water at different times of sonication 
 




Figure 5.15 demonstrates the diffractometer results of sonocrystallised 
curcumin (sono16, 17, and 18) using ethanol, acetone and isopropanol 
curcumin solution and heptane as an antisolvent, respectively. The XRPD 
patterns indicate that obtained curcumin polymorph is form 1, compared to the 
reference pattern of form 1. Using heptane antisolvent, curcumin form 1 was 
obtained even with isopropanol solvent, these results are confirmed by 
thermograms data from DSC, from which a single endothermic peak was 
present and it corresponds to a melting temperature of curcumin form 1.  
 















Xray pattern of sonocrystallized curcumin heptane antisolvent
 
Figure 5. 15 XRPD patterns of sonocrystallised curcumin particles from 
ethanol, acetone and isopropanol and heptane as an antisolvent. 
 
In conclusion, XRPD data of sonocrystallised curcumin using different solvents 
and antisolvents are supported by the DSC results. Two curcumin polymorphs, 
form 1 and form 3, were observed using ultrasound precipitation methods. 
Curcumin form 1 and form 3 can be identified visually according to their colour, 
since curcumin form 1 has a yellow-orange colour, and form 3 has a red colour 
(Liu et al. 2015). Form 3 of curcumin has been observed when isopropanol and 
water were used as a solvent and antisolvent, respectively. This may be 




attributed to the hydrogen bond disturbance between curcumin molecules 
(Thorat et al. 2014; Thorat and Dalvi 2015) as well as the low level of 
supersaturation and hence low nucleation rate (McCrone 1965; Bernstein et al. 
1999). Whereas in heptane antisolvent with isopropanol, the supersaturation 
level of curcumin may increase due to the high vapour pressure of heptane 
solvent compared to water as well as the viscosity of heptane less than water, 
which could increase the nucleation rate and then crystal growth which in turn 
reduces the chance of hydrogen bonding to be disturbed.  On the other hand, in 
the case of the ethanol and acetone, the level of the supersaturation was higher 
than it was in isopropanol, therefore, the nucleation rate could be faster and the 
ultrasound was unable to prevent hydrogen bonding between the curcumin 
molecules. The results from the diffractometer and thermal analyses are in 
agreement, as in form 3, two thermal events were observed and for form 1 a 
single endothermic peak was seen.  
5.3.5. Surface energy analysis of curcumin particles 
The free surface energy of curcumin was characterised using inverse gas 
chromatography (IGC) by injection of a series of n-alkanes (hexane to nonane) 
and two polar probes (ethyl acetate and chloroform). In this work, we are trying 
to correlate the free surface energy of curcumin with its performance during 
inhalation.  
The surface free energy or surface energy (  ) is defined as the energy that 
creates a unit area of surface. The total free surface energy is composed of 
different physical forces and it is usually divided into several components 
(Grimsey et al. 2002). All materials have non-polar (dispersive) forces, and most 
of the materials have polar forces such as hydrogen bonding or acid base 




forces (Fowkes 1964; Grimsey et al. 2002). Therefore, the surface free energy 
is split into dispersive ( d) and polar (specific  sp) components, thus the total 
free energy is the sum of both energies of the dispersive and the specific 
energy (Fowkes 1964; Van Oss et al. 1988).  
The specific, dispersive and total surface energy of sonocrystallised curcumin 
using water and a heptane antisolvent are presented in figure 5.16 and 5.17, 
respectively. The lactose carrier free surface energy characterisation is shown 
in figure 5.18. The work of adhesion between processed curcumin particles and 
the lactose carrier is illustrated in figure 5.19, and the work of cohesion between 
the curcumin particles is shown in figure 5.20.  
 
 
Figure 5. 16 Surface energy of sonocrystallised curcumin, sono8: particles 
precipitated from isopropanol-water; sono2: particles precipitated from ethanol-


































Figure 5. 17 Surface energy of sonocrystallised curcumin, sono16: particles 




Figure 5. 18 Surface energy of lactose (lactohale200) which is used in DPI 






































Surface free energy of lactose 





Figure 5. 19 The work of adhesion between sonocrystallised curcumin and 
lactose, sono16: particles precipitated from ethanol-heptane, sono17: particles 
precipitated from acetone-heptane. 
 
 
Figure 5. 20 The work of cohesion between sonocrystallised curcumin, sono16: 
particles precipitated from ethanol-heptane, sono17: particles precipitated from 
acetone-heptane 
 
The specific components of the sonocrystallised curcumin produced by 
acetone, ethanol solvent and water antisolvent (sono2 and sono14) are very 
similar as  sp for sono2 (by ethanol) is 1.67 mJ/m2 and 1.47 mJ/m2 for sono14 
(by acetone) acetone, this difference in the  sp is attributed to the differences in 
the polarity of both solvents. However, the dispersive components of curcumin 

























Work of cohesion of sonocrysatllised curcumin 




obtained from ethanol and 39.7mJ/m2 from acetone. The differences in the 
dispersive energy are attributed to the fact that acetone is less polar than 
ethanol and therefore the dispersive energy in the sonocrystallised curcumin is 
higher than it is in ethanol. This finding is in agreement with another study which 
was  conducted by Storey (Storey 2008) on ibuprofen, in which the ibuprofen 
showed a different dispersive and specific energy according to the used solvent 
polarity. 
The specific components of curcumin polymorph 3 (sono8), which is produced 
by using isopropanol and water as an antisolvent, is notably greater than the 
one found in sonocrystallised curcumin polymorph 1 (whether it is obtained by 
acetone (sono14) and ethanol (sono2). The  sp in sonocrystallised curcumin 
polymorph 3 is 3.15mJ/m2, whereas in curcumin polymorph 1 is 1.67mJ/m2 and 
1.47mJ/m2 for ethanol and acetone solvent, respectively. This finding could be 
attributed to the rearrangement of curcumin structure to surface of curcumin 
particles during crystallisation. The non-polar surface energy of the polymorph 3 
of curcumin is 34.19mJ/m2, which is very similar to the dispersive energy of 
curcumin polymorph 1, which is produced using ethanol (sono2); this is due to 
the closeness in polarity of ethanol and isopropanol.  
Sonocrystallisation of curcumin using a nonpolar antisolvent, such as heptane, 
has changed the surface energy of curcumin and this was more noticeable on 
the polar energy rather than dispersive energy of curcumin. The specific energy 
of curcumin has been reduced from 1.67mJ/m2 and 1.47mJ/m2 to 0.33mJ/m2 
and 0.40mJm2 when the heptane antisolvent was used. The dispersive energy 
of sonocrystallised curcumin has not changed when the water antisolvent was 
replaced by heptane, as it was 34.71mJ/m2 and 39.75mJ/m2 when water is 




used and it is 34.96mJ/m2 and 39.84mJ/m2 in the case of heptane antisolvent. 
This finding is in agreement with Grimsey’s work on poly(l-actide)microparticles, 
in which dispersive surface energy was less sensitive to processing techniques, 
whereas the polar surface energy has been dramatically changed (Grimsey et 
al. 1999). 
The surface energy characterisation has also been determined for a lactose 
carrier to work out the work of adhesion between the curcumin particles and the 
carrier (lactose). The results indicate a low surface energy for lactose, which 
has polar and non-polar surface energy 6mJ/m2 and 35mJ/m2, respectively.  
The work of adhesion between the drug particles and the carrier determines the 
energy that is needed to be applied to detach interest particles from the lactose 
surface. This energy is related to surface energy of both the curcumin particles 
and the lactose carrier. The work of adhesion between sonocrystallised 
curcumin and the lactose (sono16) is lower than the work of adhesion between 
the carrier and curcumin crystallised from acetone (sono17), this is attributed to 
the lower free surface energy of curcumin sono16 (which is obtained from 
ethanol solvent). 
5.3.6. Dry powder inhaler preparations 
Sonocrystallised curcumin particles were mixed with lactose at two ratios of 
10% (1:9, drug to lactose) and 2% (1:67.5, drug to lactose). These ratios 
illustrated a good performance in the air jet milled curcumin studies (see 
chapter 4), therefore were used for the sonocrystallisation formulations.  
Sono5, Sono11, Sono14, sono16 and sono17 samples were selected to be 
mixed with lactose at the above ratios. Sono5, sono11, sono14, formed cake 
particles during filtration and when they were mixed with lactose; the drug 




particles did not disperse throughout the carrier. Therefore, those formulations 
were excluded from any further testing (i.e. aerodynamic characterisation). 
Formulations using sono16 and sono17 were as well dispersed when they were 
mixed with lactose. 
5.3.7. Aerodynamic characterisation using next generation impactor 
 Formulations from acetone (sono17): sono17-1 is the formulation drug-
lactose ratio of 1:9, and sono17-2 is the formulation of drug-lactose ratio 
1:67.5. 
The aerodynamic behaviour (FPF%, MMAD, and GSD) of curcuminoid 
components (bisdemethoxycurcumin, demethoxycurcumin and curcumin) are 
presented in table 5.13, the mass distribution of curcuminoids among NGI 
stages are shown in figures 5.21 and 5.22. The mean (n=3) of fine particles 
fraction (FPF), mass median aerodynamic diameter (MMAD) and geometric 
standard  deviation (GSD) were calculated using Copley Inhaler Testing Data 
analysis software (CITDAS). 
  




Table 5. 13 The mean (n=3) of the aerodynamic parameters of DPI formulation 
of curcuminoids of sono17 (sonocrystallised curcumin particles precipitated 
from acetone-heptane). 
Aerodynamic parameters of curcuminoids DPI Formulations, sono17 
Drug Formulations FPF% MMAD (µm) GSD 
Bisdemethoxycurcumin 
Sono17-1 (1:9) 32.12 3.29 2.69 
Sono17-2 (1:67.5) 32.85 2.89 2.96 
Demethoxycurcumin 
Sono17-1 (1:9) 30.06 3.54 3.04 
Sono17-2 (1:67.5) 30.36 3.06 2.92 
Curcumin 
Sono17-1 (1:9) 29.94 3.76 2.46 
Sono17-2 (1:67.5) 32.13 3.12 2.69 
FPF% is fine particle fraction, MMAD is the mass median aerodynamic diameter, and GSD is the 
geometric standard deviation. 
 
Figure 5. 21 Mass distribution of DPI formulation (sono17-2) of sonocrystallised 
curcumin particles from acetone-heptane (sono17). BDC: 






























Figure 5. 22 Mass distribution of DPI formulation (sono17-1) of sonocrystallised 
curcumin particles from acetone-heptane (sono17). BDC: 
bisdemethoxycurcumin, DC: demethoxycurcumin, C: curcumin 
 
The FPF% of the three curcuminoid components was determined (i.e. curcumin, 
demethoxycurcumin and bisdemethoxycurcumin), and found to be around 30% 
throughout both formulations. The MMAD of both formulations is also about 
3.2µm, which means 50% of the particles are below 3.2µm. The GSD ranges 
from 2.4 to 3 for both formulations and among curcuminoid components. These 
data (FPF 30%) are satisfactory in DPI formulations, because most of the 
inhaled formulations have a FPF% above 25% (Yakubu, 2009). The low fraction 
of the fine particle dose in both formulations could be attributed to a high 
particle size of D90, which has shown to be above 5µm, as any particles above 
this size (5µm) are usually deposited in on the throat. Also, the free surface 
energy of sonocrystallised curcumin from acetone was slightly high and 
therefore, the adhesion force was high too, this usually leads to poor 
aerodynamic performance of DPI formulations. Both formulations with different 
ratio of drug-lactose present an almost similar FPF% (30%). This suggests that 





























curcumin. This similarity of both results (FPF%) could be related to the fact that 
the work of adhesion (81J/m2) is very close to the work of cohesion (80.81J/m2) 
as shown in section 5.3.3. The energy between the agglomerate 
sonocrystallised particles curcumin is almost equal to the energy between the 
curcumin particles and the lactose. Therefore, increasing the ratio of lactose to 
curcumin in this case has not shown improvement on the formulation 
performance.  This could be attributed to the fact that when the particles are 
detached from the carriers surface they stay as an agglomeration as shown in 
figure 5.26 and thus increase the size of the individual particles which leads to 
low FPF%.  
 Formulation from ethanol (sono16): sono16-1 is the formulation of 
drug:lactose ratio 1:9, and sono16-2 is the formulation of drug:lactose 
ratio 1:67.5.  
The aerodynamic characterisation of the DPI formulations sonocrystallised 
curcuminoids (curcumin and demethoxycurcumin and bisdemethoxycurcumin) 
form ethanol (sono16) as represented in table 5.14. The mass distribution of the 
drugs throughout the NGI stages is shown in figures 5.23 and 5.24. The mean 
(n=3) of fine particles fraction (FPF), mass median aerodynamic diameter 
(MMAD) and geometric standard  deviation (GSD) were calculated using 
Copley Inhaler Testing Data analysis software (CITDAS). 
  




Table 5. 14 Aerodynamic characterisation of DPI formulation of curcuminoids of 
sono16 (sonocrystallised curcumin particles precipitated from ethanol-heptane) 
Aerodynamic parameters of curcuminoids DPI Formulations, sono16 
Drug Formulations FPF% MMAD (µm) GSD 
Bisdemethoxycurcumin 
Sono16-1 (1:9) 43.41 3.41 2.29 
Sono16-2 (1:67.5) 37.09 2.89 2.90 
Demethoxycurcumin 
Sono16-1 (1:9) 43.68 3.56 2.11 
Sono16-2 (1:67.5) 34.29 2.81 2.92 
Curcumin 
Sono16-1 (1:9) 43.49 3.68 1.95 
Sono16-2 (1:67.5) 36.62 2.86 2.77 
FPF% is fine particle fraction, MMAD is the mass median aerodynamic diameter, and GSD is the 
geometric standard deviation. 
 
 
Figure 5. 23 Mass distribution of DPI formulation (sono16-2) of sonocrystallised 
curcumin particles from ethanol-heptane (sono16). BDC: 





























Figure 5. 24 Mass distribution of DPI formulation (sono16-2) of sonocrystallised 
curcumin particles from ethanol-heptane (sono16). BDC: 
bisdemethoxycurcumin, DC: demethoxycurcumin, C: curcumin 
 
The results, which were obtained from sonocrystallised curcuminoids from 
ethanol (sono16), show that FPF% ranges from 43.4% to 43.6% for the 
formulation sono16-1 (which contains drug: lactose 1:9) among the curcuminoid 
components, whereas the formulation 16-2 (which contains drug: lactose 
1:67.5) has FPF% ranging from 34.2% to 37.0%. The MMAD for the formulation 
of sono16-1 is between 3.4µm and 3.6µm but for the formulation sono16-2 is 
2.8µm. Both DPI formulations demonstrate a well aerosol deposition and 
performance; this could be related to the low surface energy of the 
sonocrystallised curcumin particles as well as to the work of cohesion and of 
adhesion. The first formulation sono16-1 demonstrates a better performance, as 
FPF is 43%, compared to the second formulation, as its FPF is 37%. This could 
be as a result of the lower cohesion energy compared to the adhesion energy 
as shown in section 5.4.5. It is likely the adhesion work is the more dominant 
force in the second formulation (sono16-2) over cohesion, as the amount of the 































hand, in the former formulation (sono16-1), in which the amount of the drug is 
as high as 10%, the extra amount of the drug  is  likely to form a second or 
more layers of the drug particles (agglomerations) on the carrier surface. 
Therefore, the cohesion force is a dominant force in this formulation over the 
adhesion energy, as the first layer will be attached to the carrier surface by the 
adhesion energy and other agglomerate particles or the other layers of the drug 
will be more controlled by the cohesion force. Since the cohesion energy 
(70J/m2) is lower than the adhesion work (76J/m2), the particles will be 
detached from each other before their detachment from the carrier when they 
inhaled as shown in figure 5.26. Therefore, the performance of first formulation 
(with 10% of the drug, 1:9 drug: lactose) is superior to the second formulation 
(with 2% of the drug, 1:67.5, drug: lactose). 
From the data, the sonocrystallised curcumin using ethanol (sono16) solvent 
shows an improvement in the FPF% over the curcumin particles prepared using 
acetone (sono17). This is attributed to the higher surface energy and work of 
cohesion and adhesion of the later formulation. 
The results of this work led to synthesis a theory of drug particles distribution 
onto a carrier surface illustrated in Figure 5.25.The theory illustrates the 
possible effect of the adhesion and cohesion energy on performance of the DPI 
formulations. Figure 5.25-E and F represent an irregular distribution of the 
agglomerated drug particles onto the surface of carrier, Figures 5.25-C and D 
illustrates a regular distribution of drug particles on the carrier. When more drug 
particles are loaded onto the surface of the carrier, then the aerodynamic 
behaviour of drug particles will be controlled by the cohesion work, the (either 
way of regular or irregular distributions).The following points summarise the 




relationships between the cohesion and the adhesion forces and with drug-
carrier concentration linked to DPI formulation performance:   
 When the work of adhesion is equal to the work of cohesion, there will be 
no difference in the DPI formulation performance between the high or low 
concentration of the drug on the surface as is it shown in the formulation 
of sono17-1 and sono17-2. 
 When the work of cohesion is smaller than the work of adhesion, the more 
amounts of the drug onto the surface, the better performance of the 
formulation as shown in formulation of sono16-1 and sono16-2. This 
could be attributed to the fact that the particles will be detached from 
each other before their detachment from the carrier when they inhaled as 
shown in figure 5.26. 
 Results from this work could also suggest that when the work of cohesion 
is higher than the work of adhesion, the less amounts of drugs onto the 










Figure 5. 25 drug particles distributed on a carrier surface at low and high 
concentration of drugs particles in dry powder inhaler formulations 
 





Figure 5. 26 drug detachments from the carrier surface during inhalation 
 
5.4. Conclusion 
In conclusion, inhalable curcumin particles were prepared from different 
solvents (ethanol, isopropanol and acetone) and antisolvents (water and 
heptane) using ultrasound. The optimum conditions of the ultrasound to 
produce curcumin particles for inhalation are 1 min of sonication time and 50% 
of ultrasound irradiation. 
The DSC thermograms and diffractograms showed that the precipitated 
curcumin particles have polymorph 3 (form 3) when it is only produced from 
isopropanol (solvent) and water (antisolvent) while the ethanol and acetone 
solvents produce form 1 of curcumin with water antisolvent. On the other hand 
form 1 of curcumin was also obtained from ethanol, acetone and isopropanol 
with heptane (antisolvent). The SEM images presented that the sonocrystallised 
curcumin particles were based on the used solvent and antisolvent system 
during crystallisation by ultrasound. The crystal morphology of the precipitated 
particles were in plate shape when ethanol and acetone with water and heptane 




systems were used, whereas a rising seed-like shape was observed when 
isopropanol and water were used, a flower particles shape was seen with an 
isopropanol-heptane system. 
The surface energy of the precipitated curcumin particles varies depending on 
the solvent and antisolvent system. The total free surface energy for the 
particles precipitated from ethanol-water was 36.3mJ/m2, from isopropanol-
water (form 3) was 37.3mJ/m2, from acetone-water was 41.2mJ/m2, from 
ethanol-heptane was 35.2mJ/m2 and from acetone-heptane is 40.2mJ/m2. The 
variations in the surface energy were referred to the difference in the polarities 
of the solvents and antisolvents. The total free surface energy of the carrier is 
46.9mJ/m2. 
Dry powder inhaler formulations were prepared by mixing sonocrystallised 
curcumin particles with lactose, the produced particles using water antisolvent 
showed poor dispersibility with lactose as they had formed a cake during drying 
by filtration, whereas the particles obtained from heptane as an antisolvent 
dispersed very well on the carrier. Therefore particles that produced 
sonocrystallised using water as an antisolvent were excluded from aerosol 
characterisations. Also, the produced particles from isopropanol and heptane 
were excluded due to the large particle size of D90 (12µm). 
The two formulations of DPI of sonocrystallised curcumin particles (from ethanol 
and acetone with heptane as antisolvents) at two different ratios (1 to 9 and 1 to 
1 to 67.5) of curcumin:lactose, were characterised using NGI. The FPF%, 
MMAD and GSD of each individual curcuminoid component was determined. 
The DPI formulations from ethanol showed a better performance compared to 
the DPI formulation obtained from acetone, this was due to the total free surface 




energy of curcumin particles produced from acetone higher than the surface 
energy of precipitated curcumin particles from ethanol. The higher drug: lactose 
ratio of the DPI formulation, which its curcumin particles obtained from ethanol 
and heptane, illustrated better FPF% compared to the one with lower drug: 
lactose ratio, this was attributed to low cohesion energy compared to the 
adhesion energy of the curcumin particles and lactose. In the DPI formulation, 
which the curcumin particles prepared from acetone and heptane, both ratios 
present very close FPF%, this attributed to the closeness of the cohesion and 
adhesion energy of curcumin and lactose particles.  
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6 Chapter 6: Development and evaluation of nanoemulsion and 
microsuspension formulations of curcuminoids for lung cancer using 
nebuliser 
6.1. Introduction 
Liquid-based formulation is usually delivered to the lungs using a nebuliser. 
Microsuspension is the only approved solution formulation for lipophilic inhaled 
drugs. Therefore, the nebulised formulations of water insoluble that are 
available in the market are in suspension form such as budesonide 
microsuspension. However, several disadvantages have been reported by 
using microsuspension for inhalation, such as considerable heterodispersity in 
drug concentration in the aerosol droplet (Knoch and Keller 2005), short drug 
residence time of drug in the lungs due to the ciliary movement (Patravale and 
Kulkarni 2004), limited bioavailability of the micronized drug compared to the 
nanoparticles and variability in drug deposition patterns when using different 
nebulisers (Nikander et al. 1999). For these reasons, another formulation of 
curcuminoids in this study has been considered and optimised for inhalation.  
Nanoemulsion is a nanometre sized droplet of one liquid dispersed in another 
immiscible liquid, and it is generally optically transparent and thermodynamically 
stable (Bryant and Altria 2004). Nanoemulsion drug delivery systems have been 
used in different administration route, such as oral, parenteral and topical 
(Lawrence and Rees 2012). In addition to its small particles size (1-100nm), the 
nanoemulsion has the ability to solubilise both hydrophilic and hydrophobic 
drugs, hence increasing the bioavailability of the drug (Lawrence and Rees 
2012). Nanoemulsion enhanced the curcuminoids bioavailability and its activity 




when it was applied locally onto skin or taken orally (Wang et al. 2008; Cui et al. 
2009; Liu et al. 2011; Hu et al. 2012).  
Curcuminoids nanoemulsion for lung delivery has not been studied before. 
Therefore, the aim of this work is to prepare curcuminoids nanoemulsion for the 
treatment of lung cancer and another lung disease. There are few reports of 
using nanoemulsion for respiratory drug delivery (Amani et al. 2010; Nasr et al. 
2012; Nesamony et al. 2014), but these formulations contain high amount of 
surfactant and hence this limits their suitability for inhalation therapy. In this 
work, it is proposed to prepare a curcuminoid nanoemulsion using an extremely 
low amount of surfactant to avoid the formulation toxicity and to make it safe for 
inhalation. 
The in vitro genotoxicity of the nanoemulsion of curcuminoids has also been 
examined using single gel electrophoresis (comet assay) on human lymphocyte 
cells. The genotoxicity test is required to assess the safety of the formulation 
and its suitability for animal study in the future. 
In this chapter, nebulised formulations of curcuminoid (microsuspension and 
nanoemulsion) have been prepared. The formulation characterisations such as 
particle size, zeta potential, viscosity, density, aerosol output and aerodynamic 
properties were examined and reported. The aerosol output and the 
aerodynamic assessment have been carried out for all individual curcuminoids 
(curcumin, demethoxycurcumin and bisdemethoxycurcumin) in each 
formulation. It is worth reporting that no previous studies have conducted in vitro 
aerodynamic characterisation for all curcuminoids components.  





6.2.1. Nanoemulsion Preparation 
To prepare nanoemulsion that is safe for internal use, accepted pharmaceutical 
ingredients need to be considered. The reported formulations by Marsh (Marsh 
et al. 2004), which  were composed of octane 0.8% (w/w), butanol 6.6% (w/w) , 
SDS 3.3% (w/w) and phosphate buffer 89.3% (w/w), and Amani (Amani et al. 
2010), which consist of medium 1% of chain triglyceride (w/w), 10% of Tween 
80 (w/w), 1% of ethanol (w/w) and 88% normal saline (w/w), were initially 
followed to prepare the  nanoemulsion formulations and then were optimised 
accordingly to meet respiratory use. The amount of each component of 
nanoemulsion was reduced to the minimum to produce a formulation that is 
suitable and safe for respiratory drug delivery. 
Nanoemulsion formulations were prepared using different types of oil, limonene 
and oleic acid oil. Tween 80 and ethanol were used as surfactant and 
cosurfactant, respectively. Limonene and Oleic acid were used as an oily phase 
while distilled water was used as an aqueous and continuous phase (see table 
6.1). The oil (limonene or oleic acid), surfactant (Tween 80) and cosurfactant 
(ethanol) were initially mixed and the aqueous phase was then added. A clear 
solution was formed simultaneously by adding the ultrapure milli-Q water. The 
nanoemulsion was then sonicated for 10 minutes to ensure that all ingredients 
had been mixed very well. 
Loading capacity of nanoemulsion was studied by adding an excess amount of 
curcuminoid and then sonicated for 15 mins and left at room temperature for 24 
hours. The nanoemulsion was then filtered using 0.45µm syringe filter and 




diluted in a HPLC mobile phase then injected into HPLC using a validated 
HPLC method as mentioned in chapter 3 section 3.1.2.1.  
Table 6. 1 Nanoemulsion compositions (NE: Nanoemulsion) 
Formulations Surfactant% (w/w) Cosurfacnt% (w/w) Oil% (w/w) Water% (w/w) 
NE1 Tween 80 (3.3) Ethanol (6.6) Limonene (0.8) Water (89.4) 
NE2 Tween 80 (3.3) Ethanol (2.5) Limonene (0.8) Water (93.4) 
NE3 Tween 80 (1.65) Ethanol (1.25) Limonene (0.4) Water (96.7) 
NE4 Tween 80 (0.82) Ethanol (0.62) Limonene (0.2) Water (98.4) 
NE5 Tween 80 (0.33) Ethanol (0.25) Limonene (0.08) Water (99.2) 
NE6 Tween 80 (3.3) Ethanol (6.6) Oleic acid (0.8) Water (89.3) 
NE7 Tween 80 (3.3) Ethanol (6.6) Oleic acid (0.3) Water (89.8) 
NE8 Tween 80 (3.3) Ethanol (2.5) Oleic acid (0.3) Water (93.9) 
NE9 Tween 80 (1.65) Ethanol (1.25) Oleic acid (0.15) Water (96.95) 
NE10 Tween 80 (0.82) Ethanol (0.62) Oleic acid(0.075) Water (98.48) 
NE11 Tween 80 (0.33) Ethanol (0.25) Oleic acid (0.03) Water (99.39) 
 
6.2.2. Microsuspension preparation 
Saline solution was prepared by dissolving 0.9% of sodium chloride in distilled 
water. A sufficient amount of micronized curcuminoids was suspended in 0.2% 
(w/w) of Tween 80 and then diluted with saline solution to obtain a 0.02% of 
tween 80 with final concentration of 500, 250 and 100 µg of curcuminoids. 




Suspension formulation of curcuminoids was prepared to study the difference in 
the aerodynamic behaviour between the nanoemulsion and suspension when 
they are nebulised. 
Suspension is a dispersion of fine insoluble solid particles (the disperse phase) 
in a fluid which is called the dispersion medium. The suspension formulations 
are usually composed of an aqueous dispersion phase and suspending agent 
like surfactant such as polysorbate 80. The suspension remains homogenous 
after shaking for the period of filling the nebulised chamber and during 
nebulisation time. The amount of Tween 80 was used according to FDA 
regulations. 
6.2.3. Osmolality and PH 
The osmolality and pH of the nanoemulsion samples was determined at room 
temperature using Advanced 3320 Micro-Osmometer (Model 3320) and a pH 
meter (details), respectively. The Osmometer was calibrated using a standard 
solution (50 mOsm Calibration Standard). Samples were measured in triplicate 
and the mean was then calculated. Sodium chloride was used to adjust the 
osmolality of the samples. 
6.2.4. Physical stability studies 
The selected formulation was monitored for stability studies at room 
temperature for six months. The nanoemulsion solutions were kept in sealed 
glass vials at room temperature of (22ºC +/- 2ºC) and were visually examined 
every two weeks for any turbidity in the formulation. The stability was conducted 
for any changed in the physical appearance of the nanoemulsion, phase 
separation and any turbidity during the storage period at room temperature. 




6.2.5. Particles size measurement 
The nanoemulsion particle size was measured using Malvern Zetasizer Nano-
Zs dynamic light scattering (DLS) instrument. The average particle size was 
determined from three measurements. The instrument was calibrated by using 
Nanospher TM (with average diameter 59.0nm±2.5) and duke standard TM 
(with average diameter 500.0nm±0.2). 
6.2.6. Zeta potential determination 
The zeta potential of the nanoemulsion formulations was carried out at 25°C 
using a Malvern Zetasizer dynamic light scattering (DLS) instrument. The mean 
of the zeta potential was determined from three reading for each formulation. 
The samples were loaded in covet cell designed for zeta potential measurement 
and inserted into the instrument. The machine was calibrated using standard 
polystyrene latex (with zeta potential of – 50 mV±5 mV.)  
6.2.7. Density 
 The density of the formulation was examined by filling samples into a 10ml 
volumetric flask and weighing them at room temperature. Distilled water was 
filled into the same volumetric flask and weighed too. The relative density was 
determined according to the following equation:  
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑎𝑚𝑝𝑙𝑒
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑖𝑠𝑡𝑖𝑙𝑙𝑒𝑑 𝑤𝑎𝑡𝑒𝑟
 
6.2.8. Viscosity 
The viscosity of the samples was measured using vibrating viscometer (SV-10) 
at 25 0 C. The sample was loaded into viscometer container (35ml) and 
attached into the base of the instrument. 




6.2.9. CEN method for measuring aerosol output  
Figure 6.1 displays the European Standard methodology setup for measuring 
the nebuliser aerosol output (Boe et al. 2001). The aerosol output of the 
nanoemulsion was carried out using the Sidestream jet nebuliser. The chamber 
of the nebuliser was filled with 5ml of nanoemulsion sample and connected to a 
breathing simulation machine. The breathing machine was set up at sinus flow 
of 15 breathes per minute and a tidal volume of 500ml with an inspiration to 
expiration ratio of 1:1. A filter holder containing filter (A) was attached between 
the breathing machine and the nebuliser. This filter would collect the inhaled 
aerosol during the breathing cycle. A second holder containing filter (B) was 
connected to a vacuum pump set at 25L/min, and was placed at 4cm from the 
other end of the nebuliser to collect the exhaled particles without interfering with 
inhaled aerosol. The breathing machine and vacuum pump were switched on 
30 second before starting on the compressor of the nebuliser. Nebulisation time 
was recorded and the nebuliser was allowed to operate until the sputtering 
occurred. The sputtering is when the sidestream jet nebuliser produces an 
intermittent sound which indicates discontinues stream of the aerosols from the 
nebuliser. On completion of each run, both filters (A) and (B) were transferred 
into separate beakers and dissolved in appropriate solvent to collect the inhaled 
and exhaled aerosol particles of the nebulised formulation. Each sample was 
run in triplicate (n=3); the mean and the SD were calculated. Among all samples 
the amount and the percentage of the inhaled, exhaled and remaining drug in 
the nebuliser chamber were calculated.  
  











6.2.10. Aerodynamic diameter measurements and particles lungs 
depositions 
Figure 6.2 illustrates next generation impactor setup for measuring the 
aerodynamic particles size of nebulised curcuminoids formulations according to 
pharmacopeia (USP 2012, Ph. Eur 2012). NGI was placed in a cooler system at 
5°C for 30 mins before nebulisation. The jet sidestream nebuliser was kept 
outside the cooler system and connected to the NGI by T-piece as it is shown in 
figure 6.2. The NGI was connected form the other side to a flow controller which 
was already attached to a vacuum pump. The flow rate was adjusted to be 15 
L/min. The pump and the flow controller were switched on before starting the 
nebulisation. The nebuliser chamber was filled with 5ml of nanoemulsion 
samples and run after switching the pump and the controller on. The 
nebulisation was stopped first after the sputtering sound is heard and then the 
controller and the pump. The NGI cups and the nebuliser chamber were then 
washed with 20ml of the emodin solution (internal standard). Samples were 
assessed in triplicate and the nebulisation time for each one was recorded. 
  
Figure 6.1 Schematic diagram of aerosol output system, adapted from Boe  
(Boe et al. 2001) 
Breathing Machine  








Filter B Filter A  












Comet assay is a simple and sensitive method for the detection of DNA 
breakage in individual cells (Ostling and Johanson 1984). This method was 
produced by Ostling and Johanson (Ostling and Johanson 1984) and it has 
been developed further by Singh and Olive (Singh et al. 1988; Olive et al. 
1990). It has been found that DNA damages (fragments) stretches from the 
nucleus, in the form of a comet, towards the anode in alkaline electrophoresis 
gel. The DNA migration is the function of the intensity of DNA breakage. Tail 
moment, a measure of tail length and the fraction of DNA in the Comet tail, was 
used as the arbitrary unit of assessment (Anderson et al. 2003; Kumaravel and 
Jha 2006). Tail moment measures both the smallest detectable size of 
migrating DNA (reflected in the comet tail length) and the number of 
relaxed/broken pieces of DNA (represented by the intensity of DNA in the tail) 
𝑂𝑙𝑖𝑣𝑒 𝑇𝑎𝑖𝑙 𝑀𝑜𝑚𝑒𝑛𝑡 =  (𝑇𝑎𝑖𝑙. 𝑚𝑒𝑎𝑛 −  𝐻𝑒𝑎𝑑. 𝑚𝑒𝑎𝑛) 𝑋 𝑇𝑎𝑖𝑙 % 𝐷𝑁𝐴/100 
The assay was carried out using lymphocytes cells because they are excellent 
carriers for examining genomic sensitivity of any cell as their sub-populations 









Figure 6.2 NGI and nebuliser set up 




aberrations for over 40 years (Neel et al. 1989). Also, the World Health 
Organisation/International Programme for Chemical Safety recommends the 
use of lymphocytes for the detection of genotoxic insult (Albertini et al. 2000). 
Protocol 
The protocol which was carried out for comet assay was as described by Tice 
(Tice et al. 2000), and it is as follows:  
A glass slide was covered with 1% normal melting point agarose (NMP) and left 
to dry overnight. 890µl PRMI 1640 was added into Eppendorf tube, 10µl of 
curcumin nanoemulsion (NE3, NE4, NE5, NE9, NE10 and NE11) was added to 
the cell media then 100µl of whole blood sample was added to the previous 
mixture and incubated for 30 mins at 37ºC. The samples were moved to a 
centrifuge for 5 mins at 3000 rpm. 900µl from the supernatant was removed 
from the samples and 100µl of 0.5% low melting point of agarose (at 40ºC) was 
added to each sample. The cell pellets were disrupted gently and 100µl of the 
suspended cells was transferred into previous coated glass slide with 1% NMP 
and distributed by a cover slip, and left on ice for around 5 min. The cover slip 
was removed carefully from the slide and then the slide was kept in a lysis 
solution (2.5M NaCl, 100mM EDTA, 10mM Tris, 10% DMSO, 1% Triton X-100, 
pH 10) at 4ºC for overnight. The slide then transferred into gel electrophoresis 
tank with cold alkaline buffer solution (300mM NaOH, 1mM EDTA, pH <13) and 
left for about 30 mins at 4ºC. The electrophoresis was conducted at 25 voltages 
and 300mA for 30 mins at 4ºC. The samples slide was washed with neutralising 
buffer solution (400mM Tris, pH 7.5) and left for 5 min.  Ethidium bromide (60µl, 
20µg/ml) was added into the sample slides with a cover slip and incubated for 5 
mins and then examined with a fluorescent microscope equipped with CCD 




camera. A computerised image analysis system, Komet 4.0 (Kinetic Imaging, 
Liverpool, UK), was employed to measure the Comet parameters; the % Olive 
tail moment was then used for statistical analysis. 
 
Figure 6.3 Schematic structure of glass slide preparation for comet assay 
 
6.3. Results and discussions 
6.3.1. Nanoemulsion preparation and optimization 
Table 6.2 shows the visual observation of the nanoemulsion preparations. The 
limonene nanoemulsion was clear in all formulations. The oleic acid 
nanoemulsion was not formed with 0.8% of oleic acid as oil, so the oil 
























The study target was to prepare nanoemulsion with the lowest possible amount 
of ingredients (i.e. surfactant, cosurfactant and oil). Therefore, the amount of 
each nanoemulsion components was decreased to the minimum. 
Curcuminiods were dissolved in the oily phase (surfactant, cosurfactant and oil) 
and then sonicated for a few minutes to assure that the drug was completely 
dissolved. The distilled water was added gradually to the oily phase; a 
spontaneous clear transparent solution was formed. The loading capacity of 




curcuminoids in nanoemulsion (NE9, 10 and 11) was 500µg/ml, 250µg/ml and 
100µg/ml of curcuminoid respectively. Loading capacity of NE3, 4 and NE5 was 
500, 250 and 100µg/ml, respectively.  
The oleic acid is approved by the FDA to be used in respiratory preparations at 
a concentration of 0.28%. Also Tween 80 was approved to be used at 0.02% of 
formulations. In this work the minimum amount of surfactant used was 0.33% 
(NE5&11).The cosurfactant (ethanol) also was reduced from 6.6% (NE1&NE7) 
to 0.25%  (NE5&NE11).There was no change on nanoemulsion appearance 
when the surfactant, cosurfacnt and oil reduced to the minimum. However, 
nanoemulsion was not formed when reducing the percentage of the Tween 80 
or ethanol less than 0.33% and 0.25% respectively; this was because of 
insufficient amounts of the surfactant and cosurfactant to solubilise the oil.  
Limonene was also used in this research as an oil phase to produce the 
nanoemulsion. It was reported that limonene did not show any irritation or 
central nervous system related-symptoms when inhaled by human subjects 
(Falk-Filipsson et al. 1993) and it was also reported that limonene reduces the 
air way inflammation in mice (Hirota et al. 2012). Additionally, limonene has 
chemopreventive and chemotherapeutic activity against many types of cancer 
in rodents (Gould 1997) and has antioxidant activity (Bacanlı et al. 2015). 
Nanoemulsion formulations, for drug delivery, have been widely used for oral, 
parenteral and intravenous route. However, very limited studies were reported 
by using nanoemulsion formulations for lung delivery, which is likely attributed 
to the high concentration of nanoemulsion ingredients, which are not suitable for 
lungs or it is not proved to be safe for the lungs. For example, budesonide has 
been formulated in nanoemulsion to be delivered to the lungs (Amani et al. 




2010), but the Tween 80 were about 10% w/w of the formulation which is not 
suitable for the lungs according to the FDA. In other reported studies, the 
combination of surfactants (25% to 65%) were required  to be used along with  
cosurfactants (12% to 44%) to produce the nanoemulsion (Nesamony et al. 
2014), this is also likely to be  harmful to human  lungs. Whereas, in this work, 
the amount of Tween 80 (surfactant) used was ten and thirty times less than it 
was used in the reported work, which could be suitable and safer for the 
respiratory system. 
6.3.2. Osmolality 
Osmolality of nebulised formulations has an effect on the respiratory systems by 
producing bronchoconstriction and a cough; hence, it decreases the delivery of 
the drug to the lungs (Weber et al. 1997). The suitable osmolality of aerosols 
solution should be between130mOsm/kg and 500mOsm/kg, and the formulation 
should also have permeant ions (such as chloride) in concentrations of 31mM to 
300mM to ensure the airways tolerability of such formulation (Weber et al. 
1997). 
The nebulised nanoemulsion has been formulated using ultrapure milli-Q water 
as an aqueous phase (continues phase) and then osmolality was adjusted for 
each formulation by adding a suitable amount of sodium chloride. The 
suspension formulations were prepared in a saline solution by dissolving 
sodium chloride (0.9%) in distilled water. The osmolality was measured for 
nanoemulsion and suspension with curcuminiods and without it. Table 6.3 
presents the osmolality with curcuminiods. 
 




Table 6.3 Osmolality results for the nanoemulsion and suspension preparations 
and Sodium chloride concentrations in each formulation 
Formulations Concentration of NaCl mM Osmolality (mOsm/kg) 
NE2 (1000µg/ml) 0 600  ± 3.0 
NE3 (500µg/ml) 35 350 ± 2.1 
NE4 (250µg/ml) 95 345 ± 3.2 
NE5 (100µg/ml) 150 340 ± 4.5 
NE8 (1000µg/ml) 0 600 ± 4.0 
NE9 (500µg/ml) 35 353 ± 3.6 
NE10 (250µg/ml) 95 343 ± 5.8 
NE11 (100µg/ml) 150 335 ± 2.1 
Suspension1 (500µg/ml) 160 286 ± 4.0 
Suspension2 (250µg/ml) 160 285 ± 3.4 
Suspension3 (100µg/ml) 160 283 ± 2.5 
 
From the results in table 6.3, it is clear that all the formulations of nanoemulsion 
and suspension (with concentration of 500, 250 and100µg/ml) are in the ideal 
range of the osmolality. The only two formulations out of the accepted 
osmolality range for nebulisation are NE2 and NE8; this is attributed to a high 
amount of ethanol in the formulations. The ethanol forms 2.5% of the 
formulations NE2 and NE8. Therefore, these formulations with high osmolality 
and zero sodium chloride were excluded from further studies. 





The pH for nebulisation solutions need to be adjusted before approaching the 
respiratory system, because the low and high pH causes a bronchoconstriction 
and a cough. Cough is undesirable as the deposited particles may be 
expectorated before it takes effect (Weber et al. 1997). The bronchoconstriction 
can cause hypoxemia in some patients and reduces the aerosols delivered into 
the airways (Weber et al. 1997). The ideal pH for nebulised preparations should 
be between 3 and 8.5, according to USA pharmacopeia. Table 6.4 shows the 
pH for the selected formulations for both suspensions and nanoemulsion. The 
results show that all formulations have a pH in the acceptable range for 
solutions for nebulisation.  
Table 6.4 pH results of nanoemulsion and suspension formulations 
Formulations pH 
NE3 (500µg/ml) 6.93 
NE4 (250µg/ml) 6.74 
NE5 (100µg/ml) 6.33 
NE9 (500µg/ml) 6.84 
NE10 (250µg/ml) 6.77 
NE11 (100µg/ml) 6.34 
Suspension1 (500µg/ml) 5.90 
Suspension2 (250µg/ml) 5.11 
Suspension3 (100µg/ml) 5.15 





Viscosity is the resistance of the fluid to a flow; therefore, the viscosity is 
important in aerosols formulations. Ingredients of the formulations and 
concentration of the drugs may change the viscosity of the preparations, hence 
this could alter the aerosol output and the aerodynamic distributions of the 
particles (Mc Callion and Patel 1996; Weber et al. 1997).Viscosity 
measurements of the nanoemulsions and suspension preparations with 
curcuminoids at different concentrations are presented in table 6.5. 
Table 6.5 Viscosity results of nanoemulsion and suspension formulation using 
viscometer 
Formulations Viscosity (mPas) 
NE3 (500µg/ml) 1.21 
NE4 (250µg/ml) 1.13 
NE5 (100µg/ml) 1.07 
NE9 (500µg/ml) 1.28 
NE10 (250µg/ml) 1.16 
NE11 (100µg/ml) 1.08 
Suspension1 (500µg/ml) 1.04 
Suspension2 (250µg/ml) 1.05 
Suspension3 (100µg/ml) 1.04 
 
The results illustrate that the viscosity of the nanoemulsion formulations with 
either limonene oil or oleic acid oil increases as the concentration of the 




ingredients (oil, surfactant and co-surfactant) increases. The suspension 
formulation did not show any further raise in the viscosity, this is because of the 
amount of the surfactant, which was used in each formulation, and was 
constant at the of level 0.02% w/w.  
6.3.5. Density 
The density results of the nanoemulsions formulations and suspensions are 
shown in table 6.6. The results show no change in the formulations density; this 
is attributed to fact that the 98% of the formulation is water (saline) 
Table 6. 6 Density results of both preparations nanoemulsion and suspension 
Formulations Density (g/ml) 
NE3 (500µg/ml) 1.0001 
NE4 (250µg/ml) 1.0019 
NE5 (100µg/ml) 1.001 
NE9 (500µg/ml) 1.0003 
NE10 (250µg/ml) 1.0022 
NE11 (100µg/ml) 1.0036 
Suspension1 (500µg/ml) 1.00010 
Suspension2 (250µg/ml) 1.00018 
Suspension3 (100µg/ml) 1.00020 
 




6.3.6. Particle size analysis using malvern (zetasizer) 
The results of the particles size of the nanoemulsion and suspension 
formulations were given in table 6.7.  
Table 6.7 Particles size results and polydispersity index for nanoemulsion and 
suspension formulations using Zetasizer 
Formulations Particle size (nm) ± SD PDI 
NE3 (500µg/ml) 13 ± 4.83 0.13 
NE4 (250µg/ml) 12 ± 3.34 0.05 
NE5 (100µg/ml) 12 ± 3.64 0.06 
NE9 (500µg/ml) 39 ± 25.16 0.23 
NE10 (250µg/ml) 32 ± 17.67 0.15 
NE11 (100µg/ml) 31 ± 15.42 0.15 
Suspension1 (500µg/ml) 1650 ±  1015 0.19 
Suspension2 (250µg/ml) 1650 ±  1015 0.19 
Suspension3 (100µg/ml) 1650 ±  1015 0.19 
 
The particle size of the nanoemulsion prepared by limonene oil (NE3, 4 and 5) 
is smaller than the nanoemulsion produced by oleic acid (NE9, 10 and 11). The 
particle size of NE3, 4 &5 is about 12nm whereas the size of the particles in 
NE9, 10 & 11 is around 35nm. The difference in the particle droplet size is 
attributed to the difference in physicochemical properties of the oils (viscosity). 
The viscosity of limonene is about 0.923mPa at 25ºC (Haynes 2014), whereas 
the viscosity of oleic acid is 30mPa at 25ºC (Noureddini et al. 1992).  Increasing 




the viscosity of the fluid, increases the resistance to the deformation of the 
particles, hence the oleic acid is more resistant to be deformed (disperse into 
smaller droplet size) than limonene oil. The viscosity of oils has a significant 
effects on the droplet size of emulsions, as a less viscose oil produced a 
smaller droplet size of emulsion (Wooster et al. 2008; Khatibi 2013). The 
particle size of microsuspension was about 1.6µm, which was the same 
micronized solid particle of curcuminoids that were prepared beforehand and 
then were suspended in ultrapure milli-Q water containing Tween 80 and 0.9% 
sodium chloride. 
The polydispersity index (PDI) value for the NE3, NE4 and NE5 was very small 
around 0.1 to 0.05 which indicates that the particle size of nebulised formulation 
was monodispersed. Also, the low value of the PDI was shown for NE10 and 
NE11 formulations, which contains lower concentrations of drugs (100 & 250 
µg/ml) than NE9 (500µg/ml). PDI in the suspension formulation is about 0.2 
which indicates a narrow distribution of the particles size of curcuminoids in the 
formulations.  
Figure 6.4 gives some illustrative data from analysis of nanoemulsion using 
Malvern Zetasizer. 
 
Figure 6.4 An example of illustrative data analysis obtained from malvern zeta 
sizer for NE11 




6.3.7. Zeta potential 
Table 6.8 shows the zeta potential data of both formulations nanoemulsion and 
suspension 
Table 6.8 Zeta potential data for nanoemulsion and suspension formulations 
Formulations Zeta potential (mV) 
NE3 (500µg/ml) -6.14 (0.87) 
NE4 (250µg/ml) -3.59 (0.33) 
NE5 (100µg/ml) -2.75 (0.33) 
NE9 (500µg/ml) -7.79 (0.59) 
NE10 (250µg/ml) -5.75 (0.50) 
NE11 (100µg/ml) -5.46 (0.45) 
Suspension1 (500µg/ml) -5.20 (0.36) 
Suspension2 (250µg/ml) -5.13 (0.37) 
Suspension3 (100µg/ml) -4.25 (0.88) 
 
Values from -20mV, to 20mV for surface charge on particles (zeta potential), 
have been considered to provide a sufficient electrostatic activity to maintain the 
physical stability of nanoemulsion (Müller and Heinemann 1992). 
The zeta potential for nanoemulsion ranged from -6mV to -2mV in case of (NE3, 
NE4 andNE5) where the limonene oil was used, the zeta was decreased by 
decreasing the concentration of the drug. In the case of oleic acid, NE9, NE10 
and NE11, the zeta potential of nanoemulsion ranged from -7.7mV to -5.4mV. 




The microsuspension zeta potential is about -5mV among the different 
concentrations of the formulations. The low value of the zeta potential is 
because there are no ionic ingredients in the preparations. All the measured 
zeta potential is within the range of -20mv to +20mv. These data are in 
agreement with Amani’s work on nanoemulsion formulations (Amani et al. 2008)  
6.3.8. Physical stability results 
The physical instability of a colloidal system could be one of the phenomena 
explained in figure 6.5. Since the nanoemulsion is a transparent 
thermodynamically stable system, it is not expected to predicate instability of 
the formulation (McClements 2012). The instability could appear if any of the 
nanoemulsion ingredients are degraded or due to the storage conditions 
(McClements 2012). Flocculation is when the disperse phase droplets 
aggregate. Coalescence is when the aggregated droplets fuse and produce a 
large droplet. Creaming and breaking is a phase separations, as the dispersed 
phase separates and floats on the top of continuous phase. Nanoemulsion is 
usually transparent and clear from any turbidity; therefore any turbidity of the 
nanoemulsion could be an indication of poor stability of the formulation, the 
turbidity occurs because of oil droplet aggregates (Flocculation) and produces a 
larger oil droplet (coalescence) (Rahn-Chique et al. 2012). 
The data from the nanoemulsion samples, (NE3, NE4, NE5, NE9, NE10 and 
NE11), showed no phase separation during six months storage at room 
temperature (22ºC +/+ 2ºC). Moreover, the samples were clear and no turbidity 
appeared during the storage conditions. This could prove the possibility of 
preparation of a stable nanoemulsion with very low amount of surfactants which 
could be suitable and safe for inhalation. 






Figure 6.5 Schematic diagram of physical instability of emulsion 
6.3.9. Aerosol output using the jet nebuliser 
The aerosol output was determined for the individual components of 
curcuminoids, i.e. curcumin, demethoxycurcumin and bisdemethoxycurcumin, in 
each formulation (nanoemulsions and suspension) using CEN methodology 
described in section 6.2.9. 
Table 6.9 shows the percentage of bisdemethoxycurcumin, which inhaled, 
exhaled and remained in the chamber after nebulisation of suspension and 
nanoemulsion (limonene or oleic acid) formulations at concentrations of 
100µg/ml, 250µg/ml and 500µg/ml, of curcuminoids using jet nebuliser. Table 
6.10 shows the nebulisation time of each formulation and the percentage rate of 
inhaled and exhaled bisdemethoxycurcumin per minute at concentrations of 




100µg/ml, 250µg/ml and 500µg/ml of curcuminoids by using the same 
nebuliser. 
Table 6.9 The percentage of bisdemethoxycurcumin (BDC) that was nebulised 















5µg/ml of BDC) 
33.85 31.49 33.25 1.42 
NE11 
37.17 27.04 31.18 2.72 
Suspension3 





36.31 30.77 31.34 1.84 
NE10 
37.52 29.36 30.44 2.63 
Suspension2 
29.99 22.66 44.79 2.55 
NE3 
500µg/ml (contains 
25µg/ml of BDC) 
33.40 34.72 29.65 2.23 
NE9 
37.11 32.90 27.45 2.54 
Suspension1 











Table 6.10 The nebulisation time and the percentage of inhaled and exhaled 







Inhalation rate          
(% drug/min) 




5µg/ml of BDC) 
13.00 2.60 2.42 
NE11 
12.50 2.97 2.16 
Suspension3 
14.50 1.91 1.47 
NE4 
250µg/ml (contains 
12.5µg/ml of BDC) 
12.50 2.90 2.46 
NE10 
12.00 3.13 2.45 
Suspension2 
14.50 2.07 1.56 
NE3 
500µg/ml (contains 
25µg/ml of BDC) 
13.00 2.57 2.67 
NE9 
12.50 2.97 2.63 
Suspension1 
14.50 1.57 1.48 
 
Table 6.11 shows the percentage of demethoxycurcumin, which is inhaled, 
exhaled and remained in the chamber after nebulisation of suspension and 
nanoemulsion (limonene or oleic acid) formulations at concentrations of 
100µg/ml, 250µg/ml and 500µg/ml, of curcuminoids using jet nebuliser. Table 
6.12 presents the nebulisation time of each formulation and the percentage rate 
of inhaled and exhaled bisdemethoxycurcumin per minute at concentrations of 
100µg/ml, 250µg/ml and 500µg/ml, of curcuminoids using the same nebuliser. 




Table 6.11 The percentage of demethoxycurcumin (DC) that nebulised from jet 















17µg/ml of DC) 
34.75 35.73 28.79 1.09 
NE11 
31.20 33.36 32.60 2.83 
Suspension3 






33.93 33.59 30.45 2.04 
NE10 
32.78 33.00 30.94 3.29 
Suspension2 




85µg/ml of DC) 
33.40 34.72 29.65 2.23 
NE9 
37.11 32.90 27.45 2.54 
Suspension1 
22.75 21.40 53.84 2.01 
 
  




Table 6.12 The nebulisation time and the percentage of inhaled and exhaled 












(contains 17µg/ml of 
DC) 
13.00 2.67 2.75 
NE11 
12.50 2.50 2.67 
Suspension3 
14.50 1.79 1.26 
NE4 
250µg/ml 
(contains 42.5µg/ml of 
DC) 
12.50 2.71 2.69 
NE10 
12.00 2.73 2.75 
Suspension2 
14.50 1.96 1.66 
NE3 
500µg/ml 
(contains 45µg/ml of 
DC) 
13.00 2.57 2.67 
NE9 
12.50 2.97 2.63 
Suspension1 
14.50 1.57 1.48 
 
Table 6.13 and shows the percentage of curcumin, which is inhaled, exhaled 
and remained in the chamber after nebulisation of suspension and 
nanoemulsion (limonene or oleic acid) formulations at concentrations of 
100µg/ml, 250µg/ml and 500µg/ml, of curcuminoids using jet nebuliser. Table 
6.14 shows the nebulisation time of each formulation and the percentage rate of 
inhaled and exhaled bisdemethoxycurcumin per minute at concentrations of 
100µg/ml, 250µg/ml and 500µg/ml of curcuminoids y using the same nebuliser. 




Table 6.13 The percentage of curcumin (C) that nebulised from jet nebuliser at 








78µg/ml of C) 
33.85 31.49 33.25 1.42 
NE11 
37.17 27.04 31.18 2.72 
Suspension3 




195µg/ml of C) 
33.07 36.03 29.49 1.41 
NE10 
30.63 35.69 30.56 3.12 
Suspension2 




390µg/ml of C) 
33.52 34.53 30.05 1.91 
NE9 
36.53 34.03 27.05 2.40 
Suspension1 




















Table 6.14 The nebulisation time and the percentage of inhaled and exhaled 













78µg/ml of C) 
13.00 2.60 2.42 
NE11 
12.50 2.97 2.16 
Suspension3 




195µg/ml of C) 
12.50 2.65 2.88 
NE10 
12.00 2.55 2.97 
Suspension2 




390µg/ml of C) 
13.00 2.58 2.66 
NE9 
12.50 2.92 2.72 
Suspension1 
14.50 1.48 1.55 
 
The aerosols output results of bisdemethoxycurcumin, demthoxycurcumin and 
curcumin ( compnents of curcuminiods) have the same trend throughtout the 
nanoemulsion and suspension formulations. 
The results in table 6.19,6.11 and 6.13 demonstrated that slight differences in 
the percentage of curcumionids that are entrained into inhalation and exhalation 
filters or left in the nebuilser chamber between nanoemulsion formulations with 
either limoenene or oleic acid oil. The amount of the drug, which is entraind in 
the inhalation filter using nanoemulsion formulation with oleic acid oil, was three 
% higher compared to formulations with limonene oil. 




In comparing both formulations, suspension and nanoemulsion, there is a 
significant increase in the performance of the curcumionids nanoemulsion 
formulations ( either with limonene or oelic acid oil) over the suspension 
preparations. In the suspension formulations, the percentage of the drug, which 
left in the nebuliser chamber, was almost 50% of the deleivered dose whereas 
in the nanemulsion it was about 30%. Also the percentage of drug entrained 
into the inhalation filter from the nanoemulsion preparation ranged from 33% to 
37%, whereas in the suspension formulation it was about 21% to 27%. This is 
because the particles size of the nanoemulsion is smaller than the particles on 
suspension formulation. Furthermore, the nanoemulsion exists in liquid form, 
the nebulised droplet will be fully filled with a liquid form rather than soild form 
(suspension). This finding is in agreement with previous studies which were 
done on nanoemulsion of budesonide  by Amani (Amani et al. 2010). 
Tables 6.10,6.12 and 6.14 show an improvement  on the inahalation rate, which 
is an important factor in regard to pateint compliance, because of the duration of 
the required time for the nebulised dose to be taken. The rate of inhalation 
(%drug/min) is faster in the nanoemulsion formulations (NE3,NE4, NE5, 
NE9,NE10 and NE11)  than the suspension prepartions (suspension 1,2 and 3). 
Also, this finding is in agreement with Amani’s work, in which commercial 
budsonide suspension was compared to the budesionde nanoemulsion 
formulation using the same nebuliser (jet nebuliser) (Amani et al. 2010). 
Among  the nanoemulsion formulation limonene (NE 3,4 and 5) and oelic acid 
(NE 9, NE10 and NE11), there was no significant variation in the inhalation rate 
or in the amount of the inhaled drug between the nanoemulsion formulations 
with limonene oil (NE3, NE4 and NE5)  and formulations with oleic acid oil 
(NE9, NE10 and NE11 ) which have 0.33%, 0.82% and 1.65% of Tween 80, 




respectively. Besides, the aerosol output of the these nanoemulsion 
formulations was similar to those  obtained by Amani et al using nanoemulsions 
in which 10% of Tween 80 was used as surfactant. From both studies, it could 
be noticed that using high concentration of surfactant in the nanoemulsion 
formulations does not improve the aerosol output of the formulation (percentage 
of the inhaled drug, exhaled drug and left in the chamber). However, it may 
affect the nebulisation time. The average of the nebulisation time in the present 
study for 5ml of the nanoemulsion solution was in the range of  12mins to 13 
mins whereas Amani et al (Amani et al. 2010) reported the same nebulisation 
time but for 4ml of nanoemulsion formulation using 10%w/w of surfactant. 
Additionally, curcumiond suspension formulation have shown a superior aerosl 
output performance compared to the available budesoniod suspesnion 
formulation in the market (Amani et al. 2010) which has been charactersied by 
the jet nebuliser .  
6.3.10. Aerodynamic particles size characterisation 
Suspension formulations: the aerodynamic characterisation for suspension 
formulations (suspension 1, 2 and 3) of curcumin, demethoxycurcumin and 
bisdemethoxycurcumin are presented in table 6.15. The effect of the drug 
concentrations, of the suspension formulations, on the FPF and MMAD is 
described in figures 6.6 and 6.7. The mean (n=3) of the fine particles fraction 
(FPF), mass median aerodynamic diameter (MMAD) and geometric standard 
deviation (GSD) were calculated using Copley Inhaler Testing Data analysis 
software (CITDAS). The mass distribution of the drugs throughout the NGI 
stages is shown in figures 6.8, 6.9 and 6.10. 




Table6.15 The mean (n=3) of the aerodynamic data of suspension formulations 
using jet nebuliser at flow 15 L/min 




40.19 5.83 2.07 
Suspension2 
(250µg/ml) 
34.91 6.45 2.17 
Suspension1 
(500µg/ml) 
32.50 6.59 2.03 
Suspension4 
(1000µg/ml) 




37.82 6.08 2.21 
Suspension2 
(250µg/ml) 
33.44 6.43 2.05 
Suspension1 
(500µg/ml) 
30.66 6.69 2.01 




43.05 5.31 2.59 
Suspension2 
(250µg/ml) 
36.00 6.20 2.19 
Suspension1 
(500µg/ml) 
32.13 6.64 2.12 
(1000µg/ml) 26.01 7.05 2.01 
FPF%*: the percentage of Fine Particle Fraction. MMAD*: Mass Median Aerodynamic Diameter.  GSD*: 
Geometric Standard Deviation. FPD*: Fine Particle Dose. 
  





Figure 6.6 The relationships between the suspension concentrations and the 
Fine Particle Fraction of curcuminoids. BDC*: Bisdemethoxycurcumin. DC*: 
Demethoxycurcumin. C*: Curcumin. FPF*: Fine Particle Fraction. 
 
 
Figure 6.7 The relationships between the suspension concentrations and the 
Mass Median Aerodynamic Diameters (MMAD) of curcuminoids. BDC*: 










































Figure 6.8 The mean (n=3, SD) of mass distribution of curcuminoids from 
suspension 3 in NGI using jet nebuliser at flow 15 L/min 
 
 
Figure 6.9 The mean (n=3, SD) of mass distribution of curcuminoids from 





















































Figure 6.10 The mean (n=3, SD) of mass distribution of curcuminoids from 
suspension 1 in NGI using jet nebuliser at flow 15 L/min. 
 
The aerodynamic results of the suspension formulation indicate a satisfactory 
drug deposition behaviour (for concentrations of 0.1mg/ml to 0.5mg/ml), as it 
shows that about 30 to 40%of the delivered doses were able to reach the lungs. 
FPF% decreases by increasing the drug concentrations; the FPF, of 
curcuminoid ingredients, was reduced from 40% at drug concentration of 
0.1mg/ml to 26% at curcuminoids concentration of 1mg/ml. This indicates a 
poor performance for a high drug concentration of suspension during 
nebulisation (low FPF and high MMAD), whereas the same formulation with low 
drug concentration showed suprior performance in FPF% and MMAD. This 
could be due to the  the fact that nebulisers produce droplets size range from1 
to 5µm, these droplets usually carry the drug particles during nebulisation. In 
the author openion, nebulised droplets, at low drug concentrations, carry the 
suspended particles based on the actual size of suspended drug particles 
(1.6µm). For example, if the drug has a particle size of 1.6µm, it will likely reside 
in a nebulised droplets size of 2µm and above, as it is explained in figure 6.11. 






























increased, the nebulised droplets are enforced to carry more drug particles 
within droplets. Consequently, more particles have to move at the same time 
inside the large droplets, which leads to particles agglomeration and hence 
increasing their size (for example, if the individual particles has a size of 1.6µm 
the agglomerated may have a size of 2.5µm or bigger). Therefore, the small 
droplets will remain free from the agglomerated drug particles. This theory could 
explain the poor aerosolisation performance with low FPF and large MMAD of 
the formulated microsuspension of high drug concentrations. Similar 
aerosolistion perfermnce was reported by Hemmandez-Trejo (Hernández-Trejo 
et al. 2005). They found that the agglomeration of particles in suspended 
solution is a significant issue during nebulisation from jet nebuliser. 
 
         The nebulised droplets 
 
        The suspended drug particles 
(1.7µm) 
Figure 6.11 Nebulised droplets form microsuspension formulations at low drug 
concentration (A) and at high drug concentration (B) 
 
 Nanoemulsion formulations using oleic acid: The aerodynamic 
characterisation of the nanoemulsion formulations using oleic acid (NE11, NE10 
















presented in table 6.16. Figures (6.12 and 6.13) show the effect of the drug 
concentrations, of the nanoemulsion formulations, on the FPF and MMAD. The 
mass distribution of the drugs throughout the NGI stages is presented in figures 
6.14, 6.15, 6.16. The mean (n=3) of the fine particles fraction (FPF), mass 
median aerodynamic diameter (MMAD) and geometric standard deviation 
(GSD) were calculated using Copley Inhaler Testing Data analysis software 
(CITDAS).  
Table 6.16 The mean (n=3) of the aerodynamic characterisation of 
curcuminoids nanoemulsion nanoemulsion with oleic acid oil formulations using 
jet nebuliser at flow 15 L/min 
Drug Formulations FPF% MMAD (µm) GSD 
Bisdemethoxycurcumin 
NE11(100µg/ml) 45.69 4.88 2.30 
NE10 (250µg/ml) 43.78 5.39 2.36 
NE9 (500µg/ml) 42.57 5.78 2.15 
Demethoxycurcumin 
NE11(100µg/ml) 44.05 5.50 2.45 
NE10 (250µg/ml) 42.75 5.72 2.52 
NE9 (500µg/ml) 41.78 5.83 2.16 
Curcumin 
NE11(100µg/ml) 48.45 4.39 2.62 
NE10 (250µg/ml) 47.15 4.83 2.85 
NE9 (500µg/ml) 46.60 5.25 2.14 
FPF%*: the percentage of Fine Particle Fraction. MMAD*: Mass Median Aerodynamic Diameter.  GSD*: 
Geometric Standard Deviation. FPD*: Fine Particle Dose. 
 
 





Figure 6.12 The relationships between the drug nanoemulsion concentrations 
(using oleic acid oil) and the Fine Particle Fraction of curcuminoids. BDC*: 
Bisdemethoxycurcumin. DC*: Demethoxycurcumin. C*: Curcumin. FPF*: Fine 
Particle Fraction. 
 
Figure 6.13 The relationship between the nanoemulsion concentrations (using 
oleic acid oil) and the Mass Median Aerodynamic Diameters (MMAD) of 

















































Figure 6.14 The mean (n=3, SD) of mass distribution of curcuminoids 




Figure 6.15 The mean (n=3, SD) of mass distribution of curcuminoids 


























































Figure 6.16 The mean (n=3, SD) of mass distribution of curcuminoids 
nanoemulsion (NE9, with oleic acid oil) in NGI using jet nebuliser at flow 15 
L/min. 
 
The results illustrate an improvement in FPF (%) and MMAD compared to 
suspension formulations. The FPF (%) ranged from 48% to 46% for curcumin 
and from 44% to 41% for demethoxycurcumin and 45% to 42% for 
bisdemethoxycurcumin. The variation in MMAD was very small throughout the 
nanoemulsion formulations for different curcuminoid concentrations (NE9, NE10 
and NE11), The lowest MMAD was 4.3µm for the NE11 (100µg/ml) and the 
highest was 5.8µm for the NE9 (500µg/ml) whereas in suspension formulation 
the lowest MMAD was 5.8µm and the highest was 6.66µm (for concentration of 
500µg/ml) and 7.0µm (for 1000µg/ml). This shows that the suspension 
formulation containing curcuminoid at a concentration above 500µg/ml is not 
suitable for inhalation due to low FPF (%) and high MMAD. These findings are 
in agreement with Amani’s results that were reported for commercial 
budesonides suspension using jet nebuliser device.   
Nanoemulsion formulations using limonene oil: The aerodynamic 





























and NE3) for curcumin and demethoxycurcumin and bisdemethoxycurcumin are 
presented in table 6.17. Figures (6.17 and 6.18) display the effect of the drug 
concentrations, of the nanoemulsion, on the FPF and MMAD. The mass 
distribution of the drugs throughout the NGI stages is illustrated in figures 6.19, 
6.20 and 6.21. 
Table 6.17 The mean (n=3) of the aerodynamic characterisation of 
curcuminoids nanoemulsion with limonene oil formulations using jet nebuliser at 
flow 15 L/min 
Drug Formulations FPF% MMAD (µm) GSD 
Bisdemethoxycurcumin 
NE5 (100µg/ml) 51.32 4.52 2.75 
NE4 (250µg/ml) 46.17 5.34 2.35 
NE3 (500µg/ml) 44.86 5.53 2.20 
Demethoxycurcumin 
NE5 (100µg/ml) 47.30 4.97 2.20 
NE4 (250µg/ml) 46.12 5.12 2.16 
NE3 (500µg/ml) 44.07 5.63 2.19 
Curcumin 
NE5 (100µg/ml) 50.72 4.50 2.42 
NE4 (250µg/ml) 50.15 4.73 2.24 
NE3 (500µg/ml) 44.70 5.55 2.20 
FPF%*: the percentage of Fine Particle Fraction. MMAD*: Mass Median Aerodynamic Diameter.  GSD*: 
Geometric Standard Deviation. FPD*: Fine Particle Dose.  
 
 





Figure 6.17 The relationship between the drug nanoemulsion concentrations 
(using limonene oil) and the Fine Particle Fraction of curcuminoids. BDC*: 





Figure 6.18 The relationship between the drug nanoemulsion concentrations 
(using limonene oil) and the Mass Median Aerodynamic Diameters (MMAD) of 

















































Figure 6.19 The mean (n=3, SD) of mass distribution of curcuminoids 




Figure 6.20 The mean (n=3, SD) of mass distribution of curcuminoids 


























































Figure 6.21 The mean (n=3, SD) of mass distribution of curcuminoids 
nanoemulsion (NE3, with limonene oil) in NGI using jet nebuliser at flow 15 
L/min. 
 
The results of the limonene nanoemulsion formulation demonstrate an 
improvement in FPF and the MMAD compared to suspension formulations. Also 
the limonene nanoemulsion indicates a slight improvement in FPF over the oleic 
acid nanoemulsion formulations.  
The FPF (%) ranged from 44% to 50% for curcumin and from 44% to 47% for 
demethoxycurcumin and 45% to 51% for bisdemethoxycurcumin. The variation 
in MMAD was very small throughout the nanoemulsion formulations for different 
curcuminoid concentrations (NE3, NE4 and NE5). The lowest MMAD was 
4.5µm for the NE5 (100µg/ml) and the highest was 5.6µm for the NE3 
(500µg/ml) whereas in suspension formulation the lowest MMAD was 5.8µm 
and the highest was 6.66µm (for concentration of 500µg/ml) and 7.0µm (for 
1000µg/ml). These results are similar to the oleic acid nanoemulsion formulation 
(NE9, NE10 and NE11) and in agreement with Amani’s results when 































The summary of the comparison of FPF, for the three formulations, suspension, 
limonene nanoemulsion and oleic acid nanoemulsion, is demonstrated in 
figures 6.22, 6.23, and 6.24. 
 
Figure 6.22 Comparison of fine particle fraction (FPF) between nanoemulsion 
formulations (NE5: limonene oil, NE11: oleic acid oil) and suspension 3 of 
curcuminoids for the same concentration (100µg/ml). BDC*: 
bisdemethoxycurcumin, DC*: demethoxycurcumin 
 
 
Figure 6.23 Comparison of fine particle fraction (FPF) between nanoemulsion 
formulations (NE4: limonene oil, NE10: oleic acid oil) and suspension 2 of 
curcuminoids for the same concentration (250µg/ml). BDC*: 











































Figure 6.24 fine particle fraction (FPF) comparison between nanoemulsion 
formulations (NE5: limonene oil, NE11: oleic acid oil) and suspension 3 of 
curcuminoids for the same concentration (100µg/ml). BDC*: 
bisdemethoxycurcumin, DC*: demethoxycurcumin. 
 
In all nanoemulsion formulations, the FPF (%) and MMAD were independent of 
the drug concentration, whereas in the suspension formulations FPF (%) and 
MMAD greatly varied with respect to the drug concentrations. 
 In the nanoemulsion formulations, the respirable fraction was larger compared 
to the suspension formulation, and the mass median diameter value was 
smaller. The drug amount which remained in the nebuliser chamber was 
significantly greater in the suspension formulations compared to nanoemulsion 
formulations. These findings were in agreement with the study reported by 
(Amani et al. 2010). The difference in the aerodynamic performance between 
the nanoemulsion and suspension formulations is attributed to the particle size 
of the drug in each formulation, as the particle size in the nanoemulsion is in the 
range of 12nm and 35nm but in the suspension, the particle size was 1.6µm. 
Since nebulisers produce droplets sized from 5µm to almost 1µm. The author 
theory for explaining the differences in the aerodynamic performance between 





















suspension form, it will occupy the droplet based on its size. For example, if the 
drug particles are 1.6-2µm, the drug will be carried in the larger nebulised 
droplet only as is demonstrated in figure 6.25, therefore the smaller nebulised 
droplet will be free of the drugs. Consequently, the microsuspension 
formulations exhibit a lower FPF (%) and higher MMAD. In the case of 
nanoemulsion particles, the drug is very small in size (12nm to 35nm) and the 
particles size is more uniformed, therefore all nebulised droplets will be fully 
filled with nanoparticles of the drug. For these reasons, nanoemulsion 
formulations exhibited much better fine particle fractions (FPF) and hence 
achieved deeper particle deposition compared to microsuspension formulations. 
  
 
     nebulised droplets 
    nanoemulsion particles 
with the drug (12-35nm) 
        The suspended drug 
particles (1.7µm) 
Figure 6.25. Nebulised droplets from nanoemulsion formulation (A) and from 
microsuspension formulation (B) 
 
The nanoemulsion formulation demonstrates its ability to reach to a deep lung 
deposition as particles reached to stage7 and MOQ (and the filter that is placed 
after the MOQ) in the in vitro studies which represent the alveoli. This clearly 
shows that aerosol nanoemulsion formulation has the potential to be used for 
the treatment of both central and peripheral lung cancer. 
5 µm 













6.3.11. Genotoxicity of curcumin nanoemulsion 
Genotoxicity tests of pharmaceutical products before commercialisation are 
required by regulatory agencies worldwide (Snyder and Green 2001). 
Nanoparticles were reported to have a potential harmful side effect to humans 
and could be genotoxic too (Chan 2006; Magdolenova et al. 2013). This could 
be attributed to a direct interaction of the nanoparticles with genetic material, or 
indirect damage from nanoparticle-induced reactive oxygen species, or by 
releasing toxic ions (Kisin et al. 2007; Barnes et al. 2008). Nanoparticles, due to 
their unique size, have the ability to cross the cellular membrane and may reach 
the nucleus by diffusion across the nuclear membrane or by transportation 
through nuclear pore complex, and directly interact with DNA (Barillet et al. 
2010). Nanoparticles with size 8nm to 10nm enter through a nuclear pore, 
whereas larger nanoparticle size 15nm to 60nm may access to the DNA in the 
dividing cells during the mitosis when the nuclear membrane dissolves (Xing-Jie 
Liang 2008; Singh et al. 2009; Magdolenova et al. 2013).  
Nanoemulsion of curcumin genotoxicity, DNA damage, has not been examined 
before. The genotoxicity of NE3, NE4 and NE5 is presented in figure 6.26 and 
NE9, NE10, and NE11) is shown in figure 6.27. The data indicates that there is 
no genotoxicity for the curcumin nanoemulsion on lymphocytes cells compared 
to the negative control. Changing the oil in the nanoemulsion also did not show 
any changes in the DNA damage too. DNA seems to be intact as is expressed 
in figure 6.28, as there was no comet for DNA. This finding is in agreement with 
an in vivo study which reported that solid nanoparticles (in suspension form) of 
curcumin are not genotoxic (Dandekar et al. 2010). Moreover, it was reported 
that curcumin protect lymphocytes cells from genotoxicity induced by 131 
radioiodine (Shafaghati et al. 2014), and was also used to reduce the 




genotoxicity of chemotherapies as Mitomycin C and Cisplatin  (Antunes et al. 
2005; Siddique et al. 2010). This protection of curcumin to the cells that being 
damaged is attributed to its antioxidant activity and the potential free radical 
scavengers (Srinivasan et al. 2006). 
These results could confirm the safety of the developed curcuminoids 
nanoemulsion formulations. Comet assay demonstrated that there is no DNA 
damage when the cells treated with curcumin nanoemulsion.  
 
Figure 6.26 Effect of curcuminoids nanoemulsion (with limonene oil) 







































Effect of curcumiods nanoemulsion formulations on DNA 





Figure 6.27 Effect of curcuminoids nanoemulsion (with oleic acid oil) 






































Effect of curcumioids nanoemulsion formultions on DNA 





Figure 6. 28 Lymphocyte DNA under a fluorescence microscope after treatment 
with curcuminoids nanoemulsion formulations, A & C: treated with curcuminoids 
nanoemulsion using oleic acid oil at concentrations 1 & 5 µg/ml. B &D: treated 
with curcuminoids nanoemulsion using limonene oil at concentration 1 & 5 µg/ml. 
E is an example of positive control, and F is a negative control. 
 
6.4. Conclusion 
The curcuminoids nanoemulsion formulations were prepared using a very small 
amount of surfactants (ranging from 1.6% to 0.33%). The formulations were 
found to be stable at room temperature. The particle size ranged from 12nm to 




35nm. The osmolality and pH of the formulations are suitable for inhalation; the 
viscosity was determined. The suspension formulations were also prepared 
according to FDA regulations (i.e. in regards of the amount of surfactant). The 
osmolality and pH of the suspension are presented to be suitable for the 
respiratory system. 
The aerosol output for nanoemulsion was far superior to suspension 
formulation, as 50% of the drug (suspension) remained in the nebuliser 
chamber upon completion of the run, while the residual nanoemulsion 
remaining in the chamber was less than 30%. Moreover, suspension 
formulation would be less convenient to patients as it took longer to complete 
nebulisation compared to nanoemulsion nebulised formulations. The in vitro 
aerosolisation performances for all formulations of curcuminoids were examined 
using NGI. The performance of the suspension was found to be drug 
concentration dependent, whereas the performance of nebulised nanoemulsion 
was independent. The fine particle fraction of the nanoemulsion was much 
better than the suspension formulation. 
It is clear that nanoemulsion has the ability to penetrate into both lung zones 
(central and peripheral zone), therefore, nanoemulsion could be used for lung 
cancers, whether they are located in the central or peripheral zone. On the 
other hand, suspension would be more located in the lung central zone, 
therefore, could be an option for those cancers located in the lung central zone. 
Since, curcuminoid particles in nanoemulsions (12nm and 35nm) are smaller 
than in the suspension (1.6µm); therefore, the nanoemulsion could be more 
effective against cancer cells. In addition, curcuminoid particles in the 
nanoemulsion formulation are in liquid form, so this increases both activity and 
onset of action of the drug compared to solid particles in the suspension form. 




The nanoemulsion formulation with the small amount of surfactants was found 
to be safe to DNA and did not cause any damage to genetic information of the 
lymphocyte cells. Therefore, this could indicate the safety and suitability of the 
nanoemulsion formulation to be used for further inhalation studies in both 
animals and in humans.  





General Conclusion and Future Work   




7 Chapter 7: General conclusion and future work 
7.1 General Conclusion  
This thesis is considered the first study to assess the suitability of using 
curcuminoids (curcumin, demethoxycurcumin and bisdemethoxycurcumin) for 
inhalation as dry powder inhalers without excipients and nebulisers, in which 
FPF% and the MMAD of curcumin, demethoxycurcumin and 
bisdemethoxycurcumin have been determined. The need for such formulations 
for curcuminoids originated from two points, firstly curcuminoids have strong 
anticancer activities but they have low bioavailability. Secondly, lung cancer is 
considered responsible for the highest rate of cancer deaths, also, 1when 
anticancer agents are taken orally or IV; they reach the lungs in low 
concentrations which limit their effects. Therefore, delivering curcuminoids 
directly into the lungs will treat the lung (disease) cancer locally; the 
concentrations of curcumin will be high at the cancer sites and low in the 
systemic circulations. 
The new dry powder inhaler formulation of curcumin, without excipient, is safer 
than any other formulations that contain additives (excipients which are not 
approved by FDA). The nebuliser formulation of curcuminoids, using 
nanoemulsion and microsuspension preparations, covers the needs of elderly 
and child patients and those who are unable to use DPI. These new inhaled 
formulations (DPI and nebuliser) show a promising in vitro aerodynamic 
behaviour, which makes these formulations available for in vivo studies. As the 
characteristics of inhalable particles, such as size, shapes and surface energy, 
have an impact on the formulation performance and deposition profile of the 
                                            
1
 The low drug concentration, is expected, at the lung cancer site, when the anticancer agents are 
administrated IV or orally. 




inhaled drug, theses formulations were prepared by air jet milling and 
sonocrystallisation, which are considered the most simple and fastest 
techniques in producing the desired particles. Furthermore, they are known as 
easy, less time consuming and an inexpensive process of particle production. 
The output of the in vitro samples was analysed using a developed and 
validated HPLC method.  
Environment friendly HPLC (Microemulsion high performance liquid 
chromatography) and conventional methods have been developed and 
validated for curcuminoid solution analysis, according to ICH guidelines. Both 
methods were sensitive, linear, precipices and accurate. The separation of 
curcuminoids (curcumin, demethoxycurcumin and bisdemethoxycurcumin), in 
both methods, was achieved in about 10 mins. The mobile phase of the 
microemulsion method offers several advantages over the conventional method 
that has a mobile phase composed of 55% acetonitrile and 45% phosphate 
buffer. These advantages due to the fact that 90% of the mobile phase was 
composed of phosphate buffer which makes the method inexpensive and 
nature-friendly and green as it has very low organic solvents.     
A dry powder inhaler of curcuminoids was prepared using micronized particles 
which are produced by an air jet milling process. The formulation that contains 
the curcumin particle size of D50 2.5µm (D90=5.5µm) illustrated higher inhalation 
performance compared to the formulation with a particle size of D50 3.5µm (D90 
7.7µm). The obtained FPF% of the micronized DPI formulations (D50 2.5µm) 
was very close to the recent published formulations with additives. The crystal 
structure of milled curcumin particles was found to be in form 1. The structural 
analysis (XRPD, DSC) has confirmed that the micronized curcumin particles 
have polymorph1 as the unprocessed material. 




A dry powder inhaler of curcuminoids using a sonocrystallisation technique was 
successfully achieved without any excipients. Dry powder inhaler formulations, 
which contain curcuminoid particles that were obtained from ethanol as a 
solvent and heptane as antisolvents, have shown a superior deposition profile 
compared to those formulations with jet milled particles and with those 
contained particles precipitated from acetone (solvent) and heptane as an 
antisolvent. Moreover, the aerodynamic behaviour of this formulation, which 
showed the best inhalation performance, was similar to the recent published 
work with excipients, which are not approved by the FDA for inhalation (Myrdal 
et al. 2014). The particle structure analysis (DSC&XRPD) of sonocrystallised 
curcumin particles has shown curcumin crystal structure in form 3, when the 
particles were obtained from isopropanol and water, and curcumin polymorph 1, 
when the curcumin particles were precipitated from ethanol and water as an 
antisolvent, and also curcumin polymorph 1 was formed when curcumin 
particles were precipitated from ethanol, acetone, and isopropanol solvents with 
heptane as antisolvent. The surface energy of the sonocrystallised particles 
from ethanol was lower than the surface energy of particles obtained from 
acetone and from the unprocessed materials. The particle shapes varied 
depending on the solvent-antisolvent used in the system during 
sonocrystallisation. 
 The simple approaches of obtaining inhalable curcuminoid particles without 
involving any extra excipients were an advantage of this study compared to the 
recently published one. This makes the dry powder inhaler formulations of 
curcumin safer and suitable for the respiratory system. Another advantage is 
that the aerodynamic parameters of curcuminoid components, curcumin (C), 




Demethoxycurcumin (DC) and Bisdemethoxycurcumin (BDC) were individually 
measured in this thesis. 
Nanoemulsions for nebulisation of curcuminoids were successfully prepared 
with a very low amount of surfactant (tween 80), which ranged from 1.25% to 
0.31%. This nanoemulsion system has the lowest tween 80, compared to the 
published nanoemulsion for budesonide formulation, which contains 10% of 
tween 80. Also, a microsuspension of curcuminoids was prepared according to 
the FDA regulations (tween 80 is 0.02%). The osmolality, pH and the viscosity 
of the nebuliser formulations meet the inhalation criteria. The aerodynamic 
behaviour of suspension formulation has been found to be drug concentration 
dependent, e.g. the low drug suspension concentration shows better 
performance on the higher drug concentration as FPF% decreased as the drug 
concentration increased. In the nanoemulsion preparations, the aerodynamic 
performance was independent of the drug concentrations. The inhalation profile 
of the nebulised nanoemulsion was far superior on suspensions formulations; 
this is because of lower particle size as well as the surface tension of the 
nanoemulsion formulations. Moreover, the aerosol output of the nanoemulsion 
increased as the amount which was left in the nebuliser chamber decreased 
compared to the suspension formulations. The nanoemulsion of curcumin has 
been found not to be genotoxic on lymphocyte blood cells of human. The lung 
deposition of the nebulised nanoemulsion has shown deep lung penetrations, 
this could make the nanoemulsion formulation suitable for both lung cancer 
types which exist in either the peripheral or central zones of the lungs. The 
aerodynamic parameters (FPF%, MMAD and GSD) of curcuminoid 
components, curcumin, demethoxycurcumin and bisdemethoxycurcumin were 
individually determined. 




7.2 Future Work 
The in vitro results present a promising aerodynamic behaviour of dry powder 
inhaler and nebuliser of curcuminoid formulations. Therefore, it would be useful 
to extend these in vitro findings to in vivo study on animals with lung cancer. 
The in vitro testing of the inhaled dry powder of curcumin was carried out with 
one flow rate and volume inhalation, which is according to standard compendial 
methodology.  It would be interesting to do the test with different inhalation flows 
and inhalation volumes, as patients have different stages of the disease, and 
hence they have different lung capacity and different inhalation force. This study 
was also carried out using one type of DPI device (which is a multi-dose 
reservoir). However, Inhaler devices have different resistance which has an 
effect on the formulation preference as they could require more or less 
inspiration flow to disperse the drug particles from the carrier. Hence, it is 
suggested to extend this work to include different inhaler devices such as a 
single dose inhaler device. 
In general, in dry powder inhaler formulation, formulators consider D50 to 
represent the drug particle size for inhalation formulation. It states that the D50 
needs to be less than 5µm. From this work, it would be recommended to 
consider the D90 too, which should be 5µm or less to obtain a better inhalation 
performance (FPF%).  
In this project, we have established a relation between the work of adhesion 
and cohesion and with drug concentration onto the carrier that affects the 
aerodynamic behaviour of the inhaled particles. This relation was examined 
when the work of cohesion is equal or smaller than the work of adhesion. It is 
suggested to extend this work further to investigate the performance of DPI  




formulation when the work of cohesion is higher than the work of adhesion as 
we are expecting in this case  that the less amount of the drug onto the surface, 
the better performance of the formulation of the DPI. In the nebuliser 
formulation, only one type of nebuliser devices was used which is Sidestream; 
there are other nebuliser devices such as Omron and Aeroneb, which may give 
different performance of the formulations. 
Studies using a combination therapy of curcumin and anticancer agents, such 
as paclitaxel, doxorubicin and cisplatin, have shown that curcumin produces 
synergistic effects with chemotherapeutic drugs against various cancer cell lines 
(Ganta and Amiji 2009; Duarte et al. 2010; Wang et al. 2013), therefore it would 
interesting to investigate the feasibility of producing inhaled formulation which 
contains the combination therapy. 
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